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Abstract 
 
Perfluorooctane sulfonate (PFOS) is bioaccumulative and prevalent in the human 
population.  PFOS induces hepatic steatosis in male rats at dietary exposures of 100 
ppm via an unknown mechanism.  In vitro, PFOS creates a choline ion complex.  
Choline deficiency induces hepatic steatosis in rats by decreasing VLDL secretion.  The 
primary hypothesis was that a hepatic PFOS:choline ion complex causes steatosis that 
could be prevented by dietary choline supplementation.  PFOS activation of steatosis 
related nuclear receptors (i.e., LXR, PXR, CAR, and PPAR-gamma) was investigated as 
a secondary hypothesis.  To identify a choline dietary concentration, Sprague Dawley 
rats (5-6/sex/group) were fed control diet or 5X, 10X, or 15X basal choline diets for four 
weeks.  The 5X diet was selected based on decreased body weights and body weight 
gains in the 10X (females only) and 15X groups.  Sprague Dawley rats (12/sex/group) 
were fed control, choline supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS 
diets for three weeks.  The male PFOS (±CS) rats developed hepatic steatosis, 
decreased mean serum cholesterol, and increased liver choline concentrations; the 
supplemented diet did not prevent hepatic steatosis.  Female rats did not have these 
findings, even though serum and liver PFOS concentrations were similar to the males.  
In vitro, 400 µM PFOS did not inhibit choline kinase activity, which does not support the 
primary hypothesis.   Regarding the secondary hypothesis, there was no activation 
(LXR, PXR, and CAR) or very weak activation (PPAR-gamma) by PFOS in a luciferase-
linked assay.  Also, liver mRNA activated by these nuclear receptors were not 
upregulated in rats fed PFOS.  There are no clear data from this project that support the 
primary or secondary hypothesis.  However, increased hepatic choline concentrations in 
the male PFOS rats correlates with the primary hypothesis.  This finding and the sex-
related difference in PFOS-induced hepatic steatosis warrant further investigation.  
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Chapter 1: Overview of Perfluorooctane Sulfonate (PFOS) 
and Hepatic Lipid Accumulation 
 
1.1  Introduction 
Fluorocarbons have been used for decades as industrial intermediates and surfactants 
[1].  Molecules containing perfluorinated carbon chains as part of their structure have 
been identified as bioaccumulative and/or environmentally persistent [2, 3].  One of 
these molecules is perfluorooctane sulfonate (PFOS).  PFOS is an eight-carbon, fully 
fluorinated chemical with a sulfonate head group that can be linear or have internal 
monomethyl, isopropyl or other branches (Figure 1).  The PFOS used for this 
dissertation (3M PFOS, lot 217) contains 86.9% PFOS isomers where 69.3% of the 
isomers are linear PFOS, 16.5% are monomethyl branched PFOS, 10.2% are isopropyl 
branched PFOS, and ≤1.7% are of other branch types based on the certificate of 
analysis [4]. 
 
In 1997, PFOS was identified in the serum of 3M workers [5], and since that time, its 
potential toxicity and environmental impact have been extensively investigated.  One 
identified effect is the potential for hepatocellular vacuoles to form in rats [6, 7] and 
monkeys [8] after ingesting high dose PFOS; for example, rats fed 100 ppm PFOS in the 
diet for at least four weeks [6].  It is possible that these vacuoles represented lipid 
accumulation (i.e., hepatic steatosis).   
 
This project confirmed the putative hepatic steatosis effect in rats following dietary high 
dose PFOS exposure and investigated two potential mechanisms for this effect.  The 
primary hypothesis was that PFOS formed an ion complex with choline leading to 
hepatic steatosis similar to the effects of choline deficiency.  The secondary hypothesis 
was that PFOS activated nuclear receptor(s) that can cause hepatic steatosis, for 
example the pregnane X receptor (PXR). 
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1.2  Background on Lipid Metabolism 
Lipid metabolism is the key to energy homeostasis throughout the body.  The low energy 
(i.e., fasting) state is the common state of the body, thus the lipid catabolism pathway is 
critical to maintaining energy levels in cells between meals.  In high energy (i.e., fed) 
states, lipid anabolism allows the body to store high energy triglyceride (TG) molecules 
in the adipocytes for future use.  Understanding the balance between lipid catabolism 
(Figure 2) and lipid anabolism and VLDL secretion (Figure 3) is critical to understanding 
how perturbations in these systems can lead to pathology (e.g., hepatic steatosis). 
 
When circulating serum glucose concentrations are low (e.g., fasted conditions, see 
Figure 2), glucagon is produced by the pancreas, activates adenylate cyclase in adipose 
tissue, and binds to the glucagon receptor (GCR) on the hepatocyte [9].  In the adipose 
tissue, the activated adenylate cyclase converts adenosine triphosphate (ATP) to cyclic 
adenosine monophosphate (cAMP).  Cyclic AMP-dependent protein kinase (PKA) is 
activated by the cAMP, then phosphorylates perilipin A, a lipid droplet surface protein, 
and hormone-sensitive lipase (HSL) [9].  HSL moves from the cytosol to the lipid droplet 
and hydrolyzes triglyceride to release free fatty acid (FFA).  Perilipin A must be 
phosphorylated for HSL to associate with the lipid droplet and this is one of the 
regulatory steps controlling the release of FFA.  Once liberated from the triglyceride, the 
FFA is released from the adipocyte into the blood where it binds to serum albumin and is 
transported throughout the body.  In the hepatocyte, glucagon signals the inhibition of 
sterol response element binding protein-1c (SREBP-1c), the key regulatory enzyme in 
lipid synthesis, and the conversion of ATP to cAMP  [9].  The increased cAMP activates 
adenosine monophosphate kinase (AMPK) to phosphorylate and inactivate acetyl-CoA 
carboxylase (ACC).  Phosphorylated ACC cannot catalyze the reaction of acetyl-CoA to 
malonyl-CoA, the key regulatory step in lipid synthesis [9].  AMPK and free fatty acids 
(FFA) activate the nuclear membrane bound peroxisome proliferator activated receptor 
alpha (PPAR-alpha) to enter the nucleus, bind with retinoid X receptor (RXR), and then 
bind to the peroxisome proliferation response elements (PPRE) of target genes [10].  
PPAR-alpha upregulates transcription of CD36, the key membrane transport molecule 
for FFA uptake from the bloodstream by hepatocytes [10].  PPAR-alpha also upregulates 
transcription of mRNA for cytochrome P450 4A1 (CYP4A1), the first enzyme of the fatty 
acid omega oxidation pathway.  Long and medium chain fatty acids can be first 
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subjected to omega oxidation in the endoplasmic reticulum by cytochromes of the 4A 
family (i.e., oxidized from the omega carbon, the carbon distal to the carboxylic acid); 
however, this is generally a minor oxidation pathway in rats and humans with alpha and 
beta oxidation being more important [9, 11].  PPAR-alpha also upregulates transcription 
of peroxisomal acyl-coenzyme A oxidase 1 (ACOX) and enoyl-CoA hydratase and 3-
hydroxyacyl CoA dehydrogenase (EHHADH), two enzymes in the peroxisome for lipid 
catabolism [10].  Peroxisomal oxidation leads to hydrogen peroxide formation, whereas 
mitochondrial oxidation leads to energy production in the form of NADH and FADH2.  In 
the peroxisome, each cycle of peroxisomal oxidation reduces the length of the FFA 
chain by two carbons resulting in shorter chain acyl CoA molecules (e.g., 8-carbon acyl 
CoA) [12].  Mitochondrial beta oxidation requires the transport of the FFA into the 
mitochondria through the carnitine palmitoyl transferase I (CPT 1) and carnitine 
palmitoyl-transferase II (CPT 2) pathway [10].  CPT 1 and CPT2 are also upregulated by 
PPAR-alpha [10].  CPT1 catalyzes the addition of carnitine to the acyl-CoA to permit 
transport of the acyl-CoA-carnitine (FA-carn) into the mitochondria by carnitine 
acylcarnitine translocase (CT) [13].  In the interior of the mitochondria CPT2 removes the 
carnitine from the FA-carn [13] to make the acyl-CoA available for mitochondrial beta 
oxidation.  Every round of mitochondrial beta oxidation removes two carbon molecules 
from the acyl-CoA as acetyl-CoA [9].  The released acetyl-CoA is metabolized in the 
tricarboxylic acid cycle (TCA) to ultimately produce ATP through the electron transport 
chain.  The widespread effects of PPAR-alpha make it the key regulatory nuclear 
receptor for activation of lipid catabolism and maintaining energy homeostasis during 
fasting conditions, i.e., the most common state. 
 
When circulating serum glucose concentrations are high (e.g., fed conditions, see Figure 
3), the pancreas produces insulin that binds to the tyrosine kinase receptor (TK) in the 
hepatocyte starting a signaling cascade that cleaves SREBP-1c from sterol regulatory 
element binding protein cleavage activating protein (SCAP) in the endoplasmic reticulum 
[14].  The SREBP-1c migrates to the Golgi body and becomes activated where it can 
then travel to the nucleus and bind to the sterol response element (SRE) [14].  SREBP-
1c upregulates transcription of pyruvate kinase (PK), ACC, and fatty acid synthase 
(FAS) [15].  In addition, a separate insulin signaling cascade activates phosphatase that 
dephosphorylates ACC producing active ACC that can metabolize acetyl-CoA to 
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malonyl-CoA [14].  The increased concentrations of malonyl-CoA act as a negative 
feedback loop and inhibits CPT1, thus preventing the creation of FA-carn and inhibiting 
fatty acid uptake by the mitochondria as previously described [14].  Similarly, the high 
serum glucose is taken up by the glucose 2 (GLUT2) transporter.  The glucose enters 
the glycolysis pathway and, following a series of metabolic steps, also activates the 
carbohydrate response element binding protein (ChREBP) by a series of 
dephosphorylations [14].  The activated ChREBP can bind to the carbohydrate response 
element (ChORE) and upregulate the transcription of similar genes [14].  The increased 
pyruvate is metabolized to citrate through the TCA cycle and citrate can also 
allosterically promote the metabolism of acetyl-CoA to malonyl-CoA by ACC.  Malonyl-
CoA is metabolized to palmitate by FAS through repeated additions of two carbon units.  
Adding an additional two carbon unit to palmitate yields stearate that can be converted 
to oleate by the addition of a double bond at the C9 position by stearoyl-CoA desaturase 
(SCD1) [16].  The resulting fatty acids can undergo further metabolism to acyl-CoA units 
and with the addition of glycerol-3-phosphate (gly-3-P) be converted to triglyceride (TG).  
TG is packaged into apolipoprotein B100 particles (apoB100) by microsomal triglyceride 
transfer protein (MTP) to produce nascent very low density lipoprotein (VLDL) particles 
that are transported to the Golgi body and ultimately secreted as mature VLDL [17].  The 
secreted VLDL is then transported through the circulatory system to the adipose tissue, 
where the TG is stored for use during future fasting states.  As the circulating VLDL 
releases TG to the adipose tissue, the VLDL is converted to intermediate density 
lipoprotein (IDL), low density lipoprotein (LDL) and ultimately high density lipoprotein 
(HDL), resulting in the four circulating forms of lipoprotein. 
 
The formation of apoB100 particles is dependent on the production of 
phosphatidylcholine [18].  Phosphatidylcholine (PC) production is dependent on the 
uptake of choline and metabolism through the CDP-pathway or metabolism of 
ethanolamine to phosphatidylcholine through the phosphatidylethanolamine N-
methyltransferase (PEMT) pathway [17].  The committed step in the CDP pathway is the 
metabolism of choline to phosphocholine (P-Cho) by choline kinase (CK) [19].  The 
PEMT pathway is dependent on the availability of methionine which is metabolized to S-
adenosyl methionine (S-Ado-Met) and used in the formation of PC from 
phosphatidylethanolamine (PE) by PEMT [17].  Thus, the formation and secretion of 
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VLDL particles is dependent, in part, on the proper functioning of the CDP and PEMT 
pathways.     
 
1.3 Species and Sex-related Differences in Lipid Metabolism 
Humans are less responsive to PPAR-alpha agonists compared to rats and mice [20].  
Humans produce a splice variant of PPAR-alpha mRNA that lacks exon 6 and results in 
an early stop codon and a truncated PPAR-alpha protein that is inactive [21].  This 
truncated PPAR-alpha protein is present in human liver at 3- to 5-fold lower 
concentrations than the full PPAR-alpha protein [21] and can act as an endogenous 
inhibitor of native PPAR-alpha [22].  The presence of this truncated PPAR-alpha has 
been suggested to be the source of the decreased PPAR-alpha agonist response in 
humans relative to rodents [22].   Humans also have differences in the ACOX gene 
promoter region relative to rodents that may lead to less effective PPAR-alpha activation 
even in the presence of native PPAR-alpha [23]. 
 
Fatty acids can be oxidized by omega oxidation, for long-chain fatty acids, and beta 
oxidation, for short to very long chain fatty acids [12].  Omega oxidation takes place in 
the endoplasmic reticulum by CYP4A enzymes and can be followed by peroxisomal beta 
oxidation or mitochondrial beta oxidation [12].  Humans can also perform alpha oxidation 
in the peroxisomes, releasing formyl-CoA in each round of oxidation rather than the 
acetyl-CoA produced by beta oxidation [12].  Based on the affinity of CPT1 for short-
chain fatty acids (e.g., C8 acyl-CoA), fatty acid oxidation of long chain fatty acids must 
occur prior to entry into the mitochondria.  Since, humans are less responsive to 
peroxisome proliferation than rats [20], humans generally conduct more beta oxidation in 
the mitochondria; whereas rats conduct generally more peroxisomal oxidation. 
 
Female rats are less sensitive than male rats to the hepatic steatosis effects of choline 
deficiency [24].  Female mice favor the PEMT pathway for PC production; whereas 
males favor the CDP pathway for PC production [25].  Estrogen upregulates hepatic 
PEMT expression and protein content in rats [26].  The increased usage of the PEMT 
pathway in females relative to males can decrease the effects of choline deficiency in 
females.   
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It is the balance of lipid uptake, catabolism, anabolism, and secretion that maintains 
appropriate energy homeostasis in cells.  Cellular lipid accumulation (i.e., steatosis) can 
only occur when the balance is shifted towards cellular lipid retention through increased 
uptake, increased anabolism, decreased catabolism, or decreased secretion or some 
combination thereof.  The potential for PFOS to affect the proper formation and secretion 
of VLDL particles was investigated.  If PFOS sequesters choline through a choline:PFOS 
ion complex causing decreased VLDL secretion, then that would alter this homeostasis 
leading to lipid accumulation.  Similarly, if PFOS upregulated key nuclear receptors to 
favor lipid uptake (i.e., PXR activation upregulating CD36), then that would alter lipid 
homeostasis and cause lipid accumulation.  The effects of PFOS on lipid homeostasis in 
the presence and absence of dietary choline supplementation were investigated. 
 
1.4  Sources of PFOS 
3M manufactured perfluorooctane sulfonyl fluoride (POSF), its derivatives, and PFOS as 
industrial intermediates and surfactants [27].  POSF can be reacted with methyl or ethyl 
amines, which can be further reacted to form functionalized perfluorooctanesulfonamido 
derivatives that were used in a wide variety of applications.  N-methyl- (2-
hydroxyethyl)perfluorooctanesulfonamide (N-Me-FOSE) and N-ethyl-N-(2-
hydroxyethyl)perfluorooctanesulfonamide (N-Et-FOSE) were major derivatives that were 
reacted to form various molecular structures.  POSF-derived fluorochemicals like these 
were used in multiple applications including carpet protection, food packaging, and fire 
extinguishing products [1].  These derivatives are considered the precursors of PFOS in 
the environment [27]. 
 
PFOS is a terminal metabolite of N-Et-FOSE and other POSF derivatives [28], such that 
once the metabolite is formed there are no known biochemical processes (e.g., 
biodegradability, hydrolysis, or photolysis) that can alter the structure of PFOS [27].  For 
example, [14C]PFOS was recovered unchanged in the liver of male CD rats at two- to 
three-weeks after intravenous injection of 3.5 mg/kg [14C]PFOS.  3M discontinued the 
production of POSF and related derivatives, including PFOS, by the end of 2002 based 
on evidence of widespread environmental distribution and persistence of PFOS [27]. 
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1.5  PFOS in the Environment 
The use of PFOS, N-Et-FOSE, and other POSF derivatives in such a wide variety of 
products led to the indirect release these chemicals to the environment during waste 
disposal and from industrial processes and products.  POSF derivatives are highly 
hydrophobic and readily taken up by organisms in the environment where they are 
metabolized to PFOS.  PFOS is tightly bound to serum proteins [29] and as such, it is 
not easily excreted.  As a result, PFOS has an elimination half-life of 30 to 50 days in 
rats [30], 200 days in cynomolgus monkeys [30], and 5.4 years in humans [31].  These 
factors suggest that body burdens of PFOS may accumulate in mammalian species 
following repeated exposures.  PFOS is then biomagnified through the food web with top 
predators (e.g., polar bears) accumulating concentrations of PFOS from their food 
sources [32-35].  As a result of its persistence and bioaccumulation properties, PFOS 
has spread worldwide and been identified in the blood and tissues of fish, birds, and 
other wildlife from Greenland [32, 33] to Antarctica [36].  The widespread environmental 
prevalence of PFOS and its bioaccumulation properties and environmental persistence 
led to it becoming listed as an Annex B (restricted) persistent organic pollutant by the 
Stockholm Convention [3].   
 
Efforts to control the release of PFOS and to reduce or eliminate the production of its 
precursors have been underway since 2001.  These efforts have correlated to 
decreasing PFOS concentrations in wildlife.  For example, a comparative study of PFOS 
in Greenland polar bear dams and cubs by Bytingsvik, et al. [32] showed that average 
PFOS plasma concentrations decreased in dams from approximately 450 ppb to 300 
ppb from 1998 to 2008 while cub average PFOS plasma concentrations remained 
relatively stable from approximately 380 ppb to 280 ppb over the same period.  Similarly, 
a prospective study by Rigét, et al. [37] showed that average PFOS liver concentrations 
peaked in ringed seals and polar bears in 2006 at 397 ppb and 2966 ppb, respectively, 
and decreased by 2010 to 16 ppb and 1248 ppb, respectively.  However, as production 
by 3M ended, production of PFOS and its precursor molecules began in China in 2002 
[38].  PFOS reached a peak production volume in China of 236 tons in 2006 and then 
decreased to a stable 100 tons/year from 2008 to 2012 [38].  Thus, the issue of PFOS in 
the environment may continue to be a concern for years to come. 
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1.6  PFOS and Human Exposure 
Human exposure to PFOS can occur through direct exposure to PFOS, or POSF derived 
materials that can be metabolized to PFOS, from environmental sources (e.g., food), 
commercial products, industrial products, and from occupational exposures prior to 2002 
[39].  The PFOS serum and liver body burden in humans has been an ongoing topic of 
research. 
 
In 1997, the average PFOS serum concentration in 3M workers at one production facility 
was 1,960 ppb with 95% of the tested workers having serum concentrations of ≤6,000 
ppb [5].  In 2000, the US general population had an average PFOS serum concentration 
of 34.9 ppb [40].  Similarly, in 2002, the Australian general population had an average 
PFOS serum concentration 25.9 ppb [41]. Similar to other mammals, humans 
accumulate PFOS primarily in the liver [42].  A review of paired human serum and liver 
samples by Olsen, et al. [43] showed that the mean PFOS liver to serum ratio in non-
occupationally exposed humans was 1.3:1, which was similar to the liver to serum ratios 
in monkeys that had 100-fold the serum concentrations of the human donors.  This 
makes the liver a potential target organ for toxic effects (see Sections 1.5 and 1.6 
below).     
 
Over time, PFOS serum concentrations have steadily decreased in all populations.  As 
of 2010, average PFOS serum concentrations in the general public have decreased to 
8.3 ppb in the US [40] and 10.2 ppb in Australia [41].  This decrease has generally 
conformed to the measured PFOS elimination half-life of 5.4 years in retired 
perfluorinated production workers reported by Olsen, et al. [31].  A steady decline in 
PFOS concentrations in humans is to be expected, since PFOS, and the precursors to 
PFOS, haven’t been manufactured in the US since 2002.  However, as previously 
stated, the production of perfluorinated precursors and PFOS in China will influence 
environmental exposures, the food web, and quite possibly PFOS serum concentrations 
in the general public in the future.   
 
1.7  PFOS and Serum Cholesterol Effects in Humans  
PFOS serum concentrations in the general public were measured as part of a cross-
sectional epidemiology study on perfluorooctanoic acid, i. e., the C8 Health Project [44].  
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Some studies have used the C8 Health Project data to suggest correlations between 
increased PFOS serum concentrations and increased serum concentrations of alanine 
aminotransferase (ALT) [45], serum total cholesterol [46], and non-high density 
lipoprotein cholesterol (non-HDL) [47].  However, these correlations are being disputed 
by Kerger, et al. [48] because the C8 Health Project is 1) cross-sectional, 2) the 
magnitude of mean serum cholesterol increases across the exposures was small (i. e., 
12 mg/dL), and 3) the lowest exposure quartile in the C8 Health Project had a lower 
prevalence of high cholesterol than the general US population, which may have biased 
the outcome towards an apparent dose-response where one does not actually exist. 
 
A four-year longitudinal study was performed by Fitz-Simon, et al. [49] by following-up 
with 560 subjects from the C8 cohort in 2010 who were not taking lipid lowering 
medications during the interim from 2006-2010.  Fitz-Simon, et al. showed these 
subjects had an overall 50% decrease in mean serum PFOS concentration with only a 
slight increase in mean serum LDL concentration (1.8 ± 26.6%).  Even with this apparent 
increase in mean LDL concentration following reduction in serum PFOS concentration, 
the authors suggested a trend that a greater decrease in serum PFOS concentration 
produced a greater decrease in serum LDL cholesterol whereby a subject with a 50% 
decrease in serum PFOS concentration would be predicted to have a 5% decrease in 
serum LDL concentration.  Fitz-Simon, et al. concluded that this longitudinal study 
supported the previous cross-sectional findings.  However, even if the proposed trend 
were an accurate reflection of the population, the toxicological relevance of a 5% 
decrease in mean serum cholesterol is questionable given that a controlled dietary 
intake can produce a 15% decrease in serum total cholesterol [50] and statin drug 
therapies can reduce serum LDL cholesterol by 25% to 60% [50].   
 
A two-year longitudinal study was performed by Olsen, et al. [51] using 179 workers who 
were demolishing perfluoroalkyl manufacturing facilities from 2008 to 2010 and were not 
taking lipid lowering medications.  Olsen, et al. showed no adverse associations 
between serum concentrations of PFOA, PFOS, non-HDL cholesterol, HDL, or hepatic 
clinical chemistries (i.e., ALT, aspartate aminotransferase (AST), alkaline phosphatase, 
and total bilirubin).  This study demonstrated that PFOS exposure did not lead to 
increased serum non-HDL cholesterol.   
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Based on a review of the longitudinal study data and the deficiencies noted in the cross-
sectional studies above, it is unlikely that there are adverse hepatic or cholesterol effects 
in humans at serum PFOS concentrations measured in the general population or 
workers.  Also, as described below, high serum PFOS concentrations in animals are 
associated with decreased serum cholesterol concentrations and hepatic lipid 
accumulation rather than increased serum cholesterol concentrations. 
 
1.8  PFOS and Hepatic Effects in Rats and Monkeys 
Goldenthal, et al. [52] demonstrated that PFOS caused hepatic vacuolation and 
hepatocellular hypertrophy in rats fed ≥100 ppm K+ PFOS in the diet for 90 days.  This 
result was further investigated by Seacat, et al. [7] who showed that dietary exposure of 
5 or 20 ppm K+ PFOS for 14 weeks in Sprague Dawley rats (5/sex/group) caused 
hepatic vacuolation, decreased serum total cholesterol, and/or increased serum ALT 
(Table 1).  No hepatic biomarker or histopathology changes were noted in rats fed the 
same diets for four weeks [7].   
 
Similarly, Curran, et al. [6] demonstrated that Sprague Dawley rats fed 50 or 100 ppm K+ 
PFOS in the diet had hepatic “cytoplasmic homogeneity,” decreased serum triglycerides 
(values not reported), and decreased serum cholesterol (Table 2).  Cytoplasmic 
homogeneity is generally caused by peroxisome proliferation or expansion of the smooth 
ER and can be associated with hepatocellular vacuolation.  Curran, et al. did not report 
hepatocellular vacuolation; however, it appears to be present in the rat fed 100 ppm 
K+PFOS in Figure 3B of the Curran, et al. publication [6].  Regardless, Curran, et al. [6] 
also reported changes in hepatic fatty acid profiles including increased total 
monounsaturated fatty acid and linoleic acid and decreased total polyunsaturated fatty 
acids and longer chain fatty acids.   These fatty acid changes are consistent with 
increased hepatic peroxisomal metabolism of long-chain fatty acids and possibly the 
accumulation of short-chain fatty acids.  PFOS is a known peroxisome proliferator and 
promotes omega oxidation in the endoplasmic reticulum and beta oxidation in the 
peroxisomes [53, 54].  The increased mRNA expression of cytochrome P450 4A22 
(CYP4A22), promoting omega oxidation, and acyl-coenzymeA oxidase 1 (ACOX1), 
promoting beta oxidation, reported by Curran, et al. [6] is supporting evidence for 
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peroxisome proliferation in this study.  Peroxisome proliferation increases oxidation of 
fatty acids and would not account for the lipid accumulation in this study. 
 
Additional support for hepatic lipid accumulation was shown by Seacat, et al. [8] in male 
and female cynomolgus monkeys (at least 4/sex/group) administered 0.75 mg/kg-day 
PFOS via daily oral gavage for 183 days.  Hepatocellular vacuolation was confirmed by 
scanning electron microscopy in the 0.75 mg/kg-day male and female groups on day 
183 (Figure 4).  This finding was not observed at the lower PFOS doses tested (i.e., 0.03 
or 0.15 mg/kg-day PFOS) or in the control group.  The vacuolation was reversed in the 
0.75 mg/kg-day group following 7 months of recovery.  Similar to the findings in rats, 
decreased serum total cholesterol and HDL cholesterol were also observed in this study 
(Table 3).  The recovery data support the conclusion that the observed hepatic 
vacuolation is not evidence of hepatocyte damage, but rather related to lipid metabolism 
and/or secretion. 
 
The potential for decreased lipid secretion following PFOS exposure was investigated by 
Bijland, et al. [55] in APOE*3-Leiden CETP mice.  Wild-type mice generally circulate 
almost all lipoproteins as HDL with lower concentrations of circulating VLDL and LDL 
relative to humans.  However, APOE*3-Leiden CETP mice have poor clearance of 
apoB-containing lipoproteins (e.g. LDL) and when fed a Western diet their serum 
lipoprotein profile becomes similar to a human lipoprotein profile with higher serum 
LDL/VLDL concentrations than HDL concentrations [56].  APOE*3-Leiden CETP mice 
(at least 6/group) were fed a Western diet with or without 30 ppm PFOS for 4- or 6-
weeks.  PFOS caused a marked decrease in plasma triglycerides (TG), HDL, and non-
HDL cholesterol.  The deceased very low density lipoprotein (VLDL) was caused mainly 
by decreased production of VLDL-TG and VLDL apolipoprotein B by as much as 80% in 
PFOS-treated animals relative to the control group.  The authors concluded that the 
decreased plasma VLDL was a result of decreased hepatic secretion. 
 
The findings in rats, mice, and monkeys clearly show that hepatic vacuolation is caused 
by repeated high-dose oral exposure to PFOS and it appears related to lipid 
accumulation.  Lipid accumulation is a result of changes in lipid anabolism, catabolism, 
or secretion. 
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1.9  Primary Hypothesis: PFOS forms an ion complex with choline causing a 
functional choline deficiency and thus hepatic lipid accumulation in rats 
A schematic for the hypotheses regarding PFOS interference with lipid metabolism 
leading to hepatic steatosis is provided in Figure 5.  Choline is an essential nutrient 
required for the proper formation and secretion of VLDL particles [57].  Rats fed a diet 
deficient in methionine and choline develop hepatic steatosis (i.e., lipid accumulation) at 
week 2, hepatic inflammation at week 5, and hepatic pericellular fibrosis that progresses 
from weeks 12 through 17 [58].  The intracellular vacuoles produced by choline 
deficiency in rats (Figure 6) appear similar to the vacuoles produced by PFOS exposure 
in monkeys (Figure 4).  In addition, these rats developed increased ALT and decreased 
VLDL secretion.  The methionine- and choline-deficient diets have been used for years 
to create hepatic steatosis in animal models [58-60].  The primary hypothesis is based 
on this mechanism whereby hepatic choline deficiency leads to hepatic steatosis. 
 
PFOS has been shown to create an ion complex with choline (Figure 7) in an in vitro 
methanol solution and in ex vivo liver samples [61].  PFOS was added to increasing 
concentrations of choline in methanol in vitro.  As the molar ratio of choline:PFOS 
increased, the LC/MS-MS detection of the free PFOS concentration decreased, which 
supports the hypothesis that PFOS is complexing with choline in vitro (Table 4).  PFOS 
also formed a complex with choline in a liver matrix ex vivo.  The complex was not 
detected initially at room temperature using LC/MS-MS; however, when the samples 
were incubated at 37°C for 48 hours the complex was detected in the sample.  It is 
possible that heating the matrix caused increased enzyme activity and released 
additional choline molecules into the matrix resulting in the formation of a stable ion 
complex.  The detection of this ion complex both in vitro and ex vivo supports the 
hypothesis that sufficiently high hepatic concentrations of PFOS could sequester choline 
in vivo leading to a functional choline deficiency and hepatic steatosis. 
 
The choline ion complex hypothesis was evaluated by a 3-week study in rats fed control 
diet or diet containing 120 ppm K+ PFOS (i.e., 100 ppm PFOS when accounting for salt 
and purity) both with and without choline supplementation (Chapter 3).  The choline 
supplementation dose was selected based on the NOAEL in a 4-week choline 
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supplementation rangefinder study in rats (Chapter 2).  The hypothesis was also 
evaluated by testing the potential for PFOS to inhibit choline kinase activity by 
sequestering choline in vitro (Chapter 3). 
 
1.10 Secondary hypothesis: PFOS activates nuclear receptors known to cause 
hepatic steatosis 
Peroxisome proliferator-activated receptor gamma (PPAR-gamma), constitutive 
androstane receptor (CAR) and PXR are nuclear receptors that have been implicated in 
the induction of hepatic steatosis [62-64].  The effects of PPAR-gamma and PXR are 
somewhat linked, because activated PXR upregulates PPAR-gamma mRNA production 
[65].  Rifampicin, a potent PXR agonist, has been known for decades to cause hepatic 
steatosis in rats  [66, 67] and humans [68].  PXR is a xenobiotic sensing nuclear 
receptor that, in addition to other functions, upregulates the Cd36 gene [69], and 
overexpression of CD36 leads to hepatic lipid accumulation and storage in mice [70].  If 
PFOS is an agonist of these nuclear receptors in vivo, it would be expected to cause 
hepatic steatosis. 
 
A four-week dietary study by Elcombe, et al. [71] showed that PFOS induced hepatic 
protein expression and activity of cytochrome P450 4A1 (CYP4A1), cytochrome P450 
2B1/2 (CYP2B1/2), and cytochrome P450 3A1 (CYP3A1) relative to the control group in 
male Sprague Dawley rats (10/timepoint/group) fed 20 ppm or 100 ppm PFOS in the diet 
for 1, 7, or 28 days.  CYP4A1, CYP2B1/2, and CYP3A1 were used as markers for the 
activation of the peroxisome proliferator-activated receptor alpha (PPAR-alpha), 
constitutive androstane receptor (CAR), and pregnane X receptor (PXR) nuclear 
receptors, respectively.  The mean increased activities induced in each PFOS group 
were lower than the increased activity caused by the positive controls used on the study 
(i.e., 50 ppm Wy 14,643 for CYP4A and 500 ppm phenobarbital for CYP2B1/2 and 
CYP3A1).  However, these data suggest that CAR or PXR activation may occur 
following PFOS dietary exposure in rats. 
 
Bjork, et al. [72] showed that 25 µM PFOS administered to primary rat hepatocytes 
upregulated mRNA production of CD36 (Table 5).  Multiple other genes were affected by 
PFOS administration in this study including genes that are downstream of PPAR-
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gamma, PXR, and CAR activation as well as liver X receptor alpha (LXR-alpha) and 
PPAR-alpha activation.  The mRNA profile in Bjork, et al. [72] demonstrates that the liver 
is under tremendous lipid metabolic stress as pathways for beta-peroxidation and lipid 
transport are both upregulated.  In addition, PFOS was identified as an agonist for 
human PXR, human CAR3, and mouse, rat, and human PPAR-alpha and PPAR-gamma 
in luciferase assays at concentrations of ≥100 µM [73, 74].   
 
The nuclear receptor activation hypothesis was tested by an evaluation of the hepatic 
mRNA profile for key genes (e.g., CD36) in the 3-week PFOS rat study and the potential 
for PFOS to activate rat PXR, CAR, LXR-beta, and PPPAR-gamma as well as human 
LXR-alpha was evaluated in a luciferase assay (Chapter 3).  
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Chapter 2: Investigation of Four-week Dietary Choline 
Supplementation in Sprague Dawley Rats 
 
2.1  Overview 
The following study was performed to investigate the maximum tolerated dose or no 
observed adverse effect level following four-week dietary choline supplementation in 
Sprague Dawley rats.  This rangefinder provided the information to select the 
appropriate choline supplementation level for the PFOS and choline supplemented study 
(Chapter 3).  This chapter has been submitted for publication. 
 
2.2  Synopsis 
Choline is an essential nutrient utilized for phosphatidylcholine biosynthesis, and 
lipoprotein packaging and secretion.  Recently, choline supplementation has been used 
by athletes and the public for weight loss.  However, the potential toxicological impact of 
high-level choline dietary supplementation has not been investigated since 1945.  This 
study examined the effects of choline dietary supplementation in Sprague Dawley rats 
for four weeks.  Rats were fed diets containing choline at basal levels (control, AIN-93G, 
2.5 mg choline bitartrate/kg diet) or 5, 10, or 15 times (5X, 10X, or 15X) the basal diet 
concentration.  In groups fed choline-supplemented diets, there were no toxicologically 
relevant findings in clinical observations, food intake, clinical chemistry, mean liver 
weights (absolute and relative), or liver histopathology.  However, decreased average 
body weights (8.5% to 10.2%) and body weight gains (24% to 31%) were noted for the 
10X choline-supplemented (females only) and 15X choline-supplemented (both sexes) 
groups relative to the control groups from day 3 onward.  These body weight effects 
were not related to a persistent reduction in average food intake and thus were 
considered evidence of a maximum tolerated dose.  Serum cholesterol was increased in 
the 15X choline supplemented male rats relative to the controls, an expected effect of 
choline supplementation; however, there were no changes in the serum cholesterol of 
female rats.  Serum choline concentrations were increased in female rats relative to the 
male rats without regard to the dietary concentration of choline.  Conclusion. The 
maximum tolerated dose for male and female rats were the 15X and 10X choline 
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supplements, respectively, based on decreased body weight and body weight gains.  
This study supported the conclusions of a clinical trial that showed a high choline diet 
can decrease body weight. 
 
2.3  Introduction 
Choline is an essential dietary nutrient found in leafy green vegetables, eggs, and meat 
[57].  It is a central molecule for the biosynthesis of phosphatidylcholine in the liver that 
is then used for cellular and organelle membranes as well as a surface molecule in 
lipoprotein packaging [19].  Recently, commercially available choline supplements have 
been used by individuals attempting to decrease body weight [75, 76].  However, there is 
limited information on the toxicity of dietary choline supplementation.  For example, the 
Institute of Medicine tolerable upper limit [77] was selected based on a single case 
report of hypotension following oral administration of 7500 mg/day choline for two weeks 
and vomiting, salivation, sweating, diarrhea, and fishy body odor at 16,000 mg/day 
choline for two weeks.  In 1998, the Institute of Medicine recommended additional 
animal studies to investigate increasing levels of dietary choline intake on organ systems 
including the liver [77].  Sahu, et al. [78] showed that intraperitoneal injections of 45, 150, 
or 225 mg/kg-day choline chloride to rats (corresponding to 0.1, 0.33, and 0.5 of the 
intraperitoneal LD50 in male rats, 450 mg/kg) for 5 days/week for 5 weeks (24 injections) 
caused decreased body weights in the 150 and 225 mg/kg-day groups relative to the 
control group that persisted through 26 weeks of recovery as well as splenic and thymic 
cellular depletion at 8 months. An additional group of rats was injected intraperitoneally 
with 150 mg/kg-day choline chloride for 8 weeks and at 6 months there were lymph node 
architecture changes, hyperreactive bronchiolar epithelium, and hepatic lymphocyte 
infiltration.  Sahu, et al. [78] also reported that some animals died during the course of 
the experiment, but the timing and conditions prior to death were not reported.  Recent 
rat studies have fed diets supplemented with up to 5 times the choline nutritional 
requirement in rat growth diets (750 mg choline/kg diet (0.075 %w/w) [79]) for 7 weeks 
[80] or 12 weeks [81] demonstrated no evidence of toxicity.  However, the potential for 
choline toxicity following dietary intake at higher levels than the recent studies has not 
been investigated in rats since 1945 [82], and that study had deficiencies that limit its 
utility.    
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In 1945, Hodge [82] studied the effect of feeding rats diets containing supplemental 
choline at 0.01, 1.0, 2.7, 5.0, and 10.0% by weight (w/w) for three to four months.    
Given that standard rodent growth diets, such as AIN-93G purified diet [83], contain 
0.1% w/w choline (1000 mg choline/kg diet), the diets used by Hodge contained choline 
at 0.1 to 100 times (0.1X to 100X) the concentration of choline in commercial rat diets.  
In diets supplemented with ≥2.7% w/w choline (27X), Hodge found that decreased body 
weight occurred with no reported change in liver weight or histology.  However, there 
were deficiencies in this study in that only limited descriptions of the study methods were 
provided, the study did not contain a basal diet control group, the number of rats was 
reported as 5/group with no indication of sex/group, and the strain of rats was not 
reported.  In addition, the range of low dose choline supplemented diets was too large, 
because there was only one group (i.e., 10X) between 0.1X and 27X choline supplement 
relative to a standard basal diet.   
 
Because the available toxicological dataset did not provide a good basis to understand 
the toxicological effects of choline dietary supplementation at moderate levels of 
exposure (e.g., up to 15X basal choline), the present study was undertaken to fill this 
gap in knowledge.  Briefly, rats were fed diets for four weeks with 5X, 10X, or 15X 
supplemental choline and effects were compared with rats fed the basal diet.  This 
investigation focused on histopathology and clinical chemistry effects on the liver, 
because liver is important for choline metabolism and lipoprotein production.  These data 
allowed determination of a maximum tolerated dose for choline dietary supplementation 
in rats and could be useful for assessing effects of human choline supplementation. 
 
2.4  Experimental Procedures 
2.4.1 Diets 
Modified pellet diets based on AIN-93G purified diet [83] were obtained from Harlan 
Teklad containing basal choline (control, 2.5 g choline bitartrate/kg diet, 0.1% w/w 
choline, catalog number TD.94045, lot 989904, undyed), 5X choline supplement (12.5 g 
choline bitartrate/kg diet, 0.57% w/w choline, catalog number TD.120403, lot 989912, 
red dyed), 10X choline supplement (25.0 g choline bitartrate/kg diet, 1.15% w/w choline, 
catalog number TD.120404, lot 989921, yellow dyed), and 15X choline supplement (37.5 
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g choline bitartrate/kg diet, 1.7% w/w choline, catalog number TD.120405, lot 989939, 
green dyed).  The diets are presented in Table 6.  The diets were color-coded by the 
vendor using food-grade dyes to aid appropriate dosing.  The amount of corn starch 
used in each choline supplemented diet was reduced to make up the weight-balance for 
the increased choline bitartrate.  Calculated diet caloric content was 3.8, 3.7, 3.7, and 
3.6 kcal/g for the control, 5X, 10X, and 15X diets, respectively.  These slight differences 
in caloric content were believed to have no potential to affect the study outcome.  All 
diets were stored at approximately 4°C during the study and used prior to the expiration 
dates per the vendor instructions.   
 
Diet homogeneity was verified by choline analysis at Covance Laboratories (Madison, 
WI) using a method adapted from AOAC Official Method 999.14 – Choline in infant 
formula and milk [84].   Briefly, three samples of each diet were obtained from the 
bottom, middle, and top of each container.  The diet samples were hydrolyzed at 70°C 
and, following pH adjustment to 3.75 ± 0.25 with sodium hydroxide or hydrochloric acid 
as appropriate,  treated with phospholipase D followed by choline oxidase to produce 
peroxide.  In the presence of peroxidase, phenol was oxidized and a chromophore was 
produced with 4-aminoantipyrine.  Absorbance of this chromophore at 505 nm was 
directly proportional to the choline content of the sample.  The lower limit of quantitation 
of this method was 0.0067% w/w choline in the diet, which was less than the lowest 
target dietary concentration in this study (i.e., 0.11% w/w, basal choline control group). 
 
2.4.2 Animal Selection and Husbandry 
This study was performed in a laboratory that is accredited by the International 
Association for the Accreditation of Laboratory Animal Care.  All procedures involving 
laboratory rats were reviewed and approved by the Institutional Animal Care and Use 
Committee associated with the facility in which the laboratory rats were housed. Animal 
care and procedures followed the U.S. Department of Health and Human Services 
guidelines (ILAR, 2010) and the “Guide for the Care and Use of Laboratory Animals” 
prepared by the National Academy of Sciences and published by the National Institutes 
of Health (NIH publication 86-23 revised 1985).  The study was performed under the 
supervision of an attending laboratory veterinarian who was available to evaluate the 
rats for pain and distress as needed.  Six- to eight-weeks-old adult Sprague Dawley rats 
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(23/sex) were obtained from Harlan Laboratories (Indianapolis, IN) at body weights 
ranging from 170.7 g to 193.9 g (males) and 134.0 g to 158.6 g (females).  The rats were 
individually housed in hanging wire cages in a dedicated animal room maintained at a 
temperature of 72  3F, relative humidity of 30-70%, with a minimum of 10 exchanges 
of room air per hour and a 12 hour light/dark cycle.  Cages were changed weekly.  Large 
marbles and Nylabone® chewables were provided to each rat as enrichment.  Tap water 
was available ad libitum throughout the study.  All rats were acclimated to the room 
conditions and fed an ad libitum basal diet for 7 days prior to randomization and the 
initiation of the study.  Five rats/sex were randomly assigned to the basal diet (control) 
and 6 rats/sex were randomly assigned to the 5X, 10X, and 15X choline supplemented 
groups.  There were no significant differences in the initial group mean body weights 
(Figures 8A and 8B).  Rats were fed the applicable control or experimental diet ad 
libitum for four weeks.   
 
2.4.3 In-Life Procedures 
Clinical observations, body weights, and food intake (accounting for spillage) were 
recorded daily.  Rats were fasted overnight prior to necropsy.  Fasted body weights were 
recorded on day 28.  All rats were euthanized on day 28 by carbon dioxide asphyxiation, 
and blood was collected in untreated Vacutainer® tubes by exsanguination via the 
abdominal aorta.  The collected blood was allowed to clot and was centrifuged at 1500 x 
g for 15 minutes at 10°C in an Avanti J30I centrifuge.  The serum was collected, 
transferred to tubes, and stored at -70°C until analysis for choline content and clinical 
chemistry parameters.  All euthanized rats were subjected to gross evaluation of all 
organs.  Liver weights were recorded.  Liver samples were collected from the right major 
lobe and left lateral lobe and fixed in neutral-buffered formalin for histopathology.   
 
2.4.4 Serum Choline Analysis 
For serum choline analysis, each standard (serial dilutions of trimethyl-d9-choline 
chloride, 5 ng/mL to 500 ng/mL, Sigma Aldrich, Catalog Number 492051-1G), blank 
(analytical grade water prepared by first passing deionized water through a Milli-Q® 
(Millipore Corporation, Billerica, MA, USA) water purification system with further 
processing through a C-18 HPLC column) and thawed rat serum sample were prepared 
as 100 µL of sample in 500 µL acetonitrile.  The samples were allowed to stand for 10 
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minutes and then were vortexed for 15 to 20 seconds.  An aliquot of 600 µL of 0.1N 
formic acid was added, and the solution was centrifuged at 3000 x g for 10 minutes.  The 
organic layer was transferred to an autovial and used for analysis.  Serum choline 
concentration was determined using a Sciex API 5000 mass spectrometer (Applied 
Biosystems / MDS-Sciex Instrument Corporation) with Turbo Ion Spray (pneumatically 
assisted electrospray ionization) in positive ion mode.  Separation was completed on a 
Phenomenex polar HPLC column (150 mm x 3.0 mm, 4 µm) with a gradient elution and 
a flow rate of 0.25 mL/min.  Buffer solutions of acetonitrile (Burdick and Jackson, distilled 
in glass grade, VWR) and 0.1N formic acid (J.T. Baker) were run with initial conditions of 
10% acetonitrile and 90% 0.1N formic acid and then the concentrations were adjusted to 
90% acetonitrile and 10% 0.1N formic acid with an analysis time of 11.0 min.  The 
transition ions were monitored at: 
Choline: 104 amu transitioned to 60 amu 
Choline Internal Standard (trimethyl-d9-labelled): 113 amu transitioned to 69 amu  
Quantitation was based on these transition ions.  Peak areas were integrated and the 
ratio of the compound to the internal standard was calculated.  The peak area ratio was 
plotted on the “Y” axis and the analyte concentration (ng/mL) was plotted on the “X” axis. 
 
Standard curves were evaluated with either a linear regression or quadratic equation 
model and reviewed for best fit.  All standards were weighted at 1/x for the regression 
analysis.  The lower limit of quantitation was assigned as the lowest standard value that 
was included on the regression fit of the standard curve.  The lower limit of quantitation 
for choline content analysis was 5 ng/mL (i.e., 5 ppb).  The quadratic regression R2 for 
the standard curve in this study was 0.9995. 
 
2.4.5 Clinical Chemistry 
Clinical chemistry analysis of the collected serum was performed by Marshfield Labs 
(Marshfield, WI).  Serum glucose, aspartate aminotransferase, alanine transaminase, 
gamma-glutamyl transferase, alkaline phosphatase, total bilirubin, direct bilirubin, 
indirect bilirubin, total cholesterol, HDL, LDL, TG, total protein, blood urea nitrogen, 
creatinine, phosphorus, calcium, sodium, potassium, chloride, bicarbonate, anion gap, 
creatine kinase, lactate dehydrogenase, amylase, lipase, albumin, globulin, 
albumin/globulin ratio, urea/creatinine ratio, and sodium/potassium ratio were all 
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measured using a Beckman Coulter AU 5800 Clinical Chemistry System (Brea, CA, 
USA).  
 
2.4.6 Histopathology  
Histopathology of the liver samples was performed by Charles River Laboratories, Inc. 
(Durham, NC).  Formalin-fixed liver samples were embedded in paraffin, 5 µm sections 
were cut using a microtome, and stained with hematoxylin and eosin for histopathology 
evaluation.  The hematoxylin and eosin stained slides were examined by a board-
certified veterinary pathologist using light microscopy.  Findings were scored for severity 
using a 0 to 4 scale (unremarkable, minimal, mild, moderate, and severe).  Flash-frozen 
samples were prepared from the formalin-fixed liver samples, 5 µm sections were cut 
using a microtome, and stained with Oil Red O for fat content evaluation.  The Oil Red 
O-stained samples were scored for the degree of fat accumulation using the same 0 to 4 
scale by the same board-certified veterinary pathologist.  
 
2.4.7 Statistical Analyses 
The in-life results were evaluated for statistical differences between groups within sex by 
one-way ANOVA with Tukey’s multiple comparisons test (GraphPad Prism®, v. 6.04).  
The potential for sex-related differences in choline intake and serum choline 
concentrations was evaluated by two-way ANOVA with Bonferroni’s multiple 
comparisons test (GraphPad Prism®, v. 6.04).  The measured choline diet 
concentrations were compared to target choline diet concentrations by one-sample t-
tests (GraphPad Prism®, v. 6.04). 
 
2.5 Results  
2.5.1 Clinical Signs 
No adverse, overt clinical signs were observed in any rat.  Green feces were noted in all 
rats in the 15X choline group from day 6 to day 28.  The green feces were similar in 
color to the green food-grade dye used in that diet and were not considered adverse.  
Although the 5X and 10X diets were red and yellow colored, respectively, no color 
change was observed in the feces of those groups.  Minor abrasions/scabs were noted 
sporadically throughout the study on the ventral neck region of one male and one female 
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rat of the 15X choline group (data not shown).  This was considered an incidental finding 
and was not choline supplement-related. 
 
2.5.2 Body Weights and Body Weight Gain 
Male rats in the 15X group had decreased mean daily body weight from day 3 through 
termination as compared to the control (8.5% - 10.2%), 5X (5.9% - 7.9%), and 10X 
(4.8% - 7.0%) groups (Figure 8A).  There were no effects on mean daily body weight of 
male rats in the 5X and 10X group as compared to the controls.  Female rats in the 15X 
group had decreased mean daily body weight (10.3% – 12.8%) from day 3 through 
termination as compared to the control group (Figure 8B).  The female 5X and 10X body 
weights were not different from the control group throughout the study with the exception 
of day 18, where the 10X group was decreased by 9% relative to the control group.  
There were no significant body weight differences between the female 5X, 10X, and 15X 
choline supplemented groups on any day.   
 
The mean weekly body weight gain in male rats was decreased in the 15X choline group 
in weeks 1 and 2 (56% and 16%, respectively) relative to the control group and was 
decreased relative to the 5X and 10X groups as well (Figure 8C).  There were no other 
differences between the male groups during weeks 1 through 4.  Mean overall body 
weight gain for males during the study was significantly decreased in the 15X group by 
26% relative to the control group.  The mean overall body weight gains in the male 5X 
and 10X groups were not different from the male control group or each other.  In week 1, 
mean female body weight gains were decreased in the 10X and 15X groups (45% and 
66%, respectively) relative to the control group (Figure 8D).  In week 2, mean female 
body weight gain in the 15X group was decreased by 33% relative to the control group.  
The female body weight gains for the 5X group was similar to the control group 
throughout the study.  There were no differences in body weight gain on weeks 3 and 4 
for female rats of any group.  Overall body weight gain was significantly decreased in the 
female 10X and 15X groups relative to the control group (24% and 31%, respectively) 
with no significant differences between the female choline supplemented groups (Figure 
8D).  
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2.5.3 Food Intake  
Mean food intake was decreased in male rats of the 10X group (26% decrease) and the 
15X group (up to 39% decrease) relative to the control group and/or the 5X group until 
day 5 (Figure 9A).  In addition, mean food intake was decreased in female rats of the 
10X group (19% decrease relative to the 5X group) and the 15X group (up to 40% 
decrease relative to all groups) until day 5 (Figure 9B).  From day 5 onward, there were 
no differences in food intake for any group of either sex.  
 
2.5.4 Dietary Choline Concentration  
The mean choline concentrations were within 7% of target concentrations with the 
exception of the control diet, where the mean choline concentration was 18% greater 
than the target concentration (Table 7).  The measured values were similar to the target 
concentrations for each diet by one-tailed t-test (p>0.05).  The coefficient of variation 
(CV) among the 3 samples for each diet was less than 8%, which indicated that the diets 
were homogenous (Table 7).      
 
2.5.5 Choline Intake 
Mean daily choline intake over the entire study for the control, 5X, 10X, and 15X groups, 
respectively, was approximately 99, 434, 868, and 1168 mg/kg-day for males and 107, 
468, 922, and 1273 mg/kg-day for females (data not shown).  The 10X and 15X females 
had increased intake relative to the corresponding male groups by 6% and 9%, 
respectively.  This increase was not considered biologically relevant. 
 
2.5.6 Serum Choline Concentrations 
A sex-related increase in mean serum choline concentration was observed without 
regard to choline supplement status (Figure 10).  All female groups had increased mean 
serum choline concentrations relative to the similarly treated male group.  There were no 
differences in mean serum choline concentrations between any control or choline 
supplemented groups of the same sex. 
 
2.5.7 Clinical Chemistry  
Blood for clinical chemistry analysis could not be obtained from two females in the 10X 
choline group because of technical difficulties during blood collection.  Blood was 
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successfully collected from all other rats. The remaining four females in the 10X choline 
group provided sufficient data for evaluation of this group’s clinical chemistry response. 
 
Most clinical chemistry parameters were within the historical reference ranges for rats 
reported by Marshfield Labs [85].  Incidental significant differences in mean serum total 
cholesterol, HDL, creatinine, urea/creatinine ratio, and albumin values that at times 
exceeded the historical control ranges were noted for male and/or female rats fed up to 
15X choline in the diet (Table 8 and Supplemental Tables 1 and 2).  There were no other 
significant differences in any other clinical chemistry parameters for either sex including 
all parameters that would be correlated with potential liver toxicity (i.e., alanine 
aminotransferase, aspartate aminotransferase, alkaline phosphatase, bilirubin (total, 
indirect and direct), gamma-glutamyl transferase, or triglycerides).  None of the 
significantly different parameters were considered toxicologically relevant. 
 
Mean serum total cholesterol was significantly increased in the male 15X rats relative to 
the control group and the 10X group and exceeded the reference range by 14%.  The 
increase was influenced by a significant increase in mean serum HDL in male 15X rats 
relative to the control and 5X groups; although, this increase in serum HDL did not 
exceed the historical control range.  There were no significant differences in female 
serum total cholesterol concentrations.  Female serum HDL was significantly increased 
in the 5X and 10X groups; however, this increase was within the reference range and 
the lack of an increase in the 15X female rats suggested that this was not a treatment-
related effect.  The increased serum total cholesterol in male rats was not considered 
toxicologically relevant because it was influenced by elevated HDL cholesterol levels. 
 
Mean serum creatinine values appeared similar across all groups for males (0.3 mg/dL) 
and females (0.3 to 0.4 mg/dL).  However, there was a greater incidence of 0.2 mg/dL 
creatinine values in the groups that were indicated as statistically significantly different 
from the control group (i.e., 10X males and 15X males and females).  However, this 
minor difference was not toxicologically relevant, because it was within the historical 
reference range [85]. 
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Mean serum urea/creatinine ratio was significantly increased in the male 15X rats 
relative to the control group and exceeded the reference range by 9.5%.  There were no 
significant differences in this parameter for the female rats.  Based on the CV of the 15X 
male value (15%), the creatinine values being within the reference range, and the lack of 
a significant increase in blood urea nitrogen, the increased male mean serum 
urea/creatinine ratio likely is caused by individual animal variability and was not 
considered toxicologically relevant. 
 
Mean serum albumin was decreased in the 15X female group.  This decrease was within 
the historical control range and was not considered toxicologically relevant.  There were 
no differences in the albumin/globulin ratio which supports this conclusion. 
 
2.5.8 Terminal Fasted Body Weights and Absolute and Relative Liver Weights 
The 15X group fasted body weights were significantly decreased by 10% to 13% relative 
to the control group (both sexes) and/or the 5X group (males only) (Table 9).  Liver 
weight was significantly decreased by 13% in the male 15X group relative to the control 
group.  There were no significant differences in the liver weight of females or liver-to-
body weight ratios of both sexes for any choline supplemented group. 
 
2.5.9 Histopathology 
Liver histopathology findings in all choline supplemented groups were similar to the 
control groups (Table 10) with the exception of minimal hepatocellular hypertrophy that 
was observed in 2 of 6 of the 15X choline males and 1 of 6 of the 10X choline females.  
No other histopathology changes or correlative clinical pathology changes (i.e., 
increased alanine aminotransferase) were noted, thus this finding was considered 
adaptive and not adverse based on the approach proposed by Hall, et al. [86].  Minimal 
inflammation was observed in the control and 5X groups (both sexes) and one male of 
the 10X group, but was absent in the 15X group.  However, this findings was only 
present in a small portion of each section examined and was considered incidental.  Oil 
Red O staining showed no clear changes in fat content in males and females across the 
treatment groups (Table 10); however, there was a trend towards decreased amount of 
fat content correlated to increasing choline supplementation across the groups.   
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2.6 Discussion 
The main effects of choline supplementation were decreased body weight and body 
weight gain in the 10X (females only) and 15X (both sexes) groups.  This effect may 
have been influenced by an acute reduction in dietary intake for these groups from study 
initiation through day 5.  However, there was no subsequent increase in dietary intake 
during the remainder of the study.  Also, there was no indication that the body weights 
were normalizing to control levels over the course of the study.  Mean daily body weights 
were decreased by 8.5% to 10.2% in the 15X male rats and by 10.3% to 12.8% in the 
15X female rats from day 3 to day 28. Body weight gain over the study was decreased 
by 24% in the 10X female rats and by 26% and 31% in the 15X male and female rats, 
respectively.  A 10% decrease in body weight gain in a 90-day study is considered a 
maximum tolerated dose [87].  Thus, the body weight changes in the present study were 
considered suggestive of a maximum tolerated dose.   
 
The decreased body weights in the present study are generally consistent with the data 
presented by Hodge [82].  In the Hodge [82] study, after one month on the choline 
supplemented diets, the 10X group had no apparent changes in body weight or body 
weight gain, the 27X group had a 20% decrease in body weight, the 50X group had a 
50% decrease in body weight, and the 100X group had a 67% decrease in body weight 
relative to the 0.1X group.  Hodge [82] maintained the rats on the diets for up to four 
months and showed that the rats of the 27X, 50X, and 100X groups did not recover to 
body weights similar to the 0.1X group.  This lack of body weight recovery was also 
observed in the present study where the 10X (females only) and the 15X (both sexes) 
did not attain control body weight levels at the end of the four-week study.  When 
considered with the results from Hodge [82], the results in the present study 
demonstrate that, even at lower choline supplement concentrations, there is a clear 
dose-dependent correlation between decreased body weight and choline 
supplementation.   
 
There was no evidence of adverse effects on the liver of male or female rats based on 
the results for multiple clinical chemistry parameters (e.g., alanine transaminase, 
aspartate aminotransferase, alkaline phosphatase, bilirubin, triglycerides, etc.), average 
liver weights, and liver histopathology.  Similarly, Hodge [82] reported no treatment-
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related histopathology findings in the liver.  Mean serum total cholesterol was increased 
in the male 15X group and exceeded the reference range.  Increased serum cholesterol 
is expected in the presence of a high choline diet based on the well-known importance of 
choline for phosphatidylcholine formation and cholesterol packaging [17, 59, 88, 89].  It 
is likely that the increased availability of choline led to an increase in phosphatidylcholine 
production and thus increased lipoprotein packaging and secretion in the liver.  This is 
supported by the trend of decreased hepatic lipid content, as shown by Oil Red O 
staining, correlated to increased choline supplementation.  However, the lack of 
significant differences in serum cholesterol concentrations in female rats suggests a 
difference in choline handling in female rats relative to the male rats. 
 
Baseline serum choline concentrations were higher in female rats relative to male rats 
(Figure 10).  There were no differences between treatment groups within each sex.  The 
sex-related difference may indicate a greater choline reservoir in female rats.  In 
considering potential mechanisms for this observation, one could speculate that females 
have a higher capacity for choline storage and production.  Possible evidence for this is 
that females of multiple species have been shown to more readily mobilize choline when 
fed choline deprivation diets.  For example, female mice can mobilize choline from 
extrahepatic tissue in response to choline deprivation [19].  Similarly, when humans 
were fed a choline-deficient diet for up to 42 days, 77% of men and 80% of 
postmenopausal women developed a choline deficient phenotype (i.e., fatty liver and/or 
muscle damage) while only 44% of premenopausal women had this phenotype [90].  
This suggests that females have a greater capacity than males to address choline 
deprivation and the serum choline results in this study would point to a larger 
homeostatic serum choline reservoir in female rats than male rats.  In addition, estrogen 
increases phosphatidylethanolamine-N-methyltransferase activity, the key enzyme in the 
conversion of phosphatidylethanolamine to phosphatidylcholine [26, 91].  
Phospholipases can cleave the phosphatidylcholine and generate choline [19].  Estrogen 
status may be an explanation for the increased serum choline concentrations in females 
in this study.  However, a sex-related difference in serum choline has not been reported 
in humans [92] and given the limited dataset in rats, the observed difference may be a 
species-specific effect and warrants further investigation. 
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The choline intakes in this study (i.e., 434 to 1273 mg/kg-day across all choline 
supplemented groups) greatly exceed the Institute of Medicine tolerable upper limit [77] 
in humans (i.e., 3500 mg/day or 60 mg/kg-day in a 58-kg woman, a standard body 
weight according to ISO 10993-17:2002 [93]).  However, even at these high intakes 
there were no clinical signs of toxicity or liver morphology changes and the main effect 
was body weight changes.  Elsawy, et al. [75] showed that administration of 2500 
mg/day choline to 10-12 female martial artists/group for one week caused approximately 
a 10.2% decrease in body fat vs. 4% decrease for the control group (placebo) and a 
12.2% decrease in body mass index vs. 7.9% decrease for the control group.  Data from 
the present study indicate that choline dietary supplementation up to 15X basal levels 
can result in decreased body weight with no adverse effects on the liver in rats which 
would support the findings by Elsawy, et al. [75]. 
 
In the absence of other clear toxicological effects, the decreased body weight and body 
weight gains, although not necessarily adverse, were considered treatment related and 
evidence of a maximum tolerated dose at 10X (females) and 15X (males) of the basal 
dietary levels.  These levels can be used to guide future research in which dietary 
choline supplementation is part of the experimental procedure.  
 
2.7  Conclusion 
The 5X choline supplemented diet was selected for use in the PFOS and choline 
supplemented study (Chapter 3), because there were no effects on mean body weights 
or body weight gain in male and female rats fed this diet. 
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Chapter 3: Investigation of the Proposed Mechanisms for 
Hepatic Steatosis Induction in Sprague Dawley Rats 
Following PFOS Exposure  
 
3.1  Overview 
The potential for choline dietary supplementation to attenuate PFOS-induced hepatic 
steatosis in male rats was investigated in the following manuscript that will be submitted 
for publication.  The potential for PFOS to inhibit the activity of choline kinase was 
investigated in vitro.  Additionally, the potential for PFOS to cause hepatic steatosis 
through a nuclear receptor-mediated pathway was investigated as a secondary 
hypothesis.  One key finding of this work was that 100 ppm PFOS in the diet induced 
hepatic steatosis in male rats, but did not induce hepatic steatosis in female rats even 
while the serum and liver PFOS concentrations were similar between the sexes. 
 
3.2  Synopsis 
PFOS is an environmentally persistent chemical.  Dietary 100 ppm PFOS fed to male 
mice and rats for four weeks caused hepatic steatosis, but the mechanism of this effect 
is unknown.  Choline deficient diets can cause similar hepatic steatotic effects.  A 
hepatic choline:PFOS ion complex has been hypothesized to mediate this effect in mice.  
This study tested the hypothesis that dietary choline supplementation can attenuate 
PFOS-induced hepatic steatosis in rats.  Sprague Dawley rats (12/sex/group) were fed 
control, choline supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + choline 
supplemented (PFOS + CS) diets for three weeks.  Male rats fed both PFOS-containing 
diets had decreased serum cholesterol (total, HDL, and LDL) and triglycerides (TG) on 
days 9, 16, and/or 23 and hepatic steatosis at termination (increased hepatic free fatty 
acids (FFA) and TG).  Female rats fed both PFOS diets had decreased serum total 
cholesterol and LDL on days 9 and 16 and decreased hepatic FFA and TG at 
termination.  Liver PFOS concentrations were similar for male and female rats fed both 
PFOS diets.  Liver choline concentrations were increased in male rats fed both PFOS 
diets, but the increase was lower in the PFOS + CS group.  Female liver choline 
concentrations were not altered by any diet.  These findings demonstrate a clear sex-
related difference in PFOS-induced hepatic steatosis in the rat.  Additional mechanisms 
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evaluated (i.e., nuclear receptor activation, mRNA upregulation, and choline kinase 
activity inhibition) did not appear to influence hepatic steatosis.  Conclusion.  Dietary 
PFOS at 100 ppm induced hepatic steatosis in male, but not female, rats that was not 
attenuated by choline supplementation at this dose level.  The mechanism of lipid 
accumulation and the sex-related differences warrant further investigation.  
 
3.3 Introduction 
PFOS is a fully-fluorinated eight-carbon molecule that is bioaccumulative in rats [30], 
monkeys [30], and humans [31] and is environmentally persistent [3].  Studies have 
shown that dietary exposures of 100 ppm PFOS in mice [94] and rats [6] for four weeks 
causes hepatic subcellular vacuolation that may indicate lipid accumulation (i.e., hepatic 
steatosis).  This level of PFOS exposure causes serum concentrations (e.g., 400 to 600 
ppm[94]) that are >30-fold relative to even the highest measured human occupational 
serum values in 1999 (approximately 12.8 ppm [5]) and 50,000-fold the general US 
population serum values in 2010 (0.008 ppm [40]).  However, the mechanism for hepatic 
steatosis induction in rats following high PFOS dietary exposure has not been 
established and warrants investigation because of the public concern for widespread 
human exposure to PFOS.   
 
One common method for inducing hepatic steatosis in animal models is the use of 
methionine-choline deficient diets [58].  Choline deficiency does not occur under normal 
feeding states, because standard laboratory rat diets are formulated with sufficient 
choline and human diets generally contain sufficient choline from leafy greens.  
However, feeding methionine-choline deficient diets to rats causes hepatic steatosis by 
week 2 that progresses to hepatic inflammation by week 5 [58] and is thus a suitable 
model to study hepatic steatosis.  Choline deficiency reduces the available 
phosphatidylcholine for very low density lipoprotein (VLDL) packaging, thus reducing 
VLDL secretion and increasing hepatic lipid retention.  These findings are consistent with 
the “hepatic cytoplasmic homogeneity,” decreased serum cholesterol, and decreased 
serum triglycerides reported by Curran, et al. [6] following 100 ppm PFOS dietary 
exposure for four weeks in Sprague Dawley rats.  Curran, et al. reported “cytoplasmic 
homogeneity,” but did not report hepatocellular vacuolation, which is apparent in the liver 
of a rat fed 100 ppm PFOS (Figure 3B of that publication).  A recent study [94] showed 
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that male mice that were fed 120 ppm K+PFOS (i.e., approximately 100 ppm PFOS 
accounting for salt and purity) in a minimal methionine-choline deficient diet had an 
exacerbated hepatic steatotic phenotype relative to male mice that were fed the minimal 
methionine-choline deficient diet alone.  In addition, the results of that study [94] 
supported the hypothesis of the formation of a hepatic choline-PFOS ion complex 
causing a functional choline deficiency as a putative mechanism that could produce the 
observed hepatic steatosis in mice.   
 
To further investigate this hypothesis, male and female Sprague Dawley rats were fed 
basal diet (control), choline supplemented diet (CS), 100 ppm PFOS diet (PFOS), or 100 
ppm PFOS with choline supplement (PFOS + CS) for three weeks to investigate the 
potential for choline supplementation to reverse or attenuate the lipid accumulation.  The 
choline supplement concentration was selected based on the results of a four-week 
choline supplement study in Sprague Dawley rats [95].  In addition, we investigated: 1) 
whether key liver mRNA transcripts involved in lipid accumulation (e.g., CD36) were 
upregulated in the PFOS-exposed rats, 2) whether PFOS can activate key nuclear 
receptors in vitro that promote lipid accumulation (e.g., pregnane X receptor (PXR)), and 
3) whether PFOS can directly inhibit choline kinase activity in vitro, because choline 
kinase converts choline to phosphocholine which is the rate-limiting step in the 
anabolism of phosphatidylcholine from choline.  
 
3.4 Experimental Procedures 
3.4.1 PFOS 
The PFOS used in this study was potassium perfluorooctanesulfonate salt (CASRN 
2795-39-3, K+PFOS, lot 217, purity 86.9%) obtained from 3M Company (St. Paul, MN).  
A detailed list of the impurities in this lot was presented by Seacat, et al. [8]. 
 
3.4.2 Diets 
AIN-93G diets were obtained from Dyets, Inc. (Bethlehem, PA) containing basal choline 
(control, 4.2 g choline bitartrate/kg diet, 1700 ppm choline, catalog number d510176, lot 
3183-2), choline supplemented (choline supplemented diet (CS), 12.5 g choline 
bitartrate/kg diet, 5125 ppm choline, catalog number d510201, lot 3183-3), basal choline 
with 100 ppm PFOS (100 ppm PFOS, 4.2 g choline bitartrate/kg with 120 ppm K+PFOS 
 32 
diet, 1700 ppm choline, catalog number d510179, lot 3183-4), and choline supplemented 
with 100 ppm PFOS (PFOS + CS, 12.5 g choline bitartrate/kg with 120 ppm K+PFOS 
diet, 5125 ppm choline, catalog number d510202, lot 3183-5).  The final dietary 
concentration of 100 ppm PFOS accounted for the potassium salt and purity.  The 
amount of sucrose used in each applicable diet was reduced to account for the weight-
balance of the increased choline bitartrate and/or added PFOS.  The caloric content of 
each diet was 3.9 kcal/g.  All diets were stored at approximately 4°C during the study 
and used prior to the expiration dates per the vendor instructions.   
 
Dietary choline concentrations were verified by choline analysis at Covance Laboratories 
(Madison, WI) using a method adapted from AOAC Official Method 999.14 – Choline in 
infant formula and milk [84].   Briefly, six samples of each diet were obtained from the 
bottom, middle, and top of each container.  The diet samples were hydrolyzed at 70°C 
and, following pH adjustment to 3.75 ± 0.25 with NaOH or HCl as appropriate,  treated 
with phospholipase D followed by choline oxidase to produce peroxide.  In the presence 
of peroxidase, phenol was oxidized, and a chromophore was produced with 4-
aminoantipyrine.  Absorbance of this chromophore at 505 nm was directly related back 
to the choline content of the sample.  The lower limit of quantitation of this method was 
67 ppm choline in the diet.  Diet PFOS concentrations were verified using a previously 
described LC-MS/MS procedure [96].  
 
3.4.3 Animal Selection and Husbandry 
This study was performed in a laboratory that is accredited by the International 
Association for the Accreditation of Laboratory Animal Care.  All procedures involving 
laboratory rats were reviewed and approved by the Institutional Animal Care and Use 
Committee associated with the facility in which the laboratory rats were housed. Animal 
care and procedures followed the U.S. Department of Health and Human Services 
guidelines (ILAR, 2010) and the “Guide for the Care and Use of Laboratory Animals” 
prepared by the National Academy of Sciences and published by the National Institutes 
of Health (NIH publication 86-23 revised 1985).  The study was performed under the 
supervision of an attending laboratory veterinarian.   
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Six- to eight-weeks-old adult Sprague Dawley rats (48/sex) were obtained from Harlan 
Laboratories (Indianapolis, IN) at body weights ranging from 223.9 to 258.0 g (males) 
and 144.1 to 175.6 g (females).  The rats were individually housed in hanging wire cages 
in a dedicated animal room maintained at a temperature of 72  3F, relative humidity of 
30-70%, with a minimum of 10 exchanges of room air per hour and a 12-hour light/dark 
cycle.  Room light intensity was maintained at or below 500 lumens during the study.  
Cages were changed weekly.  Large marbles and Nylabone® chewables were provided 
to each rat as enrichment.  Tap water was available ad libitum throughout the study.  All 
rats were acclimated to the room conditions and fed an ad libitum basal diet for 7 days 
prior to randomization and the initiation of the study.  Twelve rats/sex were randomly 
assigned to the basal diet (control), choline supplemented diet (CS), 100 ppm PFOS diet 
(PFOS), and 100 ppm PFOS with choline supplement diet (PFOS + CS) groups.  There 
were no significant differences in the initial group mean body weights (data not 
provided).  Rats were fed the applicable diet ad libitum for three weeks.   
 
3.4.4 In-Life Procedures 
Clinical observations, body weights, and food intake (accounting for spillage) were 
measured daily.  Blood was collected in plain Vacutainer® tubes (without anti-coagulant) 
via the jugular vein of non-fasted rats on days 2, 9 and 16.  Rats were fasted overnight 
prior to necropsy.  Fasted body weights were recorded on day 23.  All rats were 
euthanized on day 23 by CO2 asphyxiation, and blood was collected in plain 
Vacutainer® tubes by exsanguination via the abdominal aorta.  The collected blood was 
allowed to clot and was centrifuged at 1500 x g for 15 minutes at 10°C in an Avanti J30I 
centrifuge.  The resulting serum was collected, transferred to labelled tubes, and stored 
at -70°C until analysis for PFOS content, choline content, and clinical chemistry 
parameters.  All euthanized rats were subjected to gross evaluation of all organs.  Liver 
weights were recorded.  Liver samples were collected from the right median lobe and left 
lateral lobe and fixed in neutral-buffered formalin for histopathology.  Flash frozen liver 
samples were collected for: 1) hepatic PFOS concentration analysis; 2) hepatic 
cholesterol, triglyceride, and free fatty acid content; and 3) hepatic mRNA content 
analysis (collected in RNALater®, Applied Biosystems).  The flash frozen liver samples 
were stored at -70°C until analysis. 
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3.4.5 Serum and Liver Choline Analysis 
Serum choline concentrations were measured using a method described in Bagley, et al. 
[95].  In brief, thawed rat serum samples were prepared at a 1:6 dilution in acetonitrile, 
0.1N formic acid was added, and the solution was centrifuged at 3000 x g for 10 
minutes.  The organic layer was removed and stored at -70 °C until analysis. 
 
The liver samples were prepared for choline concentration analysis using a modification 
of the method described by Holm, et al. [97].  The frozen liver samples were prepared at 
1:6 in acetonitrile and allowed to thaw for approximately 5 minutes.  The samples were 
homogenized in tubes containing ceramic beads using a Precellys® Evolution tissue 
homogenizer (Bertin Instruments) set for 10 cycles of 20 seconds each at 8000 rpm with 
a 30 second pause between cycles.  The resulting homogenate was centrifuged at 5800 
x g for two minutes, and the supernatant was collected and stored at -70 °C until 
analysis. 
 
The prepared liver or serum samples were run on an acetonitrile gradient using a Sciex 
API 5000 mass spectrometer (Applied Biosystems / MDS-Sciex Instrument Corporation) 
with Turbo Ion Spray (pneumatically assisted electrospray ionization) in positive ion 
mode.  Separation was completed on a Phenomenex polar HPLC column (150 mm x 3.0 
mm, 4 µm).  The transition ions were monitored at: 
Choline: 104 amu transitioned to 60 amu 
Choline Internal Standard (trimethyl-d9-labelled): 113 amu transitioned to 69 amu  
The lower limit of quantitation for choline content analysis was 5 ng/mL (i.e., 5 ppb).  The 
quadratic regression R2 for the standard curve in this study was 0.9995. 
 
3.4.6 Serum and Liver PFOS Concentration Analyses 
Serum and liver PFOS concentrations were determined by LC-MS/MS using previously 
described methods [30]. 
 
3.4.7 Clinical Chemistry 
Clinical chemistry analyses of the collected serum from day 2, 9, 16, and 23 were 
performed by Marshfield Labs (Marshfield, WI).  All serum was evaluated for glucose, 
aspartate aminotransferase, alanine transaminase, gamma-glutamyl transferase, 
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alkaline phosphatase, total bilirubin, direct bilirubin, indirect bilirubin, total cholesterol, 
high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides, total protein, 
blood urea nitrogen, creatinine, phosphorus, calcium, sodium, potassium, chloride, 
bicarbonate, anion gap, creatine kinase, lactate dehydrogenase, amylase, lipase, 
albumin, globulin, albumin/globulin ratio, urea/creatinine ratio, and sodium/potassium 
ratio using a Beckman Coulter AU 5800 Clinical Chemistry System (Brea, CA, USA).   
 
3.4.8 Histopathology  
Histopathology of the liver samples was performed by Charles River Laboratories 
(Durham, NC).  Formalin-fixed liver was embedded in paraffin; 5 µm sections were cut 
using a microtome and stained with hematoxylin and eosin for histopathology evaluation.  
The hematoxylin and eosin slides were examined by a board-certified veterinary 
pathologist using light microscopy.  Findings were scored for severity using a 0 to 4 
scale (unremarkable, minimal, mild, moderate, and severe).  Two sets of flash-frozen 
samples were prepared from the formalin-fixed liver samples; 5 µm sections were cut 
using a microtome and stained with Oil Red O or osmium tetroxide for fat content 
evaluation.  The Oil Red O-, osmium tetroxide-, and hematoxylin and eosin-stained 
samples were scanned at 20X magnification using a Hamamatsu NanoZoomer® whole 
slide scanner.  Morphometric analysis was performed using the Visiopharm® software 
platform[98] with 40% of the entire tissue section sampled by systematic uniform random 
sampling.  Morphometric results are presented as the percent of the sampled area that 
was stained.   
 
3.4.9 Liver Total Free Fatty Acids, Cholesterol, and Triglyceride Analyses 
The total free fatty acids, cholesterol, and triglyceride concentrations in each flash frozen 
liver sample were analyzed by Charles River Research Animal Diagnostics Services 
(Wilmington, MA) using the Wako HR Series NEFA-HR(2) fatty acid ELISA, Wako Total 
Cholesterol ELISA kit, and the Wako Triglycerides Microtiter Assay kit (Wako 
Diagnostics, Mountain View, CA).  The protein content of each flash frozen liver sample 
was determined by bicinchoninic acid assay (PierceTM, BCA Protein Assay Kit, Rockford, 
IL).  
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3.4.10 mRNA Analyses  
Flash frozen liver samples were selected for mRNA analyses from rats (4/sex/group) 
that were fed the control and PFOS only diets.  To select this subset of rats, the osmium 
tetroxide lipid content results for each group were stratified into quartiles and one 
member of each quartile was randomly selected for mRNA analysis to reduce the 
potential for lipid content bias to influence the mRNA results.  The CS and PFOS + CS 
groups were not analyzed for mRNA production. 
 
Tissue homogenization, RNA isolation, and reverse transcription PCR were performed 
using methods described in Bjork, et al. [72].  In brief, flash frozen liver samples (0.5 cm 
long) were added to 1.5 mL of DNase stock solution (RNase-Free DNase Set, Qiagen, 
CA) that was diluted 1:8 with the Qiagen proprietary buffer (RLT) that contained 10 
µL/mL beta-mercaptoethanol.  The tissue was homogenized using an UltraTurrax T25.  
The homogenate was centrifuged on a Qiashredder column (Qiagen, CA, catalog 
number 79654) for one minute at 9600 x g and then transferred to an equal volume of 
50% ethanol.  Then, 650 µL of the solution was transferred to RNeasy mini-columns 
(Qiagen, CA), centrifuged for one minute at 8000 x g, and the mRNA was isolated using 
the RNEasy Minikit (Qiagen, CA).  The resulting RNA was quantified using a NanoDrop 
ND-1000 (Thermo Fischer Scientific, Watham, MA).  Reverse transcription was 
performed with the Omniscript RT kit (Qiagen, CA), nine random primers (IDT, Coralville, 
IA) and approximately 1.0 µg RNA per liver sample.  The resulting cDNA was stored at -
20°C until quantitative PCR was performed. 
 
Primers were designed for Rattus norvegicus enoyl-CoA hydratase and 3-hydroxyacyl 
CoA dehydrogenase (Ehhadh), stearoyl-CoA desaturase (Scd1), Rattus norvegicus 
CD36 molecule (Cd36), cell death-inducing DFFA-like effector c (fat-specific protein, 
Fsp27), and glutathione S-transferase theta 1, transcript variant X2 (Gsst1) as shown in 
Supplemental Table 3.  These rat genes were selected because the proteins they 
produce are important for oxidative stress response (GSST1) and lipid synthesis 
(SCD1), beta-oxidation (EHHADH), and transport (FSP27 and CD36).  The primers were 
designed using the Primer-BLAST interface [99] to produce a product with ≤250 base 
pairs; inclusion of at least one intron, when possible; a target melting temperature of 
60°C; and less than one degree of difference in melting temperature between the 
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forward and reverse strands.  The cDNA from the liver samples was exposed to the 
primers and quantitative PCR was performed with a Roche LightCycler and Sybr Green 
Master mix kit (Roche Applied Science, Indianapolis IN).  DNA standards were prepared 
using previously described methods [100] and the results for each primer were 
compared to the results for the 18s subunit to determine the fold-change for a given 
mRNA. 
 
3.4.11 In Vitro Nuclear Receptor Activation Analyses 
A luciferase reporter cell assay was performed by Indigo Biosciences (State College, 
PA) using HEK 293 cells transfected with plasmid hybrids for rat constitutive androstane 
receptor (CAR, NR1I3) or rat pregnane X receptor (PXR, NR1I2) and Chinese hamster 
ovary cells transfected with plasmid hybrids for human liver X receptor alpha (LXR-
alpha, NR1H3), rat liver X receptor beta (LXR-beta, NR1H3), or mouse/rat peroxisome 
proliferator-activated receptor gamma (PPAR-gamma, NR1C3).  All of the plasmids 
contained a yeast Gal4 N-terminal DNA binding domain and the reporter gene, firefly 
luciferase, was linked to the Gal4 upstream sequence.  Cytotoxicity potential was 
assessed using the Indigo Biosciences Live Cell Multiplex assay.  Cells were treated in 
triplicate with 0.1% DMSO (vehicle) or 0.4, 1.3, 3.7, 11.1, 33.3, or 100 µM PFOS for a 
24-hour exposure.  Gene-specific reference positive controls were provided by Indigo 
Biosciences and were used to validate each test.  The rat constitutive androstane 
receptor test was an inverse-agonist test to evaluate the potential for activation and 
inhibition, while the other reporter assays were performed as agonist assays. 
 
3.4.12 In Vitro Choline Kinase Activity 
The potential for PFOS to inhibit choline kinase enzyme activity was evaluated in 
recombinant human choline kinase alpha variant 1 (Abcam, accession number P35790), 
human choline kinase alpha variant 2 (OriGene, accession number NP_997634), and 
human choline kinase beta (R&D Systems, accession number Q9Y259).  Inhibition 
potential was measured using the NADH-coupled choline kinase assay described by 
Trousil, et al.[101].  In brief, the choline kinase reaction was coupled to a pyruvate-
NADH reaction as shown below and the production of NAD+ was calculated by 
measuring the depletion of NADH absorbance at 340 nm: 
Choline + ATP   –Choline Kinase →  Phosphocholine + ADP 
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ADP + Phosphoenolpyruvate –Pyruvate Kinase →  Pyruvate + ATP 
Pyruvate + NADH   –Lactate Dehydrogenase →  Lactate + NAD+ 
All reagents, pyruvate kinase (lyophilized powder), and lactate dehydrogenase 
(lyophilized powder) were obtained at the highest purity available from Sigma Aldrich.  
Triplicate wells received 400 µM PFOS in 10% DMSO, the highest soluble PFOS 
concentration, and choline concentrations from 2 µM to 1000 µM for a 15-minute 
exposure (choline kinase alpha variant 1 and choline kinase beta) or a 40-minute 
exposure (choline kinase alpha variant 2) that was in the linear region of NADH 
reduction for each enzyme.  The absorbance at 340 nm was measured and the resulting 
data were converted to a velocity of NAD+ formation in pmole/ng protein/min.  The 
concentration of PFOS in the dosing preparations was confirmed by LC/MS-MS using a 
previously described method [96].  The results of three independent experiments for 
each enzyme were collated.  
 
3.4.13 Statistical Analyses 
The in-life results were evaluated for statistical differences between groups within sex by 
one-way ANOVA with Tukey’s multiple comparisons test (GraphPad Prism®, v. 6.04).  
The potential for sex-related differences in serum and liver choline and PFOS 
concentrations were evaluated by two-way ANOVA with Bonferroni’s multiple 
comparisons test (GraphPad Prism®, v. 6.04).  The measured choline and PFOS diet 
concentrations were compared to the target choline and PFOS diet concentrations by 
one-sample t-tests (GraphPad Prism®, v. 6.04).  The PFOS concentration in the PFOS 
diet was compared to the PFOS concentration in the PFOS + CS diet by two-sample t-
test (GraphPad Prism®, v. 6.04). 
 
3.5 Results  
3.5.1 Clinical Signs 
No adverse clinical signs were observed in the control or CS groups of either sex of rats.  
Both male and female rats that were fed PFOS (+/- CS) were sensitive to light (i.e., 
repeated squinting and vocalization) from day 17 to termination (three to five of 12 in 
each sex).  One female was hyper-reactive to touch on day 22, and one male had 
shaking, tremors, and running into the cage sides on day 23.  All rats survived to 
scheduled necropsy.  Minor abrasions/scabs were noted sporadically throughout the 
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study across groups (data not provided).  The observed sensitivity to light, hyper-
reactivity, and seizures have been previously observed in rats at the same dietary PFOS 
dose after approximately four weeks of exposure in longer-term studies [52].  
 
3.5.2 Body Weights and Body Weight Gains 
Male mean body weights were decreased in the PFOS + CS group (5.1 – 8.7%) relative 
to the control group from day 9 through termination (Figure 11A).  Female mean body 
weights were decreased in the PFOS (6.2 – 12.9%) and the PFOS + CS (5.7 – 11.9%) 
groups relative to the control group starting on day 9 and day 11, respectively, through 
termination (Figure 11B).  There were no other differences in mean body weights among 
the groups for either sex.   
 
The mean body weight gains of the male and female CS groups were similar to their 
respective control groups throughout the study (Figure 11C and 11D).  Decreased mean 
body weight gains were noted in both the male and female PFOS and PFOS + CS 
groups relative to the control groups across the study.  For the males, the largest 
decreases relative to the control group were noted in Week 1 (PFOS: 26%, PFOS + CS: 
38%) and Week 3 (PFOS: 24%, PFOS + CS: 47%).  For the females, the largest 
decrease relative to the control group occurred in Week 3 (PFOS: 80%, PFOS + CS: 
81%).  There were no differences between the PFOS and PFOS + CS groups for either 
sex at any timepoint. 
 
3.5.3 Food Intake 
There were no differences in mean daily food intake among the groups for male or 
female rats throughout the study (Figures 11E and 11F). 
 
3.5.4 Dietary Choline and PFOS Concentrations  
The mean choline and PFOS concentrations were similar to the target concentrations for 
each diet with the exception of the PFOS diet, which was significantly less than the 
target concentration (Supplemental Table 4).  However, the PFOS concentrations in the 
PFOS and PFOS + CS diets were similar to each other.  The CV among the 6 samples 
for each diet was less than 13%, which indicated that the diets were homogenous 
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(Supplemental Table 4).  The diets had acceptable choline concentrations, PFOS 
concentrations, and homogeneity for use in the study. 
 
3.5.5 Choline and PFOS Intake 
Mean daily choline intake for the control, CS, PFOS, and PFOS + CS groups, 
respectively, was approximately 107, 330, 102, and 307 mg/kg-day for male rats and 
123, 375, 112, and 318 mg/kg-day for female rats (data not shown).  Mean daily PFOS 
intake for both the PFOS and PFOS + CS groups was approximately 6 mg/kg-day for 
male rats and 6.6 mg/kg-day for female rats.  Mean daily PFOS intake for the control 
and CS groups was not calculated because the diets contained less than 0.05 ppm 
PFOS (Supplemental Table 4). 
 
3.5.6 Serum Choline and PFOS Concentrations 
Non-fasted male and female mean serum choline concentrations ranged from 4 ppm to 
9 ppm for all groups with the exception of the male CS group on day 9 (Figure 12A and 
12B).  However, the male CS group day 9 mean was influenced by four rats with 14 to 
16 ppm serum choline concentrations that may have been caused by food intake shortly 
prior to blood collection.  The female groups had statistically significantly decreased 
mean serum choline concentrations relative to the male groups for all groups on day 9 
and the CS groups on day 16; however, the magnitude of these differences was small 
and was not considered biologically relevant.   On day 23, the mean serum choline 
concentration of the fasted male PFOS + CS group was increased relative to all other 
male groups.    Also on day 23, the mean serum choline concentration of the fasted 
female PFOS group was decreased relative to the control group.  Sex-related 
differences were noted in the fasted female control and CS groups on day 23 where 
mean serum choline values were increased by 57% and 76%, respectively, relative to 
the male groups.   
 
All serum PFOS concentrations of the control and CS animals were below the limit of 
quantitation (5 ppb).  Mean serum PFOS concentrations in the PFOS and PFOS + CS 
groups increased throughout the study with no differences between the groups by sex at 
any timepoint (Figures 12C and 12D).  Mean serum PFOS concentrations in female rats 
were higher than the respective male groups on days 9, 16, and 23 (Figure 12D).   
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3.5.7 Liver Choline and PFOS Concentrations 
Mean choline concentrations were increased in the male PFOS and PFOS + CS groups 
relative to the control group (Figure 12E).  The male rats fed PFOS + CS had decreased 
liver choline concentrations relative to the PFOS group, but the concentrations were not 
decreased to the control or CS group levels.  The CV for the male PFOS and PFOS + 
CS group mean liver choline concentrations were high (57% and 68%, respectively).  
However, the mean values of the male PFOS and PFOS + CS groups were much 
greater than the mean values for the male control and CS groups (10-fold and 5-fold, 
respectively).  Although there is a high degree of variability in these data, the magnitude 
of the differences between the male groups suggests that these data are accurate and 
not an artifact of the methods. There were no differences in female liver choline 
concentrations among the four treatment groups.   
 
All liver PFOS concentrations of the control and CS animals were below the limit of 
quantitation (0.05 ppm).  Mean liver PFOS concentrations were similar between the 
PFOS and PFOS + CS groups.  There was no difference between sexes (Figure 12F). 
 
3.5.8 Clinical Chemistry  
Most clinical chemistry parameters were within the historical reference ranges for rats 
reported by Marshfield Labs [85].  Selected clinical chemistry results are presented in 
Table 11 and the complete clinical chemistry results are presented in Supplemental 
Tables 5 – 12.   Some incidental statistically significant differences were noted in liver 
(i. e., aspartate aminotransferase, alanine transaminase, alkaline phosphatase, bilirubin 
(total, indirect and direct), gamma-glutamyl transferase), kidney (i.e., blood urea 
nitrogen, creatinine, urea/creatinine ratio, albumin, globulin, and albumin/globulin ratio), 
and pancreas clinical chemistry biomarkers (i.e., amylase) of male and/or female rats 
across the evaluated timepoints, but these values were within the historical reference 
ranges and were not considered toxicologically relevant. 
 
Mean serum total cholesterol, LDL, and HDL values were decreased on days 9, 16, and 
23 in male rats that were fed the PFOS and PFOS +CS diets relative to the control and 
CS groups (Table 11).  In addition, mean serum triglyceride values were decreased on 
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days 16 and 23 in male rats that were fed PFOS and PFOS + CS relative to the control 
group (Table 11).  Male rats that were fed the CS diet had increased mean serum total 
cholesterol relative to the control group on days 9 and 16, but this effect was not 
observed in fasted rats on day 23.  Mean serum total cholesterol and HDL values were 
decreased on days 9 and 16 in female rats that were fed the PFOS and PFOS + CS 
diets relative to the control and/or CS groups.  These effects were not noted in the fasted 
female rats on day 23.  There were no differences in mean serum triglyceride or LDL 
values for the female PFOS or PFOS + CS groups relative to the control group at any 
timepoint.  Lastly, there were no differences in serum cholesterol (total, HDL or LDL) or 
triglycerides values between the PFOS and PFOS + CS groups of either sex at any 
timepoint. 
 
Mean serum lactate dehydrogenase and lipase were consistently decreased for male 
and female rats that were fed PFOS and PFOS + CS relative to the control and/or CS 
groups on days 2, 9, and 16 (Table 11).  On day 23, mean serum lactate dehydrogenase 
was increased in the male PFOS and PFOS + CS groups relative to the CS group, but 
there was no difference relative to the control group.  Also, on day 23, mean serum 
lipase was decreased in the male PFOS and PFOS + CS groups relative to the control 
and CS groups.  There were no significant differences in mean serum lactate 
dehydrogenase and lipase on day 23.  While increased serum lactate dehydrogenase 
and lipase are associated with pancreatic effects [102, 103], decreased serum lactate 
dehydrogenase and lipase have no toxicological relevance and therefore are not 
considered adverse.  This conclusion is supported by the lack of differences in mean 
serum amylase values. 
 
 
3.5.9 Terminal Fasted Body Weights and Absolute and Relative Liver Weights 
There were no differences between the control and CS groups (both sexes) in mean 
fasted body weights, liver weights, or liver-to-body weight ratios (Table 12).  There were 
also no differences between the PFOS and PFOS + CS groups (both sexes) for these 
parameters.  Mean fasted body weights were decreased by 13% to 14% in the PFOS 
(females only) and by 7% to 14% in the PFOS + CS group (both sexes) relative to the 
control group and CS group.   Mean absolute liver weights were increased by 28% to 
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33% in female rats that were fed PFOS or PFOS + CS and by 65% to 75% in male rats 
that were fed PFOS or PFOS + CS relative to the control and CS groups.  Similarly, 
mean liver-to-body weight ratios were increased in both the PFOS and PFOS + CS 
groups (both sexes) relative to the control and CS groups.  These liver weight increases 
are consistent with the known hepatomegaly effects of PFOS in rats [6, 71, 104], and the 
choline supplemented diet did not alter or reverse this PFOS effect. 
 
3.5.10 Histopathology 
Liver histology of male and female rats that were fed the CS diet were similar to the 
control diet (Supplemental Table 13).  Liver histopathology findings were related to 
PFOS exposure and were not clearly influenced by choline supplement in the PFOS + 
CS group (Supplemental Table 13).  Representative hematoxylin and eosin-, Oil Red O-, 
and osmium tetroxide-stained liver sections from each group are presented in Figures 
13, 14, and 15, respectively.  Male rats that were fed the PFOS and PFOS + CS diets 
had ground-glass cytoplasmic alterations, which are consistent with the known 
peroxisome proliferation effects of PFOS in rats [6, 71, 104].  This ground-glass 
cytoplasm finding was not observed in female rats.  A small incidence of minimal to 
moderate microscopic hepatic necrosis was noted in male and female rats that were fed 
PFOS and PFOS + CS.  A qualitative difference in hepatocellular hypertrophy incidence 
and severity was noted between rats that were fed PFOS relative to rats that were fed 
PFOS + CS; however, this difference was not supported by the morphological evaluation 
of hypertrophy (Table 13).  Lipid content was increased in male rats that were fed PFOS 
and PFOS + CS relative to the control and CS groups in both the Oil Red O- and 
osmium tetroxide-stained morphological analyses (Table 13).  There were no 
reproducible differences in lipid content between the female groups when the results of 
both the Oil Red O- and osmium tetroxide-staining were considered. 
 
3.5.11 Liver Free Fatty Acids (FFA), Cholesterol, and Triglyceride (TG) 
Concentrations  
Mean hepatic FFA, cholesterol, and TG concentrations were similar between the control 
and choline supplemented groups for males and females (Figure 16 A – F).  There were 
no differences in hepatic cholesterol concentrations for any group.  Mean hepatic FFA 
and TG concentrations were increased in male rats that were fed the PFOS and PFOS + 
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CS diets without regard to choline supplement status.  However, mean hepatic FFA and 
TG concentrations were decreased in female rats that were fed the PFOS and PFOS + 
CS diets again without regard to choline supplement status.  Choline supplementation 
did not alter hepatic FFA or TG concentrations in male or female rats that were fed diets 
containing PFOS. 
 
3.5.12 mRNA Analyses 
Ehhadh was upregulated 3.7-fold in male rats and 4.1-fold in female rats that were fed 
PFOS relative to the control groups (Supplemental Table 14).  Scd1 was upregulated 9-
fold in female rats that were fed PFOS relative to the control group.  All other mRNA 
expression fold-changes in the PFOS groups were less than 2.5-fold and were not 
significantly different from the control groups. 
 
3.5.13 In Vitro Nuclear Receptor Activation 
PFOS did not activate rat LXR-beta, human LXR-alpha, or rat PXR at concentrations up 
to 100 µM (Supplemental Table 15).  PFOS was a mouse/rat PPAR-gamma agonist at 
the 100 µM concentration only.  The rat CAR inverse agonist assay did not show any 
clear dose-related activation or inhibition of CAR.  No cytotoxicity was observed at any 
concentration in any test. 
 
3.5.14 In Vitro Choline Kinase Activity Analysis 
Based on a review of the Vmax and Km for all three forms of choline kinase, PFOS did 
not inhibit choline kinase in vitro (Figure 17).  The Vmax of the control-treated choline 
kinase beta used in this assay was 6- to 8-fold lower than the choline kinase alpha 
variants. 
 
3.6  Discussion 
Based on the results of this study, male rats that were fed 100 ppm PFOS in the diet for 
three weeks had hepatic steatosis that was not attenuated by increased dietary choline.  
Zhang, et al. [94] showed that 100 ppm PFOS in the diet could exacerbate the hepatic 
lipid accumulation caused by a minimal methionine-choline deficient diet in male mice 
and demonstrated the potential for a hepatic PFOS:choline-ion complex.  Supplemental 
dietary choline prevented PFOS-induced hepatic lipid alterations in metabolism and 
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hepatic oxidative stress in male mice at 30 ppm PFOS in the diet [94].  However, in this 
study, a similar choline supplemented diet did not attenuate the PFOS-induced lipid 
accumulation in male rats fed 100 ppm PFOS in the diet.  The differences between 
these studies may indicate that at lower PFOS exposures there is a hepatic molar ratio 
of PFOS:choline that allows choline supplementation to decrease the hepatic steatotic 
effects that becomes overwhelmed at higher PFOS exposures.  Some additional support 
for this hypothesis is the hepatic choline concentrations in this study. The hepatic 
steatosis observed in male rats fed both PFOS diets occurred in the presence of 
increased hepatic choline concentrations.  Male rats fed PFOS + CS diet had decreased 
hepatic choline concentrations relative to the PFOS group, but it did not approach 
control or CS group levels and there were no differences in serum cholesterol or hepatic 
steatotic status.  Female rats fed both PFOS diets did not have hepatic steatosis or 
increased hepatic choline concentrations.  Taken together, these data suggest that there 
is a relationship between hepatic choline concentrations and the induction of hepatic 
steatosis caused by PFOS exposure.  This may be evidence for the hypothesis that in 
vivo hepatic choline accumulation resulted in a functional choline deficiency and led to 
hepatic steatosis in PFOS-exposed male rats. 
 
The PFOS-induced hepatic steatosis in this study was sex-related with no evidence of 
hepatic steatosis occurring in female rats based on the hepatic FFA and TG 
concentrations as well as the Oil Red O and osmium tetroxide staining morphometric 
results.  These findings occurred at similar hepatic PFOS concentrations in males and 
females, approximately 600 ppm, and were thus not related to hepatic PFOS 
concentration.  Scd1 mRNA was upregulated in the female PFOS group; however, this 
would suggest greater FFA synthesis in the PFOS females relative to the control and 
there was no difference in Scd1 mRNA content between males and females that were 
fed the PFOS diet.  Female primary rat hepatocytes have been shown to be more 
efficient than male hepatocytes at both oleate [105] and palmitate [106] influx.  This 
would suggest that females should have higher hepatic lipid concentrations than males 
under PFOS exposure conditions.  However, the increased efficiency of female hepatic 
cytosolic fatty acid binding protein [105] may result in a greater mobilization of lipid to 
VLDL that would then be secreted to the blood and taken up by the adipose tissue.  
Fasted female rats of the control and choline supplemented groups had increased mean 
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serum choline concentrations relative to the male rats in this study, and in our previous 
work on choline dietary supplementation in rats [95], and may be evidence that females 
are mobilizing VLDL more efficiently than males.  In addition, liver choline concentrations 
were not increased in female rats fed either PFOS-containing diet suggesting that 
female rats utilized the available choline, possibly through VLDL secretion, and 
maintained hepatic choline steady-state levels.  Also, there were no differences in 
female serum LDL and triglyceride concentrations of the PFOS groups relative to the 
control group in this study, which supports this proposed mechanism.  Relative adiposity 
was not measured in this study, but it is a potential explanation for the mobilization of 
hepatic lipid in females and deserves further study.   
 
Albino rats prefer cages with lower light intensity (<100 lux) relative to cages with light 
intensities of 100 to 380 lux [107].  Schlingmann, et al. [108] recommended a minimum 
light intensity of 210 lux at working height to improve performance of the animal care 
personnel.  In this study, the light intensity within the hanging wire cages was 
approximately 0 lux; however, during handling the rats were exposed to light intensities 
of approximately 360 – 500 lux.  This rapid change in light intensity while taking the rat 
from the cage into the room light may have contributed to the observations of light 
sensitivity in the PFOS and PFOS + CS groups. 
 
Activation of nuclear receptors (i.e., CAR, PXR, LXR-alpha, LXR-beta, and PPAR-
gamma) involved in lipid accumulation and upregulation of mRNA of enzymes involved 
in lipid metabolism (i.e., Scd1, Cd36, and Fsp27) and oxidative stress response (i.e., 
Gsst1) were investigated as potential mechanisms for PFOS-induced hepatic steatosis.  
While PFOS was a weak PPAR-gamma agonist at 100 µM in vitro, there were no other 
clear effects on nuclear receptors known to promote lipid accumulation.  In addition, 
mRNA for Scd1, Cd36, Fsp27, and Gsst1 were not upregulated in male rats.  Scd1 was 
upregulated 9-fold in female rats that were fed the PFOS diet relative to the control 
group; however, there was no lipid accumulation in female rats so the relevance of this 
finding is unclear.  Ehhadh was upregulated in both sexes, which was expected given 
the role EHHADH protein plays in peroxisomal oxidation and previous findings in vitro 
where PFOS upregulated Ehhadh mRNA in primary rat hepatocytes [72].  Taken 
together, these findings suggest that PFOS-induced hepatic steatosis in male rats is not 
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driven by activation of these nuclear receptors or through upregulation of mRNA 
involved in key hepatic steatosis pathways.  Recent studies have indicated a PXR 
agonist potential for PFOS in vitro on human PXR [109] and in vivo in mice [55] and rats 
[71, 104]; however, the luciferase data in the present study do not support the notion that 
PFOS directly activates rat PXR.. 
 
The potential for direct inhibition of choline kinase was investigated as a potential 
disruption of the first step in phosphatidylcholine synthesis.  No effects were observed 
on the activity of human choline kinase alpha (variant 1 or 2) or human choline kinase 
beta.  Rat choline kinases were not available for evaluation.  However, the rat and 
human variants of these enzymes are >85% homologous, and the differences are not 
located in the ATP or choline binding sites, so it is unlikely that there would be any 
differences in outcome if the rat choline kinase enzymes had been evaluated.  Based on 
the results in this study, PFOS does not directly inhibit choline kinase in vitro at relative 
PFOS:choline molar concentrations up to 200:1. 
 
3.7 Conclusion 
In conclusion, dietary exposure of rats to 100 ppm PFOS for three weeks caused sex-
related hepatic steatosis in males that was not attenuated by choline supplementation.     
These effects were not produced through nuclear receptor activation, upregulation of 
hepatic steatosis-promoting mRNA, or direct inhibition of choline kinase alpha-1, alpha-
2, or beta.  The sex related differences in hepatic steatosis phenotype observed in this 
study should be examined in greater detail.   
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Chapter 4: Conclusions from the Investigations 
 
These studies clearly demonstrated that 100 ppm PFOS in the diet induced hepatic 
steatosis in male, but not female, rats and that this effect was not prevented by choline 
supplementation.  The differential hepatic steatotic phenotype was typified by increased 
hepatic TG and free fatty acids and decreased serum TG, total cholesterol, and LDL in 
male rats with no observed effects on these endpoints in female rats.  This occurred at 
similar hepatic PFOS concentrations in both sexes.  These findings suggest a sex-
related difference in lipid handling whereby females are not affected by PFOS and 
continue to mobilize hepatic lipid to the serum where males do not mobilize the hepatic 
lipid. 
 
Interestingly, there was also a sex-related difference in serum choline concentrations 
under fasted conditions observed across the studies (Chapters 2 and 3) and in liver 
choline in the PFOS + CS study (Chapter 3).  In the choline supplement range finding 
study (Chapter 2), it was clear that fasted female rats had consistently higher serum 
choline concentrations than fasted male rats regardless of choline dietary intake.  This 
sex-related effect was also observed in the PFOS + CS study (Chapter 3) under fasted 
conditions at termination, but was not present under non-fasted conditions during the 
study.  In addition, the mean liver choline concentrations in male rats fed 100 ppm PFOS 
and 100 ppm PFOS + CS were approximately 4-fold higher than the mean liver choline 
concentrations in similarly fed female rats.  These findings support the hypothesis that 
female rats mobilize phosphatidylcholine and lipid more efficiently from the liver during 
fasted conditions than male rats. 
 
Direct choline kinase inhibition and nuclear receptor activation potential were evaluated 
as potential mechanisms for the PFOS-induced hepatic steatosis.  Based on the choline 
kinase activity data (Chapter 3), PFOS does not inhibit choline kinase activity in vitro at 
the limits of PFOS solubility (400 µM).  In addition, PFOS also did not induce the CAR, 
PXR, or LXR nuclear receptors in the luciferase assay.  PFOS weakly induced PPAR-
gamma at 100 µM in the luciferase assay.  The mRNA for oxidative stress response 
(Gsst1) and lipid desaturation (Scd1) and transport (Fsp27 and Cd36) were not 
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upregulated in the male rats fed 100 ppm PFOS in the diet (Chapter 3).  Rather, Scd1 
mRNA transcripts were upregulated in the female rats fed the PFOS diet for three 
weeks.  It is possible that the upregulation of Scd1 in the females indicates continued 
throughput in the production of TG (Figure 3).   
 
There are published data that support the potential for PFOS to activate PXR.   Bijland, 
et al. [55] showed that PFOS increased PXR and Cyp3a11 expression and decreased 
Cyp7a1 expression, typical findings following PXR activation, in APOE*3-Leiden CETP 
mice fed 30 ppm PFOS in a Western diet for 4 to 6 weeks.  In addition, increased liver 
CYP3A1 protein content, a marker of PXR activation, was shown in two studies by 
Elcombe, et al. [71, 104] using Sprague-Dawley rats fed 20 or 100 ppm PFOS in the diet 
for 1, 7, or 28 days.  A recent study [109] indicated that 30 µM PFOS could activate 
human PXR (32-fold activity increase relative to the negative control) in a luciferase 
reporter assay using transfected HepG2 cells.  However, in this study, the luciferase 
assay showed no evidence of activation of rat PXR at concentrations up to 100 µM 
PFOS (Chapter 3).   However, rat PXR only shares 79% identity with human PXR [110] 
and this structural difference has been suggested as the source of rat and human 
differences in CYP3A induction [110, 111], which may account for the difference 
between the luciferase assays.  Also, the rat PXR luciferase assay does not fully 
represent the in vivo condition where PFOS is present in the liver for the duration of a 
given study (e.g., up to 6 weeks).  The study in Chapter 3 did not include analysis of 
mRNA or protein content of PXR, CYP3A11 or CYP7A11.  Thus, the secondary 
hypothesis regarding PXR nuclear receptor activation cannot be fully excluded by the 
data collected in this project. 
 
Zhang, et al. [94] identified the PFOS:choline ion pair in chemico (i.e., 10 µM PFOS and 
10 µM choline in 60% acetonitrile containing 10 mM ammonium acetate) using a Waters 
G2S quadrupole time of flight mass spectrometer operating in ESI+ with tandem MS.  
This result was similar to the previous Exygen data (Figure 7).  The LC-MS/MS methods 
used for the liver PFOS and choline concentrations in rats (Chapter 3) detected only the 
free substances, in part because the 3M method is more energetic than the Zhang et al. 
method and disrupts the ion complex.  However, during the course of this project, we 
attempted to locate the choline:PFOS ion complex in liver samples using multiple 
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methods including the Zhang et al. [94] equipment and NMR; however, the complex 
could not be located in liver tissue.  It is possible that the wide variety of materials 
available for PFOS and/or choline binding in liver tissue decreased the presence of the 
ion complex such that it could not be detected.   
 
Zhang, et al. [94] showed that choline supplementation could reduce the oxidative stress 
induced by PFOS exposure in male mice at a lower PFOS dietary concentration (i.e., 30 
ppm) than the 100 ppm PFOS concentration used in Chapter 3.  In addition, Zhang, et 
al. [94] fed male C57BL/6 mice (5-6/group) either a control diet (i.e., diet containing 3.0 g 
L-methionine/kg diet and 4.2 g choline bitartrate/kg diet) or a marginal choline-
methionine deficient diet (mMCD) (i.e., diet containing 0.009 g L-methionine/kg diet and 
0.012 g choline bitartrate/kg diet) with or without 30, 60 or 120 ppm K+PFOS for 21 or 23 
days (two replicate experiments).  In that study, two mice in the 120 ppm group were 
euthanized moribund in the first replicate between day 21 and 23 and one mouse in the 
120 ppm group was euthanized on day 21 in the second replicate.   As expected, the 
mMCD diet exacerbated the hepatic effects of PFOS (i.e., increased serum ALT, bile 
acids, and total bilirubin).  The mean liver concentration of PFOS was decreased in the 
mice fed the 120 ppm PFOS + mMCD diet relative to the 120 ppm PFOS + control diet.  
The mean serum concentration of PFOS was increased for all of the PFOS groups in 
mice fed the mMCD diet relative to the correlated control diet groups.  These serum and 
liver concentrations indicate that PFOS accumulated in the liver to a greater extent in the 
presence of a normal choline diet and suggests that the proposed choline:PFOS ion 
complex is contributing to the accumulation of PFOS in the liver.  These data in mice 
support the primary hypothesis.  However, as shown in Chapter 3, choline 
supplementation had no effect on the PFOS-induced hepatic steatosis in male rats at 
100 ppm in the diet.  This finding may point to a key molar ratio difference driving a 
difference in phenotype or it may be indicative of species-specific differences in choline 
handling. 
 
The in vivo and in vitro data generated during this project do not provide clear supporting 
evidence for the primary or secondary hypothesis.  The increased liver choline 
concentrations in males fed 100 ppm PFOS would support the primary hypothesis.  
However, the lack of choline kinase inhibition in vitro and the lack of hepatic steatosis in 
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females suggest that the increased choline concentrations in the males may be 
correlated to the hepatic steatosis phenotype rather than causative.  In addition, no 
evidence was generated that supported the secondary hypothesis of PFOS activating a 
steatotic nuclear receptor (i.e., LXR, PXR, CAR, or PPAR-gamma) based on the lack of 
relevant liver mRNA transcription upregulation in male rats fed PFOS and the lack of 
activation or weak activation of nuclear receptors in the luciferase assay.  The sex-
related differences in liver choline concentrations and hepatic steatosis phenotype and 
the potential for species differences between mice and rats can be used to guide future 
research.    
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Chapter 5: Proposed Future Directions 
 
5.1 Introduction 
The potential for a choline supplemented diet to reduce oxidative stress in male mice fed 
a diet containing 30 ppm PFOS [94] and the sex-related differences noted in the 3-week 
PFOS study (Chapter 3) should guide the directions for future research.  In each case 
below, the studies are proposed to be performed in the order listed. 
 
5.2 Future Hypothesis 1: There is a molar threshold relationship between 
PFOS:choline whereby choline supplementation prevents the PFOS-induced 
hepatic steatosis at 30 ppm PFOS in the diet but not at 100 ppm PFOS in the 
diet 
As previously stated, Zhang, et al. [94] showed that choline supplementation reduced 
oxidative stress induced by 30 ppm PFOS dietary exposure in male mice.  Those data 
suggested that there may be a critical hepatic concentration threshold molar relationship 
between PFOS and choline.  In addition, the sex-related difference in liver choline 
concentrations at similar liver PFOS concentrations (Chapter 3) suggests that female 
rats are more readily utilizing choline under PFOS exposure conditions.  The developed 
liver choline measurement method (see Section 3.4.5) could be used to measure the 
choline hepatic concentrations and evaluate whether this molar ratio relative to the liver 
PFOS concentrations influences the hepatic phenotype. 
 
The difference between the mouse data at 30 ppm PFOS and the rat data at 100 ppm 
PFOS may be due to a species specific difference in choline handling; however, no 
published literature were located that would support a rat-mouse species difference in 
choline handling.  It is much more likely that this is a difference in the PFOS dose in 
each study (Zhang, et al. [94] and Chapter 3).  However, the potential for species 
specific differences in choline handling can be investigated as described below.  The 
studies for this hypothesis can also be used to further evaluate the potential for PXR 
nuclear receptor activation. 
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The following studies are proposed to investigate the molar relationship hypothesis: 
   
1. Investigate choline partitioning under PFOS-exposed conditions: The use of d9-
methyl-choline in this study would allow for tracing the fate of the dietary choline 
supplement.  Mice (6/sex/group) and rats (6/sex/group) fed diets containing d9-
methyl-choline in the basal diet (control) or choline supplemented diet each with 
or without 30 ppm PFOS for three weeks.  Snap frozen liver and serum could be 
analyzed for PFOS and d9-methyl-choline analytes and mRNA and protein 
content for PXR, Cyp3a11, and Cyp7a1.  This study would investigate whether 
there is hepatic retention of the administered d9-methyl-choline and whether 
there are species-specific differences in choline and PFOS partitioning.   
 
2. Investigate the potential for a PFOS:choline molar threshold in male mice based 
on the data presented in Zhang, et al. [94]: Male mice (12/group/timepoint) fed 
basal diet or choline supplemented diet each with or without 30 ppm PFOS for 
one, two, or three weeks.  The liver and serum choline concentrations could be 
measured at each termination to determine whether there is a critical hepatic 
PFOS:choline ratio that occurs across the study.  The PXR activation could be 
investigated in this study as well through analysis of liver mRNA and protein 
content for PXR, Cyp3a11, and Cyp7a1.  Oil Red O staining at each timepoint 
could establish when hepatic steatosis is observed.  Since the hepatic PFOS 
concentration is steadily increasing during the study, one would expect a 
threshold effect for the presentation of hepatic steatosis.  In addition, the choline 
concentration analyses could demonstrate a critical choline:PFOS molar 
relationship. 
 
3. Investigate the potential for a PFOS:choline molar threshold in male rats: 
Conduct a similar experiment to experiment 2 above using male rats to evaluate 
whether the differences observed between the Zhang, et al. data [94] and the 3-
week PFOS + CS study (Chapter 3) in this project arise from differences in PFOS 
exposure or if the difference was a result of choline handling differences between 
mice and rats. 
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5.3 Future Hypothesis 2: PFOS inhibits microsomal triglyceride transfer protein 
(MTP) in male rats thereby reducing VLDL formation leading to hepatic 
steatosis 
Based on the findings in female rats, it is likely that female rats fed PFOS are more 
efficient at packaging and secreting VLDL from the liver than male rats.  VLDL 
packaging is dependent on the proper transport of TG to the endoplasmic reticulum, 
uptake of TG by microsomal triglyceride transfer protein (MTP), and packaging with 
apolipoprotein B-100 (apoB-100) to form the growing VLDL particle (Figure 18A).  MTP 
inhibition can block the formation of the apoB-100 VLDL particle (Figure 18B).  An MTP 
inhibitor (8aR) caused decreased plasma ApoB-100, triglyceride, and cholesterol with 
increased hepatic triglyceride and cholesterol and a hepatic steatosis phenotype in 
C57BL/6 mice [112].  In addition, a liver-specific MTP knockout mouse model 
demonstrated hepatic steatosis with markedly decreased plasma apoB-100 and 
triglyceride relative to wild-type mice [113].  Lastly, upregulation of MTP has been 
suggested as a possible treatment for non-alcoholic fatty liver disease which is the 
clinical end-state for hepatic steatosis [114]. 
 
MTP expression is heavily influenced by estrogen levels.  Hepatic MTP mRNA and 
protein expression are greater in Sprague Dawley female rats than male rats and are 
regulated by estrogen [115].  In addition, estrogen enhances secretion of apoB-100 from 
BeWo cells, a placental cell line, through increased mRNA transcription of the genes 
coding for apoB-100, MTP, and protein-disulfide isomer (PDI), an MTP structural subunit 
[116].  Also, ovariectomized rats have significantly decreased hepatic MTP protein and 
mRNA leading to increased hepatic total cholesterol and TG and decrease VLDL 
synthesis and secretion leading to hepatic steatosis [117].  These effects were reversed 
by 17-beta-estradiol administration via a subcutaneous continuous release pellet at 
0.012 mg/day for 8 weeks [117].  The function of MTP as a key component of VLDL 
production and this sex-related difference in expression make it a potential target for the 
sex-related difference observed in rats fed 100 ppm PFOS in the diet for three weeks. 
PFOS could perturb the MTP pathway by binding to the MTP active site and acting as a 
competitive inhibitor.  This would decrease the TG available for the growing VLDL 
particle and result in apoB-100 proteolysis (Figure 18B).  In female rats, the increased 
levels of estrogen could increase the expression of MTP relative to males and result in a 
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normal hepatic phenotype even under PFOS exposure.  In addition, if female rats are 
mobilizing hepatic lipid to VLDL and ultimately to the adipose tissue, the adiposity profile 
of female rats fed PFOS should be similar to the control group while male rats fed PFOS 
should have less adipose tissue than the control group.  
 
The following studies are proposed to investigate the MTP hypothesis:   
1. In vitro MTP Activity Assay: MTP activity could be assessed with the Sigma 
Aldrich MTP Activity Assay kit (Catalog number MAK110) using HepG2 cells or 
primary rat hepatocytes exposed to vehicle (dimethyl sulfoxide) and increasing 
concentrations of PFOS.  If this hypothesis is correct, PFOS should act as a 
competitive inhibitor.   
2. In vivo PFOS effects prevention by estradiol administration: If MTP activity is 
inhibited by PFOS in vitro, then a 3-week study using the 100 ppm PFOS diet 
could be performed in male rats that receive a sham subcutaneous pellet or a 
pellet that releases 0.012 mg 17-beta-estradiol/day which was the same dose 
used by Barsalani et al. [117] to increase MTP protein and mRNA in 
ovarectomized rats.  At termination, the rats could be evaluated for free fatty 
acids and TG in the liver and total cholesterol and TG in the serum to verify 
whether estrogen supplementation can reverse the PFOS-induced hepatic 
steatosis. 
3. Investigate the potential for female rats fed PFOS to have relative adiposity 
similar to the control and for male rats fed PFOS to have less relative adiposity 
relative to the control:  Feed rats (5/sex/group) basal diet or 100 ppm PFOS in 
the diet for three weeks.  Relative adiposity would be measured by 1) weekly 
dual energy X-ray absorptiometry [118] during in-life and 2) total body fat 
collection at necropsy and calculation of the adiposity index ((total body 
fat/terminal body weight) x 100) [119].  At termination, collect liver for MTP 
protein and mRNA content analyses and serum for total cholesterol, VLDL, and 
TG content. 
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5.4 Future Hypothesis 3: PFOS is an agonist or antagonist for the farnesoid X 
receptor (FXR) leading to hepatic steatosis  
FXR is a nuclear receptor expressed in the liver and intestine that is involved in systemic 
lipid and glucose homeostasis [120].  The endogenous ligands for FXR are bile acids 
and FXR, when activated, has widespread effects on lipid metabolism and bile secretion 
[120].  For example, FXR agonists increase serum LDL cholesterol and decrease serum 
HDL cholesterol.  FXR agonists have even been suggested as treatments for 
nonalcoholic fatty liver disease [121].  However, these results for FXR agonists and the 
exact role of FXR is somewhat controversial, because the effects of FXR antagonists are 
mixed.  Some FXR antagonists decrease serum LDL cholesterol and increase hepatic 
TG and have the potential to cause hepatic steatosis as a side effect [122].  However, 
mice fed a high fat diet and treated with or without an intestinal FXR antagonist, glycine-
beta-muricholic acid, had gut microbiota changes (e.g., reduced Fimicutes and 
increased Bacteroidetes) that were correlated with decreased hepatic lipid and free fatty 
acid relative to the control group [123].  With regard to PFOS, Bijland, et al. [55] showed 
that PFOS decreased mRNA from genes involved in bile acid formation (Cyp7a1) and 
secretion (Slc10a1, Slc10a2, and Abcb11) in male APOE*3-Leiden CETP mice, which 
would support this hypothesis of FXR antagonism.    Given the compound-specific 
effects of FXR agonism and antagonism and the potential role of FXR in hepatic 
steatosis, the potential for PFOS to modulate hepatic and/or intestinal FXR warrants 
further study. 
 
There is no evidence of a sex-related difference in FXR expression.  However, estrogen 
receptor-alpha does promote the expression of some genes that are promoted by 
activated FXR [124, 125] indicating some overlap in regulatory responsibility.  For 
example, the expression of small heterodimer partner can be induced by both estrogen 
receptor-alpha and activated FXR [125].  Small heterodimer partner upregulates the 
expression of bile acids and promotes bile acid secretion [125].  If small heterodimer 
partner expression is increased in female rats fed PFOS relative to male rats, then 
female rats may more efficiently convert cholesterol to bile acids, resulting in a normal 
liver phenotype. 
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The following studies are proposed to investigate the FXR antagonist hypothesis: 
1. Measure mRNA from key FXR-regulated genes (i.e., Cyp7a1, Slc10a1, Slc10a2, 
and Abcb11) in the liver of rats from the 3-week study: If FXR antagonism is the 
source of the PFOS-induced phenotype in rats, then there should be decreased 
mRNA expression for genes induced by FXR (e.g., Cyp7a1) in male rats fed the 
100 ppm PFOS diet relative to the control male rats.  In addition, the mRNA 
expression in female rats should be similar between both diets. 
2. Conduct Western Blots to evaluate the FXR-regulated proteins (i.e., Cyp7a1, 
Slc10a1, Slc10a2, and Abcb11) from the same rats: If FXR antagonism is 
implicated, then there should be decreased amounts of these proteins in male 
rats fed the 100 ppm PFOS diet relative to the control male rats.      
3. In vitro co-administration assay in primary rat hepatocytes: Co-administer a 
known FXR agonist, like chenodeoxycholate [126], and PFOS to primary rat 
hepatocytes, then measure the mRNA content of known FXR targets, like small 
heterodimer partner and CYP7A1, and conduct a Western blot to analyze for 
protein content.  The method will be validated by using a known FXR antagonist, 
like guggulsterone [126], as a positive control.   
4. In vivo co-administration of an FXR agonist or FXR intestinal antagonist to 
attempt prevention of steatosis: Male rats (6/group) fed basal diet or 100 ppm 
PFOS diet and administered saline, GW4064, a known FXR agonist [127], or  
glycine-beta-muricholic acid, a known FXR antagonist [123], via daily oral gavage 
for three weeks.  If FXR is involved in vivo then the co-administration of the FXR 
agonist or antagonist should prevent the development of hepatic steatosis. 
 
5.5 Future Hypothesis 4: PFOS increases hepatic LDL receptor protein amounts 
leading to increased LDL uptake from the serum and causing hepatic steatosis 
The LDL receptor (LDLR) is a cell surface protein that transports circulating LDL from 
the serum into hepatocytes.  Hepatic LDLR is mainly regulated by circulating proprotein 
convertase subtilisin/kexin type 9 (PCSK9) that binds to LDLR which makes that LDLR a 
target for ubiquitination and subsequent proteolysis [128].  PFOS could perturb this 
process by inhibiting PCSK9 binding leading to reduced proteolysis of LDLR and 
resulting in increased hepatic LDL uptake from the serum.  PCSK9 inhibitors are 
currently being investigated as new drugs for decreasing serum LDL concentrations 
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[129].  Plasma PCSK9 levels are 10% higher in human females than males [130] 
suggesting that females would be more resistant to the effects of PCSK9 inhibition.  The 
gene expression of LDLR and PCSK9 in ovariectomized rats were both reduced relative 
to sham rats indicating the key role estrogen plays in modulating this system [131].  
However, increased endogenous serum estrogen concentrations in women caused 
apolipoprotein B-containing particles and circulating PCSK9 levels to be reduced [132].  
In rats, estradiol administration caused increased LDLR protein expression through 
transcriptional increase of the LDLR gene and reduced PCSK9 expression through 
transcriptional suppression [128].  This inverse relationship of circulating estradiol to 
PCSK9 concentration in humans and rats suggests that this is not a likely mechanism for 
the observed PFOS effects, because it runs contrary to the observed sex-related hepatic 
steatosis effects in rats.  However, the overall increased serum concentration of PCSK9 
observed in women, and potentially in rats, and the rationale of increased hepatic LDLR 
leading to increased steatosis make this a worthy avenue of investigation should the 
other hypotheses be excluded. 
 
The following studies are proposed to investigate the LDLR hypothesis: 
1. In vitro PCSK9-LDLR Activity Assay:  The potential for PFOS to inhibit PCSK9 
binding to LDLR could be measured in vitro using a fluorescent assay kit 
(BioScience Catalog# 72010).   
2. Measure hepatic LDLR and serum PCSK9 content in vivo: Rats (4/sex/group) fed 
basal diet or 100 ppm PFOS diet for three weeks and measure the hepatic LDLR 
(mRNA and protein) and PCSK9 (mRNA) and serum PCSK9 (protein).  One 
would expect sex-related differences in PCSK9 content as the female rats 
increase PCSK9 production in response to the putative PFOS effect on hepatic 
LDLR amounts. 
 
5.6 Conclusions 
These future directions provide multiple avenues of investigation based on the findings 
from this research.    The results of this project cannot rule out the potential for the 
PFOS:choline ion complex to lead to hepatic steatosis or the potential for PFOS 
activation of PXR in vivo to lead to the same phenotype.  There were no clear results 
that directly supported either the primary or secondary hypotheses.  Future studies 
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should focus on the sex-related difference in hepatic steatosis induction following high 
dose PFOS dietary exposure. 
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Illustrations 
Table 1. Hepatic Histopathology and Serum Biomarker Results from Following Dietary Exposure of up to 20 ppm K+ 
PFOS for 14-weeks in Sprague-Dawley Rats (5/sex/group) Seacat, et al. [7] 
Sex Males Females 
Dietary K+PFOS 
(ppm) 
0 0.5 2 5 20 0 0.5 2 5 20 
PFOS Serum 
Concentration 
(µg/mL, ppm) [a] 
<LOQ 
[b] 
4.04 ± 
0.80 
17.1 ± 
1.22 
43.9 ± 
4.9 
148 ± 14 2.67 ± 
4.58 
6.96 ± 
0.99 
27.3 ± 
2.3 
64.4 ± 
5.5 
223 ± 22 
PFOS Liver 
Concentration 
(µg/mL, ppm) [a] 
0.46 ± 
0.06 
23.8 ± 
3.5 
74.0 ± 
6.2 
358 ± 29 568 ±107 12.0 ± 
22.4 
19.2 ± 
3.8 
69.2 ± 
3.5 
370 ± 22 635 ± 49 
Serum Total 
Cholesterol (mg/dL) [a] 
63 ± 13 53 ± 17 51 ± 15 57 ± 7 37 ± 13* 75 ± 15 88 ± 27 87 ± 24 70 ± 13 66 ± 14 
Serum Alanine 
Aminotransferase 
(IU/I) [a] 
36 ± 7 41 ± 6 41 ± 5 44 ± 14 65 ± 53* 34 ± 2.4 36 ± 9 37 ± 18 34 ± 5 39 ± 18 
Hepatocellular 
Cytoplasmic 
Vacuolation Present 
[c] 
- - - Yes Yes - - - - Yes 
* indicates p<0.05 relative to the control group using Dunnett’s test.  
[a] Values are mean ± standard deviation.   
[b] LOQ = limit of quantitation (0.046 ppm).  
[c] Incidence was not reported by Seacat, et al. [7]. 
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Table 2. Hepatic Histopathology and Serum Biomarker Results Following Dietary Exposure of up to 100 ppm K+ PFOS 
for 4-weeks in Sprague-Dawley Rats (15/sex/group) from Curran, et al. [6] 
Sex Males Females 
Dietary K+PFOS 
(ppm) 
0 2 20 50 100 0 2 20 50 100 
PFOS Serum 
Concentration 
(µg/mL, ppm) [a] 
0.47 ± 
0.27 
0.95 ± 
0.13 
13.45 ± 
1.48 
20.93 ± 
2.36 
29.88 ± 
3.53 
0.95 ± 
0.51 
1.50 ± 
0.23 
15.40 ± 
1.56 
31.93 ± 
3.59 
43.20 ± 
3.95 
PFOS Liver 
Concentration 
(µg/mL, ppm) [a] 
0.79 ± 
0.49 
48.28 ± 
5.81 
560.23  ± 
104.43 
856.90 ± 
353.83 
1030.40 
± 162.80 
0.89 ± 
0.44 
43.44 ± 
6.79 
716.55 ± 
59.15 
596.75 ± 
158.01 
1008.59 
± 49.41 
Serum Total 
Cholesterol 
(mmol/L) [a] 
2.54 ± 
0.63 
2.46 ± 
0.55 
2.06 ± 
0.43 
1.63 ± 
0.31* 
0.31 ± 
0.18* 
2.06 ± 
0.36 
2.02 ± 
0.51 
1.66 ± 
0.28 
1.37 ± 
0.24* 
0.52 ± 
0.16* 
Serum Alanine 
Aminotransferase 
(U/L) [a] 
29.33 ± 
7.26 
30.07 ± 
10.82 
30.73 ± 
4.73 
37.87 ± 
16.31 
48.53 ± 
17.48* 
22.27 ± 
4.88 
26.33 ± 
5.16 
23.47 ± 
4.61 
27.70 ± 
6.876 
28.33 ± 
7.55 
Hepatocellular 
Cytoplasmic 
Homogeneity [b] 
0/4 0/4 0/4 1/4 3/4 0/4 0/4 0/4 1/4 3/4 
* indicates p<0.05 relative to the control group by ANOVA and pairwise comparison.  
[a] Values are mean ± standard deviation.   
[b] Only four rats/sex/group were subjected to histopathology.  May be a similar finding to the vacuolation reported by Seacat, et al. [7]. 
 
 62 
Table 3. Hepatic Histopathology and Serum Biomarker Results Following Daily Oral Gavage of up to 0.75 mg/kg-day K+ 
PFOS for 183 days in Cynomolgus Monkeys (at least 4/sex/group) from Seacat, et al. [8] 
Sex Males Females 
K+PFOS (mg/kg-
day) 
0 0.03 0.15 0.75 0 0.03 0.15 0.75 
PFOS Serum 
Concentration 
(µg/mL, ppm) [a] 
0.05 ± 0.01 15.8 ± 1.4 82.6 ± 25.2 173 ± 37 0.05 ± 0.02 13.2 ± 1.4 66.8 ± 10.8 171 ± 22 
PFOS Liver 
Concentration 
(µg/mL, ppm) [a] 
0.12 ± 0.03 17.3 ± 4.7 58.8 ± 19.5 395 ± 24 0.11 ± 0.02 22.8 ± 2.1 69.5 ± 14.9 273 ± 14 
Serum Total 
Cholesterol (mg/dL) 
[a] 
152 ± 28 110 ± 17** 147 ± 24 48 ± 19*,** 160 ± 47 122 ± 22 129 ± 22 82 ± 15*,** 
Serum Alanine 
Aminotransferase 
(mg/dL) [a] 
63 ± 11 42 ± 4** 48 ± 14 13 ± 5** 56 ± 16 42 ± 9 36 ± 12** 21 ± 7** 
Hepatocellular 
Vacuolation [b] 
- - - Yes - - - Yes 
* Significantly decreased from pretreatment values (day -27) by a two-tailed paired Student’s t-test. 
** Significantly different from control using Dunnett’s t-test (p<0.05, 2-tailed, homoscedastic). 
[a] Values are mean ± standard deviation.   
[b] Incidence was not reported by Seacat, et al. [8]. 
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Table 4. Free PFOS LC/MS-MS Peak Decreases when Choline Concentration is Increased 
Sample Choline  
(g) 
PFOS 
(g) 
Methanol 
(mL) 
Choline:PFOS 
Molar Ratio 
Intensity 
Free Choline 
(+244 m/z) 
Free PFOS 
(+578 m/z) 
Complex 
(+707 m/z) 
1 0.0124 0.05082 10 1.17 1.00E+06 5.50E+06 7.80E+06 
2 0.0205 0.05053 10 1.95 1.20E+06 4.00E+06 7.50E+06 
3 0.0559 0.05272 10 5.09 4.00E+06 1.80E+06 7.10E+06 
4 0.1125 0.05564 10 9.70 5.20E+06 0.50E+06 6.80E+06 
5 0.2393 0.05005 10 22.94 7.20E+06 Not detected 5.00E+06 
Free Choline (+244 m/z) is two choline molecules + one [Cl-] molecule 
Free PFOS (+578 m/z) is [PFOS-][K+][K+] 
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Table 5.  Evaluation of mRNA Affected by 25 µM PFOS in Primary Rat Hepatocytes from Bjork, et al. [72] 
Metabolic 
Pathway 
Result after 
PFOS 
treatment 
Rat mRNA 
Name 
mRNA 
Abbr.  
Fold-
change 
Nuclear receptor, hormone, 
etc. known to upregulate this 
gene  
Nuclear receptor, hormone, 
etc. known to downregulate 
this gene 
Fatty acid 
oxidation 
Upregulated 
Aldehyde 
dehydrogenase 1 
family, member 
A1 
Aldh1a1 1.5 PPAR-alpha [133] 
PXR [62] 
CAR [62] 
Unknown 
Acyl-Coenzyme 
A oxidase 1, 
palmitoyl  
Acox1 3 PPAR-alpha [72] Unknown 
Enoyl-Coenzyme 
A, hydratase 
Ehhadh 21.8 PPAR-alpha [72] T3 [134] 
Cytochrome 
P450, family 4, 
sub-family A, 
polypeptide 1 
Cyp4a1 27.3 PPAR-alpha [72] T3 [135] 
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Table 5.  Evaluation of mRNA Affected by 25 µM PFOS in Primary Rat Hepatocytes from Bjork, et al. [72] 
Metabolic 
Pathway 
Result after 
PFOS 
treatment 
Rat mRNA 
Name 
mRNA 
Abbr.  
Fold-
change 
Nuclear receptor, hormone, 
etc. known to upregulate this 
gene  
Nuclear receptor, hormone, 
etc. known to downregulate 
this gene 
Fatty acid 
synthesis 
Downregulated 
Fatty acid 
synthase 
Fasn 0.7 LXR-alpha [136] Long chain fatty acids [137] 
Upregulated 
Sterol regulatory 
element binding 
transcription 
factor 1 
Srebf1 1.9 LXR-alpha [72] Unknown 
Stearoyl-CoA 
desaturase 1 
Scd1 4 PXR [65] 
LXR-alpha [138] 
Mainly hormonal regulation 
through ERK 1/2 MAPK 
(3,3’,5-triiodothyronine (T3)) 
or inhibition insulin stimulating 
effects (glucagon) [139] 
Ketogenesis Upregulated 
3-Hydroxy-3-
methylglutaryl-
Coenzyme A 
synthase 2 
(mitochondrial) 
Hmgcs2 1.9 PPAR-alpha [140] PXR [141] 
Fatty acid 
influx 
cellular 
transporter 
Upregulated 
CD36 molecule 
(thrombospondin 
receptor) 
Cd36 2.8 PXR [65] 
PPAR-gamma [65] 
LXR-alpha [65] 
Unknown 
Glucose 
influx/efflux 
cellular 
transporter 
Downregulated 
Solute carrier 
family 2 
(facilitated 
glucose 
transporter), 
member 2 
Slc2a2 
also 
known 
as 
Glut2 
0.6 FOXA2 [142] PXR [143] 
PXR can inhibit of the FOXA2 
dependent upregulation (e.g., 
Hmgcs2) [141] 
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Table 5.  Evaluation of mRNA Affected by 25 µM PFOS in Primary Rat Hepatocytes from Bjork, et al. [72] 
Metabolic 
Pathway 
Result after 
PFOS 
treatment 
Rat mRNA 
Name 
mRNA 
Abbr.  
Fold-
change 
Nuclear receptor, hormone, 
etc. known to upregulate this 
gene  
Nuclear receptor, hormone, 
etc. known to downregulate 
this gene 
Glycolysis 
Upregulated 
Pyruvate 
dehydrogenase 
kinase, isozyme 
4 
Pdk4 7.3 PPAR-alpha [144] 
FOXO1 [145] 
Insulin suppresses FOXO 
upregulation [146] 
Downregulated 
Pyruvate kinase, 
liver and red 
blood cells 
Pklr 0.2 HNF-4 [147] Possibly PXR.  PXR agonists 
can inhibit HNF4-alpha 
dependent upregulation in 
other genes [148]. 
 
Glycerolipid 
synthesis 
Upregulated 
Glycerol-3-
phosphate 
acyltransferase, 
mitochondrial 
Gpam 1.5 PPAR-gamma [149] 
LXR-alpha [149] 
CCAAT/Enhancer binding 
protein alpha (CEBPA) [149] 
FOXA1 [150] 
Glycerol kinase Gk 3.6 PPAR-alpha [151]  Unknown 
Urea Cycle 
Down-
regulated 
Orthine 
carbamoyltrans-
ferase 
Otc 0.6 HNF-4 [152] Possibly PXR.  PXR agonists 
can inhibit HNF4-alpha 
dependent upregulation in 
other genes [148] 
Argininosuccinate 
synthetase 1 
Ass1 0.6 CREB [153] PPAR-alpha [154] 
 
Possibly PXR.  Activated 
PXR can bind to CREB and 
lead to suppression of some 
genes (e.g. Glucose-6-
phosphate [155]). 
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Table 6. Compositions of the Modified AIN-93G Purified Diets (Control and 5X, 10X, and 15X Basal 
Choline Supplemented Diets) 
Ingredient / Content Control 5X Choline 10X Choline 15X Choline 
Casein (g/kg) 200.0 200.0 200.0 200.0 
L-Cystine (g/kg) 3.0 3.0 3.0 3.0 
Corn Starch (g/kg) 397.486 389.386 374.886 362.386 
Maltodextrin (g/kg) 132.0 132.0 132.0 132.0 
Sucrose (g/kg) 100.0 100.0 100.0 100.0 
Soybean Oil (g/kg) 70.0 70.0 70.0 70.0 
Cellulose (g/kg) 50.0 50.0 50.0 50.0 
Mineral Mix, AIN-93G-MX 
(94046, g/kg) 
35.0 35.0 35.0 35.0 
Vitamin Mix, AIN-93-VX 
(94047, g/kg) 
10.0 10.0 10.0 10.0 
Choline Bitartrate (g/kg) 2.5 12.5 25.0 37.5 
Tert-Butylhydroquinone, 
antioxidant (g/kg) 
0.014 0.014 0.014 0.014 
Food-grade color additive1 None Red (0.1 g/kg) Yellow (0.1 g/kg) Green (0.1 g/kg) 
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Table 6. Compositions of the Modified AIN-93G Purified Diets (Control and 5X, 10X, and 15X Basal 
Choline Supplemented Diets) 
Ingredient / Content Control 5X Choline 10X Choline 15X Choline 
Protein content (% w/w) 17.7 17.7 17.7 17.7 
Carbohydrate (% w/w) 60.1 59.2 58.0 56.9 
Fat (% w/w) 7.2 7.2 7.2 7.2 
Energy (kcal/g) 3.8 3.7 3.7 3.6 
1. The pigments used were Red = FD&C Red #40 (CAS# 25956-17-6) Yellow = FD&C Yellow #5 (CAS# 
1934-21-0) and Green = FD&C Yellow #5 (CAS# 1934-21-0) and FD&C Green #3, (CAS# 2353-45-9). 
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Table 7.  Choline Dietary Concentrations (%w/w) in the Control (Basal Choline), 5X, 10X, and 15X Choline 
Supplemented Diets 
Diet Target 
Choline 
Concentration 
(% w/w) 
Bottom 
sample 
(% w/w) 
Mid 
Sample 
(% w/w) 
Top 
Sample 
(% w/w) 
Mean Choline 
Concentration 
(% w/w, ±SD)1 
Coefficient 
of 
Variation  
Percent of Target 
Concentration 
(measured mean 
relative to target 
mean) 
Control 
 
0.11 0.134 0.136 0.120 0.13 ± 0.01 7.7% 118% 
5X Choline 
 
0.57 0.608 0.573 0.567 0.58 ± 0.02 3.4% 102% 
10X Choline 
 
1.15 1.13 1.27 1.11 1.17 ± 0.09 7.7% 102% 
15X Choline 
 
1.72 1.53 1.68 1.61 1.61 ± 0.08 5.0% 94% 
Lower limit of quantitation = 0.0067% w/w choline 
1. No significance difference between the mean and the target concentration for each diet based on one-sample t-tests 
(p<0.05, GraphPad Prism®, v. 6.04). 
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Table 8. Selected Mean (±SD) Clinical Chemistry Results From Rats that were fed Control Diet or Diets Supplemented 
with 5X, 10X, or 15X Basal Choline for Four Weeks1 
Sex Male Female2 
Parameter 
(units) 
Control 
(basal 
choline) 
5X Choline 
10X 
Choline 
15X 
Choline 
Control 
(basal 
choline) 
5X Choline 
10X 
Choline 
15X 
Choline 
Aspartate 
aminotransferase 
(U/L) 
107.8 ± 
21.7 
97.8 ± 11.1 97.0 ± 10.1 98.5 ± 22.7 
103.2 ± 
13.0 
109.5 ± 7.7 100.8 ± 9.5 98.8 ± 6.9 
Alanine 
transaminase 
(U/L) 
35.6 ± 1.1 33.7 ± 3.7 32.8 ± 6.9 39.8 ± 8.9 34.4 ± 6.8 34.5 ± 2.2 33.8 ± 6.3 34.8 ± 10.8 
Total bilirubin 
(mg/dL)3 
<0.1 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 
Gamma-glutamyl 
transferase 
(U/L)3 
<3 <3 <3 <3 <3 <3 <3 <3 
Total cholesterol 
(mg/dL) 
80.8 ± 5.9 92.3 ± 10.3 87.5 ± 7.7d 
105.2 ± 
11.3a,c 
86.4 ± 9.4 94.5 ± 9.9 
100.0 ± 
24.7 
89.2 ± 14.9 
High density 
lipoprotein 
(mg/dL) 
27.6 ± 1.5 27.0 ± 2.0d 29.7 ± 2.3 
34.7 ± 
5.1a,b 
27.8 ± 2.7 32.7 ± 1.2a 33.5 ± 3.7 a 32.3 ± 3.2 
 71 
Table 8. Selected Mean (±SD) Clinical Chemistry Results From Rats that were fed Control Diet or Diets Supplemented 
with 5X, 10X, or 15X Basal Choline for Four Weeks1 
Sex Male Female2 
Parameter 
(units) 
Control 
(basal 
choline) 
5X Choline 
10X 
Choline 
15X 
Choline 
Control 
(basal 
choline) 
5X Choline 
10X 
Choline 
15X 
Choline 
Low density 
lipoprotein 
(mg/dL) 
8.2 ± 1.6 9.5 ± 1.6 9.0 ± 2.4 10.7 ± 1.9 6.4 ± 0.9 6.3 ± 0.8 6.8 ± 1.0 7.3 ± 1.0 
Blood urea 
nitrogen (mg/dL) 
16.4 ± 1.5 16.3 ± 2.1 16.3 ± 1.5 16.8 ± 2.1 19.2 ± 1.8 17.3 ± 2.4 18.0 ± 1.6 17.2 ± 2.7 
Creatinine 
(mg/dL) 
0.3 ± 0.1 0.3 ± 0.0 0.3 ± 0.1a 0.3 ± 0.1a 0.4 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1a 
Urea/Creatinine 
Ratio 
49.2 ± 8.3 58.7 ± 10.4 67.7 ± 14.5 
69.0 ± 
10.2a 
54.0 ± 6.5 53.5 ± 12.9 56.3 ± 9.4 66.7 ± 19.3 
Albumin (g/dL) 3.6 ± 0.0 3.6 ± 0.2 3.6 ± 0.1 3.5 ± 0.2 3.6 ± 0.2 3.6 ± 0.1d 3.5 ± 0.1 3.3 ± 0.1a,b 
Globulin (g/dL) 3.4 ± 0.2 3.4 ± 0.2 3.5 ± 0.1 3.4 ± 0.2  3.2 ± 0.2 3.2 ± 0.2 3.3 ± 0.1 3.2 ± 0.1 
Albumin/Globulin 
Ratio 
1.1 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.1 ± 0.0 1.1 ± 0.1 1.1 ± 0.0 1.1 ± 0.1 
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Table 8. Selected Mean (±SD) Clinical Chemistry Results From Rats that were fed Control Diet or Diets Supplemented 
with 5X, 10X, or 15X Basal Choline for Four Weeks1 
Sex Male Female2 
Parameter 
(units) 
Control 
(basal 
choline) 
5X Choline 
10X 
Choline 
15X 
Choline 
Control 
(basal 
choline) 
5X Choline 
10X 
Choline 
15X 
Choline 
1. Mean (±SD) values for all evaluated clinical chemistry parameters are provided in Supplemental Table 1 (males) and 2 
(females). 
2. N = 5 control males and 6 males/choline supplement group.  Not enough blood was not successfully collected from two females 
of the 10X choline group for clinical chemistry analysis due to technical difficulties.  Sufficient animals remained for evaluation 
of this group.  N = 4 female rats for the 10X Choline group, 5 control females, and 6 females/group for the remaining choline 
supplement groups. 
3. Total bilirubin and gamma-glutamyl transferase values were at or below the limits of detection, 0.1 mg/dL and 3 U/L, 
respectively. 
Letter code indicates significantly different parameter by group using one-way ANOVA with Tukey’s multiple comparisons test 
(p<0.05, GraphPad Prism®, v. 6.04). (a) vs. control, (b) vs. 5X, (c) vs. 10X, and (d) vs. 15X. 
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Table 9. Fasted Body Weights, Absolute Liver Weights, and Relative Liver Weights for Male and Female Sprague Dawley 
Rats fed Control Diet or Diets Supplemented with 5X, 10X, or 15X Basal Choline for Four Weeks 
Sex Male Female 
Parameter 
(units) 
Control 
(basal 
choline)1 
5X Choline 
10X 
Choline 
15X 
Choline 
Control 
(basal 
choline) 
5X Choline 
10X 
Choline 
15X 
Choline 
Fasted Body 
Weight (g) 
301.8 ± 8.9 
294.0 ± 
10.0c 
291.3 ± 9.5 
271.4 ± 
17.7a,b 
209.3 ± 
19.9 
197.8 ± 
12.4 
190.6 ± 8.2 182.4 ± 6.0a 
Liver Weight (g) 10.3 ± 0.8 9.5 ± 0.5 9.7 ± 0.6 8.9 ± 0.9a 6.4 ± 1.0 6.4 ± 0.5 6.2 ± 0.5 5.8 ± 0.4 
Liver-to-Body 
Weight ratio 
0.034 ± 
0.002 
0.032 ± 
0.0009 
0.033 ± 
0.001 
0.033 ± 
0.002 
0.030 ± 
0.002 
0.032 ± 
0.001 
0.032 ± 
0.002 
0.032 ± 
0.002 
1.  N = 5 control rats/sex and 6 choline supplement rats/sex/group.   
 
Letter code indicates significantly different parameter by group within sex using one-way ANOVA with Tukey’s multiple 
comparisons test (p<0.05, GraphPad Prism®, v. 6.04). (a) vs. control, (b) vs. 5X, (c) vs. 15X.  There were no significant differences 
between the 10X groups and any other group for any parameter. 
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Table 10. Incidence and Severity of Liver Histopathology Results for Male and Female Sprague Dawley Rats fed Control 
Diet or Diets Supplemented with 5X, 10X, or 15X Basal Choline for Four Weeks 
Sex Male Female 
Group 
Control 
(basal 
choline) 
5X Choline 
10X 
Choline 
15X 
Choline 
Control 
(basal 
choline) 
5X Choline 
10X 
Choline 
15X 
Choline 
Number of 
Animals 
5 6 6 6 5 6 6 6 
Parameter 
(severity) 
 
Inflammation 3 3 1 0 2 1 0 0 
 - Minimal 3 3 1 - [a] 2 1 - - 
Necrosis, focal, 
hepatocytes 
1 1 0 0 0 0 0 0 
 - Minimal 1 0 - - - - - - 
Vacuolation, 
hepatocellular, 
periportal 
0 0 0 0 2 2 0 0 
  - Minimal - - - - 1 2 - - 
  - Mild - - - - - - - - 
  - Moderate - - - - 1 - - - 
Hypertrophy, 
hepatocellular 
0 0 0 2 0 0 1 0 
  - Minimal - - - 2 - - 1 - 
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Table 10. Incidence and Severity of Liver Histopathology Results for Male and Female Sprague Dawley Rats fed Control 
Diet or Diets Supplemented with 5X, 10X, or 15X Basal Choline for Four Weeks 
Sex Male Female 
Group 
Control 
(basal 
choline) 
5X Choline 
10X 
Choline 
15X 
Choline 
Control 
(basal 
choline) 
5X Choline 
10X 
Choline 
15X 
Choline 
Number of 
Animals 
5 6 6 6 5 6 6 6 
Parameter 
(severity) 
 
Oil Red O 
Staining 
5 6 6 6 5 6 6 6 
  - Minimal - 2 3 4 - - 1 4 
  - Mild 5 4 3 2 3 5 5 2 
  - Moderate - - - - 2 1 - - 
[a] – indicates there were no observations for this group at this severity. 
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Table 11.  Selected Mean (±SD) Clinical Chemistry Results of Male and Female Sprague Dawley Rats (n = 12/sex/group) fed Control, 
Choline Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks1 
Sex Male Female 
Group 
Control 
(basal 
diet) CS2 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS2 
Control 
(basal diet) CS 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS 
Day 23  
Aspartate 
aminotransferase 
(U/L) 
69 ± 7.2 61 ± 6.7a 58 ± 3.8a 61 ± 6.3a 65 ± 7.0 60 ± 8.1c 70 ± 9.9b 60 ± 5.0c 
Alanine transaminase 
(U/L) 
29 ± 4.0 27 ± 3.1 26 ± 3.0 25 ± 3.1a 19 ± 3.6 20 ± 1.9 21 ± 3.2 21 ± 2.3 
Total bilirubin (mg/dL) 0.02 ± 0.0 0.03 ± 0.0 0.01 ± 0.03 0.01 ± 0.03 0.0 ± 0.04 0.01 ± 0.03 0.01 ± 0.0 0.0 ± 0.0 
Total cholesterol 
(mg/dL) 
104 ± 9.6 103 ± 12.0 97 ± 9.7 101 ± 5.5 82 ± 15.0 93 ± 9.0 97 ± 12.9a 98 ± 15.7a 
High density 
lipoprotein (mg/dL) 
36 ± 3.3 35 ± 3.4 36 ± 3.0 37 ± 2.3 29.8 ± 3.54 29.6 ± 2.5 30.8 ± 2.7 30.6 ± 2.9 
Low density 
lipoprotein (mg/dL) 
22 ± 2.7 21 ± 3.3 c, d 17 ± 2.3  a, b 17 ± 1.6 a, b 12.9 ± 1.84 14.2 ± 2.2 14.8 ± 2.4 13.6 ± 2.5 
Triglycerides (mg/dL) 117 ± 40.6 159 ± 57.6 119 ± 39.1 115 ± 51.2 50 ± 13.6 52 ± 20.2 70 ± 38.3 54 ± 18.6 
Blood urea nitrogen 
(mg/dL) 
15 ± 1.8 16 ± 2.7c, d 13 ± 2.5b 13 ± 2.1b 15.7 ± 3.1 14.4 ± 2.8 12.9 ± 2.3 12.4 ± 2.6a 
Creatinine (mg/dL) 0.1 ± 0.1 0.1 ± 0.05 0.1 ± 0.04 0.1 ± 0.1 0.1 ± 0.04 0.1 ± 0.03 0.2 ± 0.1 0.1 ± 0.0 
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Table 11.  Selected Mean (±SD) Clinical Chemistry Results of Male and Female Sprague Dawley Rats (n = 12/sex/group) fed Control, 
Choline Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks1 
Sex Male Female 
Group 
Control 
(basal 
diet) CS2 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS2 
Control 
(basal diet) CS 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS 
Urea/Creatinine Ratio 121 ± 47.0 142 ± 45.1 123 ± 40.8 104 ± 36.6 145.8 ± 40.84 137 ± 31.8 99.6 ± 44.9 102 ± 34.5 
Albumin (g/dL) 3.3 ± 0.1 3.2 ± 0.1 3.2 ± 0.1 3.3 ± 0.1 3.1 ± 0.54 3.2 ± 0.2 3.3 ± 0.2 3.3 ± 0.1 
Globulin (g/dL) 2.7 ± 0.1 2.7 ± 0.2 2.6 ± 0.1 2.8 ± 0.1 2.2 ± 0.4 2.3 ± 0.1 2.4 ± 0.1a 2.5 ± 0.1a, b 
Albumin/Globulin 
Ratio 
1.2 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 1.5 ± 0.3 1.4 ± 0.1 1.4 ± 0.1 1.3 ± 0.1 
Lactate 
dehydrogenase (U/L) 
298 ± 186 171 ± 142.6 119 ± 65.2a 161 ± 57.8a 457 ± 97.9 291 ± 185 565 ± 320b, d 210 ± 91c 
Lipase (U/L) 6.4 ± 1.0 7.3 ± 1.3 c, d 
4.1 ± 0.8 a, 
b 
3.9 ± 1.4 a, 
b 
1.9 ± 0.9 2.2 ± 1.1c 3.7 ± 1.2a, b, d 2.3 ± 1.0c 
Day 93  
Aspartate 
aminotransferase 
(U/L) 
89 ± 20.0 76 ± 8.3a 64 ± 5.2a 63 ± 6.8a  70 ± 7.5 59 ± 5.1a 59 ± 5.3a 58 ± 3.9a 
Alanine transaminase 
(U/L) 
32 ± 6.3 28 ± 3.2 28 ± 3.7 26 ± 3.7a 26 ± 5.1 22 ± 4.3 26 ± 5.9 24 ± 3.8 
Total bilirubin (mg/dL) 0.1 ± 0.1 0.0 ± 0.1 a 
0.02 ± 0.04 
a 
0.01 ± 
0.03a 
0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
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Table 11.  Selected Mean (±SD) Clinical Chemistry Results of Male and Female Sprague Dawley Rats (n = 12/sex/group) fed Control, 
Choline Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks1 
Sex Male Female 
Group 
Control 
(basal 
diet) CS2 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS2 
Control 
(basal diet) CS 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS 
Total cholesterol 
(mg/dL) 
96 ± 9.4 
106 ± 7.7a, c, 
d 
74 ± 8.1a, b 81 ± 7.9a, b 92 ± 7.6 99 ± 12.3c, d 82 ± 12.0b 83 ± 11.4b 
High density 
lipoprotein (mg/dL) 
40 ± 3.4 43 ± 3.5c, d 31 ± 4.3a, b 32 ± 2.9a, b 33.4 ± 2.5 34.7 ± 2.3c 32.4 ± 3.4b 30.8 ± 2.1 
Low density 
lipoprotein (mg/dL) 
17 ± 2.2 16 ± 1.9c, d 13 ± 2.3a, b 13 ± 2.2a, b 13.0 ± 2.2 13.1 ± 2.5 10.9 ± 2.4 11.0 ± 2.7 
Triglycerides (mg/dL) 116 ± 38.5 121 ± 46.6c 85 ± 23.6 80 ± 17.9b 46 ± 6.8 54 ± 23.8 50.6 ± 9.6 57 ± 13.1 
Blood urea nitrogen 
(mg/dL) 
13 ± 1.8 12 ± 1.6d 10 ± 2.3a 8.6 ± 1.6a, b 14 ± 2.1 15 ± 2.8c, d 11 ± 3.0a, b 11 ± 2.1a, b 
Creatinine (mg/dL) 0.2 ± 0.1 0.2 ± 0.03 0.2 ± 0.04 0.2 ± 0.03 0.2 ± 0.04 0.2 ± 0.05 0.2 ± 0.1 0.2 ± 0.0 
Urea/Creatinine Ratio 56 ± 12.4 59 ± 9.8 54 ± 22.1 47 ± 15.9 74.0 ±12.7 66.0 ± 15.4 53.5 ± 23.5 59.6 ± 27.2 
Albumin (g/dL) 3.6 ± 0.1 3.5 ± 0.1c 3.7 ± 0.1a, b 3.6 ± 0.1c 3.7 ± 0.1 3.6 ± 0.1c, d 3.9 ± 0.1a, b 3.7 ± 0.2b, c 
Globulin (g/dL) 2.8 ± 0.2 2.9 ± 0.1 2.8 ± 0.1 2.8 ± 0.1 2.5 ± 0.1 2.6 ± 0.1 2.6 ± 0.1 2.5 ± 0.1b, c 
Albumin/Globulin 
Ratio 
1.3 ± 0.1 
1.2 ± 0.05 c, 
d 
1.4 ± 0.1a, b 1.3 ± 0.1b 1.4 ± 0.1 1.4 ± 0.0c, d 1.5 ± 0.1b 1.5 ± 0.1b 
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Table 11.  Selected Mean (±SD) Clinical Chemistry Results of Male and Female Sprague Dawley Rats (n = 12/sex/group) fed Control, 
Choline Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks1 
Sex Male Female 
Group 
Control 
(basal 
diet) CS2 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS2 
Control 
(basal diet) CS 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS 
Lactate 
dehydrogenase (U/L) 
1008 ± 
584.2 
789 ± 326.3 
c, d 
391 ± 
142.8a, b 
337 ± 
156.2a, b 
507 ± 196.4  282 ± 159 a, d 209 ± 66.3a 
124 ± 
72.9a, b 
Lipase (U/L) 5.8 ± 1.3 7.9 ± 0.9c, d 4.3 ± 1.1a, b 4.8 ± 2.8b 4.4 ± 0.7 6.0 ± 1.3a, c, d 4.3 ± 0.9b, d 
2.9 ± 0.7a, 
b, c 
Day163  
Aspartate 
aminotransferase 
(U/L) 
63 ± 8.3 58 ± 4.6 62 ± 7.2 57 ± 5.5 65 ± 6.2 58 ± 5.4a 60 ± 4.5 60 ± 5.44 
Alanine transaminase 
(U/L) 
28 ± 7.2 26 ± 3.7 30 ± 7.0 25 ± 7.2 28 ± 4.5 27 ± 2.8 27 ± 3.9 30 ± 6.44 
Total bilirubin (mg/dL) 0.03 ± 0.1 0.02 ± 0.04 0.02 ± 0.04 0.03 ± 0.05 0.03 ± 0.05 0.0 ± 0.0 c 0.04 ± 0.1 b, d 0.0 ± 0.04 c 
Total cholesterol 
(mg/dL) 
87 ± 10.7 
105 ± 13.3a, 
c, d 
54 ± 7.4a, b 58 ± 7.3a, b 89 ± 10.3 94 ± 8.0c, d 68 ± 7.8a, b 
73 ± 16.74, 
a, b 
High density 
lipoprotein (mg/dL) 
38 ± 3.9 41 ± 3.9c, d 26 ± 2.6a, b 25 ± 3.3a, b 36 ± 3.0 37 ± 2.2c, d 30 ± 3.3a, b 
30 ± 4.94,  a, 
b 
Low density 
lipoprotein (mg/dL) 
14 ± 2.6 16 ± 2.1c, d 7.8 ± 1.4 a, b 8.1 ± 1.2a, b 10.3 ± 1.5 9.4 ± 1.2 9.3 ± 1.8 9.5 ± 3.04 
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Table 11.  Selected Mean (±SD) Clinical Chemistry Results of Male and Female Sprague Dawley Rats (n = 12/sex/group) fed Control, 
Choline Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks1 
Sex Male Female 
Group 
Control 
(basal 
diet) CS2 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS2 
Control 
(basal diet) CS 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS 
Triglycerides (mg/dL) 120 ± 36.6 
131 ± 26.5c, 
d 
71 ± 19.3a, 
b 
67 ± 23.6a, 
b 
53 ± 15.6 54 ± 15.3 58 ± 17.3 41 ± 10.04 
Blood urea nitrogen 
(mg/dL) 
14 ± 1.0 14 ± 2.1 14 ± 2.6 13 ± 1.6 16 ± 1.9 16 ± 1.7c, d 12 ± 2.4a, b 
13 ± 3.34,  a, 
b 
Creatinine (mg/dL) 0.2 ± 0.0 0.2 ± 0.03 0.2 ± 0.03 0.2 ± 0.03 0.2 ± 0.0 0.2 ± 0.0 0.3 ± 0.1 0.2 ± 0.04 
Urea/Creatinine Ratio 67 ± 10.4 66 ± 12.9 67 ± 13.1 69 ± 26.4 73 ± 19.4 71 ± 12.4c 49 ± 16.2a, b 63 ± 16.64 
Albumin (g/dL) 3.5 ± 0.1 3.5 ± 0.2c 3.8 ± 0.2a, b 3.6 ± 0.1c 3.7 ± 0.1 3.7 ± 0.1c, d 4.0 ± 0.1a, b, d 
3.9 ± 0.24,  
b, c 
Globulin (g/dL) 2.8 ± 0.1 2.8 ± 0.2c, d 2.6 ± 0.1a, b 2.6 ± 0.1a, b 2.7 ± 0.1 2.7 ± 0.2 2.8 ± 0.2 2.7 ± 0.24 
Albumin/Globulin 
Ratio 
1.2 ± 0.1 1.2 ± 0.1c, d 1.5 ± 0.1a, b 1.4 ± 0.1a, b 1.4 ± 0.0 1.4 ± 0.1 1.5 ± 0.1 1.5 ± 0.14 
Lactate 
dehydrogenase (U/L) 
370 ± 218 163 ± 58.2a 167 ± 82.1a 187 ± 92.3a 419 ± 145 230 ± 117 277 ± 96.0a 203 ± 80.3a 
Lipase (U/L) 6.6 ± 1.4 7.8 ± 1.5c, d  3.8 ± 0.9a, b 3.8 ± 1.6a, b 6.4 ± 0.9 6.1 ± 1.1c, d 4.6 ± 0.7a, b, d 
3.3 ± 0.6a, 
b, c 
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Table 11.  Selected Mean (±SD) Clinical Chemistry Results of Male and Female Sprague Dawley Rats (n = 12/sex/group) fed Control, 
Choline Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks1 
Sex Male Female 
Group 
Control 
(basal 
diet) CS2 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS2 
Control 
(basal diet) CS 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS 
Day 233  
Aspartate 
aminotransferase 
(U/L) 
80 ± 8.9 80 ± 7.5 95 ± 15.2 96 ± 31.2 92 ± 24.54 69.5 ± 5.6a 67 ± 7.4a 72 ± 14.5a 
Alanine transaminase 
(U/L) 
25 ± 4.7 25 ± 4.7c, d 
54 ± 16.2a, 
b 
49 ± 22.8a, 
b 
32 ± 20.1 21 ± 3.8 25 ± 4.2 29 ± 6.6 
Total bilirubin (mg/dL) 0.1 ± 0.1 0.1 ± 0.0c, d 
0.3 ± 0.1a, b, 
d 
0.2 ± 0.1a, b, 
c 
0.1 ± 0.1 0.0 ± 0.0 0.1 ± 0.1 0.1 ± 0.0 
Total cholesterol 
(mg/dL) 
84 ± 108 89 ± 9.5c, d 46 ± 5.2a, b 47 ± 7.3a, b 93 ± 10.5 94 ± 13.1 79 ± 14.3 78 ± 18.5 
High density 
lipoprotein (mg/dL) 
25 ± 3.7 27 ± 3.1c 22 ± 2.9b 24 ± 3.4b 31.1 ± 2.8 31.0 ± 3.1 30.0 ± 4.0 31 ± 4.5 
Low density 
lipoprotein (mg/dL) 
14 ± 3.8 11 ± 1.6a, c, d 3.6 ± 0.7a, b 4.1 ± 1.3a, b 9.8 ± 1.7 10.8 ± 2.0c 8.1 ± 2.0b 8.5 ± 3.3 
Triglycerides (mg/dL) 57 ± 9.3 53 ± 14.9c, d 28 ± 6.3a, b 31 ± 5.0a, b 48 ± 8.7 37 ± 3.7 36 ± 4.6 44 ± 21.6 
Blood urea nitrogen 
(mg/dL) 
15 ± 1.7 13 ± 1.0a, c, d 18 ± 2.1a, b 16 ± 2.0b 15 ± 1.2 14 ± 2.2d 19 ± 1.8 
22 ± 10.4a, 
b 
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Table 11.  Selected Mean (±SD) Clinical Chemistry Results of Male and Female Sprague Dawley Rats (n = 12/sex/group) fed Control, 
Choline Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks1 
Sex Male Female 
Group 
Control 
(basal 
diet) CS2 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS2 
Control 
(basal diet) CS 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS 
Creatinine (mg/dL) 0.3 ± 0.1 0.3 ± 0.0c, d 
0.2 ± 0.04a, 
b 
0.2 ± 0.04a, 
b 
0.4 ± 0.1 0.3 ± 0.1 0.3 ± 0.0a 0.3 ± 0.0a 
Urea/Creatinine Ratio 52 ± 37.4 43 ± 9.3c, d 
84 ± 14.7a, 
b 
94 ± 25.7a, 
b 
44.0 ± 11.0 51.8 ± 13.2c, d 75 ± 20.4a, b 
86 ± 20.9a, 
b 
Albumin (g/dL) 3.6 ± 0.2 3.6 ± 0.2c, d 3.9 ± 0.1a, b 3.9 ± 0.1a, b 3.9 ± 0.2 3.6 ± 0.1a, c, d 4.4 ± 0.2a, b 4.2 ± 0.4a, b 
Globulin (g/dL) 2.9 ± 0.2 2.8 ± 0.2 3.0 ± 0.2 3.0 ± 0.2 2.8 ± 0.2 2.8 ± 0.2 3.0 ± 0.2 3.1 ± 0.3a 
Albumin/Globulin 
Ratio 
1.3 ± 0.1 1.3 ± 0.1 1.3 ± 0.1 1.3 ± 0.1 1.4 ± 0.1 1.3 ± 0.1c, d 1.5 ± 0.1a, b, d 1.4 ± 0.1c 
Lactate 
dehydrogenase (U/L) 
358 ± 148 
270 ± 83.3c, 
d 
678 ± 134b 627 ± 594b 680 ± 885 165 ± 30.8a 347 ± 76.4 281 ± 90.0 
Lipase (U/L) 8.3 ± 2.2 9.4 ± 2.5c, d 5.5 ± 2.1 a, b 5.1 ± 2.3a, b 9.9 ± 2.5 7.4 ± 1.7 5.3 ± 1.1 12 ± 22.1 
1. Mean (±SD) values for all evaluated clinical chemistry parameters are provided in Supplemental Tables 5 - 12. 
2. CS indicates the choline supplemented diet. 
3. Blood was collected from non-fasted rats on days 2, 9, and 16.  The rats were fasted overnight prior to blood collection on day 23. 
4. Insufficient serum was available for analysis from one to six rats for this parameter (see the Supplemental Tables for the specific number of 
animals per parameter).  The available sera was sufficient for evaluation of this parameter. 
Letter code indicates significantly different parameter by group using one-way ANOVA with Tukey’s multiple comparisons test (p<0.05, 
GraphPad Prism®, v. 6.04). (a) vs. control, (b) vs. CS, (c) vs. PFOS, and (d) vs. PFOS + CS. 
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Table 12. Fasted Body Weights, Absolute Liver Weights, and Relative Liver Weights of Male and Female Sprague Dawley 
Rats fed Control, Choline Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
Sex Male Female 
Parameter 
(units) 
Control 
(basal 
choline) 
Choline 
Supplemen
ted (CS) 
100 ppm 
PFOS 
100 ppm 
PFOS + CS 
Control 
(basal 
choline) 
Choline 
Supplemen
ted (CS) 
100 ppm 
PFOS 
100 ppm 
PFOS + CS 
Fasted 
Body 
Weight (g) 
301.2 ± 17.2 294.6 ± 13.2 284.9 ± 22.4 
274.9 ± 12.5 
a,b 
187.0 ± 8.8 189.4 ± 11.1 
162.7 ± 10.4 
a,b 
163.5 ± 13.2 
a,b 
Liver 
Weight (g) 
9.3 ± 1.2 8.9 ± 1.4 16.4 ± 1.6 a,b 
15.1 ± 0.8 
a,b 
5.9 ± 0.6 5.7 ± 0.5 7.6 ± 0.6 a,b 7.7 ± 1.0 a,b 
Liver-to-BW 
ratio 
0.031 ± 
0.003 
0.030 ± 
0.004 
0.057 ± 
0.003 a,b 
0.055 ± 
0.003 a,b 
0.032 ± 
0.003 
0.030 ± 
0.001 
0.047 ± 
0.002 a,b 
0.047 ± 
0.005 a,b 
1.  N = 12 rats/sex/group.   
Letter code indicates significantly different parameter by group within sex using one-way ANOVA with Tukey’s multiple 
comparisons test (p<0.05, GraphPad Prism®, v. 6.04). (a) vs. control and (b) vs. choline supplement (CS). There were no 
differences between the PFOS and PFOS + CS groups for either sex in any parameter. 
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Table 13.  Mean (±SD) Percent Area of Hepatocellular Lipid (Oil Red O or Osmium Tetroxide Staining) and 
Hypertrophy (Hematoxylin and Eosin Staining) in Male and Female Sprague Dawley Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
Sex Male Female 
Group 
Control 
(basal 
diet) 
Choline 
Suppl.1 
(CS) 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS 
Control 
(basal 
diet) 
Choline 
Suppl. 
(CS) 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS 
Stain   
Oil Red O for 
lipid (% area) 
2.432 ± 
1.131 
2.492 ± 
1.239 
52.424 ± 
19.369 a,b 
54.296 ± 
16.988 a,b 
6.454 ± 
2.388 
15.958 ± 
8.240 a 
4.179 ± 
1.308 b 
6.580 ± 
2.848 b 
Osmium 
tetroxide for 
lipid (% area) 
0.283 ± 
0.148 
0.219 ± 
0.102 
9.023 ± 
10.802 a,b 
7.715 ± 
4.578 a,b 
0.290 ± 
0.178 
0.352 ± 
0.170 
0.152 ± 
0.095 
0.339 ± 
0.343 
Hematoxylin 
and eosin for 
hepatocellular 
hypertrophy 
(% area) 
85.117 ± 
2.179 
85.433 ± 
1.626 
89.408 ± 
1.748 a,b 
89.232 ± 
1.576 a,b 
80.870 ± 
1.905 
78.334 ± 
3.520 
85.594 ± 
1.798 a,b 
86.606 ± 
1.617 a,b 
N = 12/sex/group. 
1.  Choline Supplemented. 
Statistically significant differences are indicated for each group comparison vs. control (a) and vs. CS (b) using one-way 
ANOVA with Tukey’s multiple comparisons test, p<0.05.  There were no differences between the PFOS and PFOS + CS 
groups. 
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Linear PFOS Branched PFOS (example) 
Figure 1. Structures of linear and branched PFOS.  The branch can occur at multiple places along the PFOS backbone as an 
internal monomethyl or isopropyl branch or other branches [4]. 
 
 86 
 
 
Figure 2.  Lipid catabolism during low energy states (e.g., fasted conditions).  Based on information in Lehninger Principles 
of Biochemistry [9] 
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Figure 3.  Lipid synthesis and VLDL secretion during high energy states (e.g., fed conditions).  Based on information in 
Lehninger Principles of Biochemistry [14]. 
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Figure 4.  Scanning electron microscopy from Seacat, et al. [8] of (A) control liver on day 184, (B) 0.75 mg/kg-day PFOS-
treated liver on day 184, and (C) 0.75 mg/kg-day PFOS-treated liver after 211 days of recovery (i.e., day 393) from male 
cynomolgus monkeys  
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Figure 5.  Hypotheses for possible PFOS mechanisms of action on lipid metabolism resulting in hepatic 
steatosis.  Hypotheses 1 and 2 were evaluated in this project.  Future hypotheses (FH) 1 through 4 are also shown (see 
Chapter 5). 
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Figure 6. Comparison of light microscopy of the livers from a control diet-fed rat (A) and an MCD diet-fed rat (B) at 
5 weeks from George, et al. [58].  The main images are 60X magnification and the insert is 400x magnification.  
Evidence of hepatic steatosis is shown in the insert with inflammatory cell infiltrate indicated by the arrows. 
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Figure 7.  PFOS ion complex with choline. PFOS (molecular weight 499) forms an ion complex with two molecules of choline 
(molecular weight 104) to form a 707 molecular weight complex with a net +1 positive charge.  
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Figure 8. Mean (±SD) body weights and body weight gains in male (A and C) and 
female (B and D) Sprague Dawley rats fed control diet or 5X, 10X, or 15X choline 
supplemented diet for four weeks.  N = 5 control rats/sex and 6 choline supplemented 
rats/sex/group.  (A) 15X choline supplement male group was significantly different from 
all other male groups (*) and all male groups except the 10X group (#) on the indicated 
days, p≤0.05. (B) Mean body weights of the 10X females (#) and 15X females (*) were 
significantly decreased relative to the female control group on the indicated days, 
p≤0.05.  (C and D) Letter code indicates significantly different groups by week or 
throughout the study, p≤0.05.   
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Figure 9. Mean (±SD) food intake in in male (A) and female (B) Sprague Dawley 
rats fed control diet or 5X, 10X, or 15X choline supplemented diet for four weeks.  
N = 5 control rats/sex and 6 choline supplemented rats/sex/group.  Significantly 
decreased food intake relative to the control (*), 5X (#), and/or 10X ($) groups, p≤0.05. 
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Figure 10. Mean (±SD) serum choline concentrations (ppm) at necropsy in male 
and female Sprague Dawley rats fed control diet or 5X, 10X, or 15X choline 
supplemented diet for four weeks.  N = 5 control rats/sex and 6 choline supplemented 
rats/sex/group.  Letter code indicates significant differences between groups, p≤0.05. 
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Figure 11.  Effects of 3-week exposure to basal diet (control), choline 
supplemented diet (CS), 100 ppm PFOS diet, or 100 ppm PFOS + CS diet on male 
(A, C, and E) and female (B, D, and F) Sprague Dawley rat mean (±SD) body 
weights, body weight gains, and food intake, respectively.  N = 12 rats/sex/group.  
(A) * PFOS + CS male group was significantly different from the male control group, 
p≤0.05.  (B) PFOS (#) and PFOS + CS (*) females were significantly decreased relative 
to the female control and CS groups, p≤0.05.  (C) Values with different letters are 
significantly different, p≤0.05.  (D) Values with different letters are significantly different, 
p≤0.05.  (E) No significant differences, p>0.05.  (F) No significant differences, p>0.05.  
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Figure 12.  Effects of 3-week exposure to basal diet (control), choline supplemented diet 
(CS), 100 ppm PFOS diet, or 100 ppm PFOS + CS diet on male (A, C, E, and F) and female 
(B, D, E, and F) Sprague Dawley rat mean (±SD) serum choline, serum PFOS, liver choline, 
and liver PFOS concentrations, respectively.  N = 12 rats/sex/group.  (A) * CS group mean 
was increased relative all other group means, p≤0.05.  # PFOS + CS group mean was increased 
relative all other group means, p≤0.05. (B)  * PFOS group mean was decreased relative to the 
control group mean, p≤0.05.  a. All female group means were decreased relative to the respective 
male group means, p≤0.05.  b. Female CS group mean was decreased relative to the male CS 
group, p≤0.05.  c. Female control and CS group means were increased relative to the respective 
male groups, p≤0.05. (C and D) No significant differences between groups of the same sex, 
p>0.05.  Control and CS group values were below the limit of detection (0.05 ppm).  # Female 
PFOS concentration was significantly increased relative to the male groups, p≤0.05. (E and F) 
Values with different letters are significantly different, p≤0.05.
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Figure 13.  Representative hematoxylin and eosin-stained liver (40X magnification) at termination from male and female 
Sprague Dawley rats fed basal diet (control), choline supplemented diet (CS), 100 ppm PFOS diet, or 100 ppm PFOS + CS 
diet for three weeks. 
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Figure 14.  Representative Oil Red O-stained liver (40X magnification) at termination from male and female Sprague Dawley 
rats fed basal diet (control), choline supplemented diet (CS), 100 ppm PFOS diet, or 100 ppm PFOS + CS diet for three 
weeks.  Lipid droplets are stained red by Oil Red O. 
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Figure 15.  Representative osmium tetroxide-stained liver (40X magnification) at termination from male and female Sprague 
Dawley rats fed basal diet (control), choline supplemented diet (CS), 100 ppm PFOS diet, or 100 ppm PFOS + CS diet for 
three weeks.  Lipid droplets are stained black by osmium tetroxide. 
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Figure 16. Effects of 3-week exposure to basal diet (control) choline supplemented diet 
(CS), 100 ppm PFOS diet, or 100 ppm PFOS + CS diet on male (A, C, E) and female (B, D, F) 
Sprague Dawley rat mean (±SD) hepatic free fatty acid, cholesterol, and triglyceride 
concentrations, respectively.  Values with different letters are significantly different, p≤0.05.  N 
= 12 rats/sex/group.   
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Figure 17.  PFOS (400 µM) did not inhibit human choline kinase alpha variant 1 (A), human choline kinase alpha variant 2 
(B), or human choline kinase beta (C) in an NADH-coupled choline kinase activity assay.   
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A B 
  
Figure 18.  Very low density lipoprotein (VLDL) particle formation in the endoplasmic reticulum.  (A) In the presence of ApoB-
100, MTP takes up triglyceride (TG) from the cytoplasm.  The growing ApoB-100 preliminary particle continues to receive TG from 
MTP until it is large enough to be secreted from the endoplasmic reticulum and migrate to the Golgi body to continue packaging as a 
VLDL particle.  (B) An inhibitor can interfere with this process by competing for the TG binding site in MTP.  This reduces or 
eliminates the formation of the growing apoB-100 preliminary VLDL particle which would then be proteolyzed.  MTP inhibitors are 
known to cause hepatic steatosis and decreased serum TG.  PFOS may induce the hepatic steatosis phenotype in male rats by 
inhibiting MTP. 
 103 
Bibliography 
1. 3M Company. Fluorochemical use, distribution, and release.  US EPA Submission 8EHQ-
0699-373.  1999  [cited 2016 June 22]; Available from: 
https://yosemite.epa.gov/oppts/epatscat8.nsf/by+Service/C5176FCC52E2CFE685257AF
6006A975F/$File/89(811769W).pdf. 
 
2. Buck, R.C., et al., Perfluoroalkyl and polyfluoroalkyl substances in the environment: 
terminology, classification, and origins. Integr Environ Assess Manag, 2011. 7(4): p. 513-
41. 
 
3. United Nations. Stockholm Convention on Persistent Organic Pollutants.  Adoption of 
Amendments to Annexes A, B, and C.  2009  [cited 2012 April 23]; Available from: 
http://chm.pops.int/Convention/ThePOPs/TheNewPOPs/tabid/2511/Default.aspx. 
 
4. Kestner, T. and Exygen Research, Certificate of analysis for perfluorooctane sulfonate 
(PFOS), 3M lot 217. October 31, 2006.  Unpublished. 2016. 
 
5. Olsen, G.W., et al., Serum perfluorooctane sulfonate and hepatic and lipid clinical 
chemistry tests in fluorochemical production employees. J Occup Environ Med, 1999. 
41(9): p. 799-806. 
 
6. Curran, I., et al., Altered fatty acid homeostasis and related toxicologic sequelae in rats 
exposed to dietary potassium perfluorooctanesulfonate (PFOS). J Toxicol Environ Health 
A, 2008. 71(23): p. 1526-41. 
 
7. Seacat, A.M., et al., Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate 
in rats. Toxicology, 2003. 183(1-3): p. 117-31. 
 
8. Seacat, A.M., et al., Subchronic toxicity studies on perfluorooctanesulfonate potassium 
salt in cynomolgus monkeys. Toxicol Sci, 2002. 68(1): p. 249-64. 
 
9. Nelson, D.L. and M.M. Cox, Fatty acid catabolism, in Lehninger Principles of 
Biochemistry.  5th Ed. 2008. p. 647-665. 
 
10. Pawlak, M., P. Lefebvre, and B. Staels, Molecular mechanism of PPARalpha action and its 
impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver 
disease. J Hepatol, 2015. 62(3): p. 720-33. 
 
 104 
11. Miura, Y., The biological significance of omega-oxidation of fatty acids. Proc Jpn Acad 
Ser B Phys Biol Sci, 2013. 89(8): p. 370-82. 
 
12. Wanders, R.J., et al., Peroxisomes, lipid metabolism and lipotoxicity. Biochim Biophys 
Acta, 2010. 1801(3): p. 272-80. 
 
13. Storch, J. and A.E. Thumser, The fatty acid transport function of fatty acid-binding 
proteins. Biochim Biophys Acta, 2000. 1486(1): p. 28-44. 
 
14. Nelson, D.L. and M.M. Cox, Lipid Biosynthesis, in Lehninger Principles of Biochemistry.  
5th Ed. 2008. p. 805-819. 
 
15. Ferre, P. and F. Foufelle, Hepatic steatosis: a role for de novo lipogenesis and the 
transcription factor SREBP-1c. Diabetes Obes Metab, 2010. 12 Suppl 2: p. 83-92. 
 
16. Igal, R.A., Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell 
proliferation, programmed cell death and transformation to cancer. Carcinogenesis, 
2010. 31(9): p. 1509-15. 
 
17. Cole, L.K., J.E. Vance, and D.E. Vance, Phosphatidylcholine biosynthesis and lipoprotein 
metabolism. Biochim Biophys Acta, 2012. 1821(5): p. 754-61. 
 
18. Boren, J., et al., The molecular mechanism for the assembly and secretion of ApoB-100-
containing lipoproteins. Prog Lipid Res, 1991. 30(2-3): p. 205-18. 
 
19. Li, Z. and D.E. Vance, Phosphatidylcholine and choline homeostasis. Journal of Lipid 
Research, 2008. 49(6): p. 1187-94. 
 
20. Kane, C.D., O.L. Francone, and K.A. Stevens, Differential regulation of the cynomolgus, 
human, and rat acyl-CoA oxidase promoters by PPARalpha. Gene, 2006. 380(2): p. 84-94. 
 
21. Kersten, S. and R. Stienstra, The role and regulation of the peroxisome proliferator 
activated receptor alpha in human liver. Biochimie, 2017. 
 
22. Thomas, M., et al., The truncated splice variant of peroxisome proliferator-activated 
receptor alpha, PPARalpha-tr, autonomously regulates proliferative and pro-
inflammatory genes. BMC Cancer, 2015. 15: p. 488. 
 
23. Roberts, R.A., Peroxisome proliferators: mechanisms of adverse effects in rodents and 
molecular basis for species differences. Arch Toxicol, 1999. 73(8-9): p. 413-8. 
 105 
 
24. Tessitore, L., et al., Sexually differentiated response to choline in choline deficiency and 
ethionine intoxication. Int J Exp Pathol, 1995. 76(2): p. 125-9. 
 
25. Noga, A.A. and D.E. Vance, A gender-specific role for phosphatidylethanolamine N-
methyltransferase-derived phosphatidylcholine in the regulation of plasma high density 
and very low density lipoproteins in mice. J Biol Chem, 2003. 278(24): p. 21851-9. 
 
26. Drouva, S.V., et al., Estradiol activates methylating enzyme(s) involved in the conversion 
of phosphatidylethanolamine to phosphatidylcholine in rat pituitary membranes. 
Endocrinology, 1986. 119(6): p. 2611-22. 
 
27. 3M Company. Environmental and health assessment of perfluorooctane sulfonic acid 
and its salts.  2003  [cited 2016 November 9]; Available from: 
http://multimedia.3m.com/mws/media/370351O/3m-pfos-risk-assessmt-2003.pdf. 
 
28. Xu, L., et al., Biotransformation of N-ethyl-N-(2-
hydroxyethyl)perfluorooctanesulfonamide by rat liver microsomes, cytosol, and slices 
and by expressed rat and human cytochromes P450. Chem Res Toxicol, 2004. 17(6): p. 
767-75. 
 
29. Butenhoff, J.L., et al., Distribution of perfluorooctanesulfonate and perfluorooctanoate 
into human plasma lipoprotein fractions. Toxicol Lett, 2012. 210(3): p. 360-5. 
 
30. Chang, S.C., et al., Comparative pharmacokinetics of perfluorooctanesulfonate (PFOS) in 
rats, mice, and monkeys. Reprod Toxicol, 2012. 33(4): p. 428-40. 
 
31. Olsen, G.W., et al., Half-life of serum elimination of 
perfluorooctanesulfonate,perfluorohexanesulfonate, and perfluorooctanoate in retired 
fluorochemical production workers. Environ Health Perspect, 2007. 115(9): p. 1298-305. 
 
32. Bossi, R., et al., Preliminary screening of perfluorooctane sulfonate (PFOS) and other 
fluorochemicals in fish, birds and marine mammals from Greenland and the Faroe 
Islands. Environ Pollut, 2005. 136(2): p. 323-9. 
 
33. Bytingsvik, J., et al., Perfluoroalkyl substances in polar bear mother-cub pairs: a 
comparative study based on plasma levels from 1998 and 2008. Environ Int, 2012. 49: p. 
92-9. 
 
 106 
34. Giesy, J.P. and K. Kannan, Global distribution of perfluorooctane sulfonate in wildlife. 
Environ Sci Technol, 2001. 35(7): p. 1339-42. 
 
35. Greaves, A.K. and R.J. Letcher, Linear and branched perfluorooctane sulfonate (PFOS) 
isomer patterns differ among several tissues and blood of polar bears. Chemosphere, 
2013. 93(3): p. 574-80. 
 
36. Schiavone, A., et al., Perfluorinated contaminants in fur seal pups and penguin eggs from 
South Shetland, Antarctica. Sci Total Environ, 2009. 407(12): p. 3899-904. 
 
37. Riget, F., et al., Trends of perfluorochemicals in Greenland ringed seals and polar bears: 
indications of shifts to decreasing trends. Chemosphere, 2013. 93(8): p. 1607-14. 
 
38. Zhang, L., et al., The inventory of sources, environmental releases and risk assessment 
for perfluorooctane sulfonate in China. Environ Pollut, 2012. 165: p. 193-8. 
 
39. Butenhoff, J.L., G.W. Olsen, and A. Pfahles-Hutchens, The applicability of biomonitoring 
data for perfluorooctanesulfonate to the environmental public health continuum. 
Environ Health Perspect, 2006. 114(11): p. 1776-82. 
 
40. Olsen, G.W., et al., Temporal trends of perfluoroalkyl concentrations in American Red 
Cross adult blood donors, 2000-2010. Environ Sci Technol, 2012. 46(11): p. 6330-8. 
 
41. Toms, L.M., et al., Decline in perfluorooctane sulfonate and perfluorooctanoate serum 
concentrations in an Australian population from 2002 to 2011. Environ Int, 2014. 71: p. 
74-80. 
 
42. Perez, F., et al., Accumulation of perfluoroalkyl substances in human tissues. Environ Int, 
2013. 59: p. 354-62. 
 
43. Olsen, G.W., et al., Human donor liver and serum concentrations of 
perfluorooctanesulfonate and other perfluorochemicals. Environ Sci Technol, 2003. 
37(5): p. 888-91. 
 
44. C8 Science Panel. C8 Health Project.  2013  [cited 2016 July 7]; Available from: 
http://c8sciencepanel.org/. 
 
45. Gallo, V., et al., Serum Perfluorooctanoate (PFOA) and Perfluorooctane Sulfonate (PFOS) 
Concentrations and Liver Function Biomarkers in a Population with Elevated PFOA 
Exposure. Environ Health Perspect, 2012. 
 107 
 
46. Frisbee, S.J., et al., Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in 
children and adolescents: results from the C8 Health Project. Arch Pediatr Adolesc Med, 
2010. 164(9): p. 860-9. 
 
47. Nelson, J.W., E.E. Hatch, and T.F. Webster, Exposure to polyfluoroalkyl chemicals and 
cholesterol, body weight, and insulin resistance in the general U.S. population. Environ 
Health Perspect, 2010. 118(2): p. 197-202. 
 
48. Kerger, B.D., T.L. Copeland, and A.P. DeCaprio, Tenuous dose-response correlations for 
common disease states: case study of cholesterol and perfluorooctanoate/sulfonate 
(PFOA/PFOS) in the C8 Health Project. Drug Chem Toxicol, 2011. 34(4): p. 396-404. 
 
49. Fitz-Simon, N., et al., Reductions in serum lipids with a 4-year decline in serum 
perfluorooctanoic acid and perfluorooctanesulfonic acid. Epidemiology, 2013. 24(4): p. 
569-76. 
 
50. Rosenthal, R.L., Effectiveness of altering serum cholesterol levels without drugs. Proc 
(Bayl Univ Med Cent), 2000. 13(4): p. 351-5. 
 
51. Olsen, G.W., et al., Longitudinal assessment of lipid and hepatic clinical parameters in 
workers involved with the demolition of perfluoroalkyl manufacturing facilities. J Occup 
Environ Med, 2012. 54(8): p. 974-83. 
 
52. Goldenthal, E.I., et al. 90-day subacute rat study.  Study Number 137-085. International 
Research and Development Corp. Mattawan MI.  Available on USEPA Public Docket AR-
226-0139  1978a. 
 
53. Haughom, B. and O. Spydevold, The mechanism underlying the hypolipemic effect of 
perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid. 
Biochim Biophys Acta, 1992. 1128(1): p. 65-72. 
 
54. Sohlenius, A.K., et al., Perfluorooctane sulfonic acid is a potent inducer of peroxisomal 
fatty acid beta-oxidation and other activities known to be affected by peroxisome 
proliferators in mouse liver. Pharmacol Toxicol, 1993. 72(2): p. 90-3. 
 
55. Bijland, S., et al., Perfluoroalkyl sulfonates cause alkyl chain length-dependent hepatic 
steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE*3-
Leiden CETP mice. Toxicol Sci, 2011. 123(1): p. 290-303. 
 
 108 
56. Westerterp, M., et al., Cholesteryl ester transfer protein decreases high-density 
lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler 
Thromb Vasc Biol, 2006. 26(11): p. 2552-9. 
 
57. Zeisel, S.H. and K.A. da Costa, Choline: an essential nutrient for public health. Nutrition 
Reviews, 2009. 67(11): p. 615-23. 
 
58. George, J., et al., Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a 
rat model of chronic steatohepatitis. J Hepatol, 2003. 39(5): p. 756-64. 
 
59. Corbin, K.D. and S.H. Zeisel, Choline metabolism provides novel insights into nonalcoholic 
fatty liver disease and its progression. Curr Opin Gastroenterol, 2012. 28(2): p. 159-65. 
 
60. Marcolin, E., et al., Methionine- and choline-deficient diet induces hepatic changes 
characteristic of non-alcoholic steatohepatitis. Arq Gastroenterol, 2011. 48(1): p. 72-9. 
 
61. Butenhoff, J., J.M. Flaherty, and P. Connolly, Unpublished data.  Ion-Pair Complex 
Identification and Quantitation Project, in Report 023-086. 2003, Exygen Research 
Laboratory. 
 
62. Maglich, J.M., et al., Nuclear pregnane x receptor and constitutive androstane receptor 
regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol 
Pharmacol, 2002. 62(3): p. 638-46. 
 
63. Moya, M., et al., Enhanced steatosis by nuclear receptor ligands: a study in cultured 
human hepatocytes and hepatoma cells with a characterized nuclear receptor 
expression profile. Chem Biol Interact, 2010. 184(3): p. 376-87. 
 
64. Zhou, J., et al., Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and 
PPARgamma in promoting steatosis. Gastroenterology, 2008. 134(2): p. 556-67. 
 
65. Lee, J.H., J. Zhou, and W. Xie, PXR and LXR in hepatic steatosis: a new dog and an old 
dog with new tricks. Mol Pharm, 2008. 5(1): p. 60-6. 
 
66. Piriou, A., et al., Fatty liver induced by high doses of rifampicin in the rat: possible 
relation with an inhibition of RNA polymerases in eukariotic cells. Arch Toxicol Suppl, 
1979(2): p. 333-7. 
 
67. Truhaut, R., et al., [Liver steatogenic power of high doses of rifampicin in rats]. C R Acad 
Sci Hebd Seances Acad Sci D, 1978. 286(6): p. 493-7. 
 109 
 
68. Morere, P., et al., [Information obtained by liver biopsy in 100 tuberculous patients]. 
Sem Hop, 1975. 51(31-34): p. 2095-102. 
 
69. di Masi, A., et al., Nuclear receptors CAR and PXR: Molecular, functional, and biomedical 
aspects. Mol Aspects Med, 2009. 30(5): p. 297-343. 
 
70. Koonen, D.P., et al., Increased hepatic CD36 expression contributes to dyslipidemia 
associated with diet-induced obesity. Diabetes, 2007. 56(12): p. 2863-71. 
 
71. Elcombe, C.R., et al., Hepatocellular hypertrophy and cell proliferation in Sprague-
Dawley rats from dietary exposure to potassium perfluorooctanesulfonate results from 
increased expression of xenosensor nuclear receptors PPARalpha and CAR/PXR. 
Toxicology, 2012. 293(1-3): p. 16-29. 
 
72. Bjork, J.A., J.L. Butenhoff, and K.B. Wallace, Multiplicity of nuclear receptor activation by 
PFOA and PFOS in primary human and rodent hepatocytes. Toxicology, 2011. 288(1-3): 
p. 8-17. 
 
73. Vanden Heuvel, J.P., et al., Differential activation of nuclear receptors by perfluorinated 
fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat 
peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-
beta, and retinoid X receptor-alpha. Toxicol Sci, 2006. 92(2): p. 476-89. 
 
74. Butenhoff, J., In vitro luciferase assay to demonstrate nuclear receptor activation by 
PFOS.  3M Study 11-108. 2011, 3M. 
 
75. Elsawy, G., O. Abdelrahman, and A. Hamza, Effect of choline supplementation on rapid 
weight loss and biochemical variables among female taekwondo and judo athletes. 
Journal of Human Kinetics, 2014. 40: p. 77-82. 
 
76. Grunewald, K.K. and R.S. Bailey, Commercially marketed supplements for bodybuilding 
athletes. Sports Medicine, 1993. 15(2): p. 90-103. 
 
77. Institute of Medicine, Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin 
B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline.  Chapter 12: Choline.  Pg. 
408-414. 1998, Washington DC: National Academy Press. 
 
78. Sahu, A.P., et al., Effect of chronic choline administration in rats. Indian Journal of 
Experimental Biology, 1986. 24(2): p. 91-6. 
 110 
 
79. National Research Council, Nutritional Requirements of Laboratory Animals.  Fourth 
Revised Edition. 1995, National Academy Press: Washington, DC. p. pg. 13. 
 
80. Moreno, H.C., et al., Choline dietary supplementation improves LiCl-induced context 
aversion retention in adult rats. Physiol Behav, 2012. 106(4): p. 451-6. 
 
81. Moreno, H., I. de Brugada, and G. Hall, Chronic dietary choline supplementation 
modulates attentional change in adult rats. Behavioural Brain Research, 2013. 243: p. 
278-85. 
 
82. Hodge, H.C., Chronic oral toxicity of choline chloride in rats. Proceedings of the Society 
for Experimental Biology and Medicine, 1945. 58: p. 212-215. 
 
83. Reeves, P.G., F.H. Nielsen, and G.C. Fahey, Jr., AIN-93 purified diets for laboratory 
rodents: final report of the American Institute of Nutrition ad hoc writing committee on 
the reformulation of the AIN-76A rodent diet. Journal of Nutrition, 1993. 123(11): p. 
1939-51. 
 
84. AOAC International, Official Methods of Analysis of AOAC International.  Official Method 
999.14.  Choline in infant formula and milk. 18th ed. 2005: AOAC International, 
Gaithersburg, MD, USA. 
 
85. Marshfield Labs. Clinical chemistry reference ranges by species.  2016 Last Updated 
December 5, 2014 [cited 2016 August 11]; Available from: 
https://www.marshfieldlabs.org/sites/ltrm/Vet/Documents/ALL%20ReferenceRanges.p
df. 
 
86. Hall, A.P., et al., Liver hypertrophy: a review of adaptive (adverse and non-adverse) 
changes--conclusions from the 3rd International ESTP Expert Workshop. Toxicologic 
Pathology, 2012. 40(7): p. 971-94. 
 
87. Eaton, D.L. and S.G. Gilbert, Casarett & Doull's Toxicology: The basic science of poisons.  
Chapt 2: Principles of Toxicology.  p. 32. 7th ed, ed. C.D. Klaassen. 2008, New York, NY 
USA: McGraw-Hill Companies, Inc. 
 
88. Vance, D.E., Role of phosphatidylcholine biosynthesis in the regulation of lipoprotein 
homeostasis. Current Opinion in Lipidology, 2008. 19(3): p. 229-34. 
 
89. Biasi, E., The effects of dietary choline. Neurosci Bull, 2011. 27(5): p. 330-42. 
 111 
 
90. Fischer, L.M., et al., Sex and menopausal status influence human dietary requirements 
for the nutrient choline. American Journal of Clinical Nutrition, 2007. 85(5): p. 1275-85. 
 
91. Young, D.L., Estradiol- and testosterone-induced alterations in phosphatidylcholine and 
triglyceride synthesis in hepatic endoplasmic reticulum. J Lipid Res, 1971. 12(5): p. 590-5. 
 
92. Melse-Boonstra, A., et al., Betaine concentration as a determinant of fasting total 
homocysteine concentrations and the effect of folic acid supplementation on betaine 
concentrations. American Journal of Clinical Nutrition, 2005. 81(6): p. 1378-82. 
 
93. International Organization for Standardization (ISO), ISO 10993: Biological evaluation of 
medical devices.  Part 17: Establishment of allowable limits for leachable substances. 
2002. 
 
94. Zhang, L., et al., Editor's Highlight: Perfluorooctane Sulfonate-Choline Ion Pair Formation: 
A Potential Mechanism Modulating Hepatic Steatosis and Oxidative Stress in Mice. 
Toxicol Sci, 2016. 153(1): p. 186-97. 
 
95. Bagley, B.D., et al., Investigation of Potential Toxicological Effects of Subchronic Choline 
Dietary Supplementation in Sprague Dawley Rats. Submitted Manuscript. 
 
96. Zhao, W., et al., Na+/Taurocholate Cotransporting Polypeptide and Apical Sodium-
Dependent Bile Acid Transporter Are Involved in the Disposition of Perfluoroalkyl 
Sulfonates in Humans and Rats. Toxicol Sci, 2015. 146(2): p. 363-73. 
 
97. Holm, P.I., et al., Determination of choline, betaine, and dimethylglycine in plasma by a 
high-throughput method based on normal-phase chromatography-tandem mass 
spectrometry. Clin Chem, 2003. 49(2): p. 286-94. 
 
98. Visiopharm® Visiopharm® Integrator System. ver. 4.4.4.0. Available from: 
http://www.visiopharm.com/ 
 
99. NIH. National Center for Biotechnology Information (NCBI).  Primer-BLAST.   [cited 2016 
August 23]; Available from: https://www.ncbi.nlm.nih.gov/tools/primer-blast/. 
 
100. Bjork, J.A. and K.B. Wallace, Structure-activity relationships and human relevance for 
perfluoroalkyl acid-induced transcriptional activation of peroxisome proliferation in liver 
cell cultures. Toxicol Sci, 2009. 111(1): p. 89-99. 
 
 112 
101. Trousil, S., et al., Design of symmetrical and nonsymmetrical N,N-dimethylaminopyridine 
derivatives as highly potent choline kinase alpha inhibitors. Medchemcomm, 2013. 
2013(4): p. 693-696. 
 
102. Alhan, E., et al., Effects of omega-3 fatty acids on acute necrotizing pancreatitis in rats. 
Eur Surg Res, 2006. 38(3): p. 314-21. 
 
103. Frossard, J.L., M.L. Steer, and C.M. Pastor, Acute pancreatitis. Lancet, 2008. 371(9607): 
p. 143-52. 
 
104. Elcombe, C.R., et al., Evaluation of hepatic and thyroid responses in male Sprague 
Dawley rats for up to eighty-four days following seven days of dietary exposure to 
potassium perfluorooctanesulfonate. Toxicology, 2012. 293(1-3): p. 30-40. 
 
105. Sorrentino, D., et al., Sex differences in hepatic fatty acid uptake reflect a greater affinity 
of the transport system in females. Am J Physiol, 1992. 263(3 Pt 1): p. G380-5. 
 
106. Luxon, B.A., et al., Sex differences in multiple steps in hepatic transport of palmitate 
support a balanced uptake mechanism. Am J Physiol, 1998. 274(1 Pt 1): p. G52-61. 
 
107. Castelhano-Carlos, M.J. and V. Baumans, The impact of light, noise, cage cleaning and 
in-house transport on welfare and stress of laboratory rats. Lab Anim, 2009. 43(4): p. 
311-27. 
 
108. Schlingmann, F., et al., Light intensity in animal rooms and cages in relation to the care 
and management of albino rats. Anim Technol, 1993. 44: p. 97-107. 
 
109. Zhang, Y., et al., Poly- and perfluorinated compounds activate human pregnane X 
receptor. Toxicology 2017(DOI: http://dx.doi.org/10.1016/j.tox.2017.01.012). 
 
110. Zhang, H., et al., Rat pregnane X receptor: molecular cloning, tissue distribution, and 
xenobiotic regulation. Arch Biochem Biophys, 1999. 368(1): p. 14-22. 
 
111. Elcombe, C.R., et al., Mode of action and human relevance analysis for nuclear receptor-
mediated liver toxicity: A case study with phenobarbital as a model constitutive 
androstane receptor (CAR) activator. Crit Rev Toxicol, 2014. 44(1): p. 64-82. 
 
112. Liao, W., et al., Blocking microsomal triglyceride transfer protein interferes with apoB 
secretion without causing retention or stress in the ER. J Lipid Res, 2003. 44(5): p. 978-
85. 
 113 
 
113. Minehira, K., et al., Blocking VLDL secretion causes hepatic steatosis but does not affect 
peripheral lipid stores or insulin sensitivity in mice. J Lipid Res, 2008. 49(9): p. 2038-44. 
 
114. Pereira, I.V., J.T. Stefano, and C.P. Oliveira, Microsomal triglyceride transfer protein and 
nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol, 2011. 5(2): p. 245-51. 
 
115. Ameen, C. and J. Oscarsson, Sex difference in hepatic microsomal triglyceride transfer 
protein expression is determined by the growth hormone secretory pattern in the rat. 
Endocrinology, 2003. 144(9): p. 3914-21. 
 
116. Kamper, M., et al., Estrogen enhances secretion of apolipoprotein B-100 containing 
lipoproteins by BeWo cells. Biochimie, 2015. 112: p. 121-8. 
 
117. Barsalani, R., N.A. Chapados, and J.M. Lavoie, Hepatic VLDL-TG production and MTP 
gene expression are decreased in ovariectomized rats: effects of exercise training. Horm 
Metab Res, 2010. 42(12): p. 860-7. 
 
118. Leopoldo, A.S., et al., Classification of different degrees of adiposity in sedentary rats. 
Braz J Med Biol Res, 2016. 49(4): p. e5028. 
 
119. Taylor, B.A. and S.J. Phillips, Detection of obesity QTLs on mouse chromosomes 1 and 7 
by selective DNA pooling. Genomics, 1996. 34(3): p. 389-98. 
 
120. Modica, S., R.M. Gadaleta, and A. Moschetta, Deciphering the nuclear bile acid receptor 
FXR paradigm. Nucl Recept Signal, 2010. 8: p. e005. 
 
121. Sanyal, A.J., Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease. 
Dig Dis, 2015. 33(3): p. 426-32. 
 
122. Lamers, C., M. Schubert-Zsilavecz, and D. Merk, Medicinal chemistry and 
pharmacological effects of Farnesoid X Receptor (FXR) antagonists. Curr Top Med Chem, 
2014. 14(19): p. 2188-205. 
 
123. Zhang, L., et al., Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls 
Hepatic Lipid Metabolism. mSystems, 2016. 1(5). 
 
124. Chen, Y., et al., Estrogen and Estrogen Receptor-alpha-Mediated Transrepression of Bile 
Salt Export Pump. Mol Endocrinol, 2015. 29(4): p. 613-26. 
 
 114 
125. Lai, K., D.C. Harnish, and M.J. Evans, Estrogen receptor alpha regulates expression of the 
orphan receptor small heterodimer partner. J Biol Chem, 2003. 278(38): p. 36418-29. 
 
126. Cui, J., et al., Guggulsterone is a farnesoid X receptor antagonist in coactivator 
association assays but acts to enhance transcription of bile salt export pump. J Biol 
Chem, 2003. 278(12): p. 10214-20. 
 
127. Ali, A.H., E.J. Carey, and K.D. Lindor, Recent advances in the development of farnesoid X 
receptor agonists. Ann Transl Med, 2015. 3(1): p. 5. 
 
128. Persson, L., et al., Importance of proprotein convertase subtilisin/kexin type 9 in the 
hormonal and dietary regulation of rat liver low-density lipoprotein receptors. 
Endocrinology, 2009. 150(3): p. 1140-6. 
 
129. Petrides, F., et al., The promises of PCSK9 inhibition. Curr Opin Lipidol, 2013. 24(4): p. 
307-12. 
 
130. Ghosh, M., et al., Influence of physiological changes in endogenous estrogen on 
circulating PCSK9 and LDL cholesterol. J Lipid Res, 2015. 56(2): p. 463-9. 
 
131. Ngo Sock, E.T., N.A. Chapados, and J.M. Lavoie, LDL receptor and Pcsk9 transcripts are 
decreased in liver of ovariectomized rats: effects of exercise training. Horm Metab Res, 
2014. 46(8): p. 550-5. 
 
132. Persson, L., et al., Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but 
not Lp(a) or bile acid synthesis in women. Arterioscler Thromb Vasc Biol, 2012. 32(3): p. 
810-4. 
 
133. Aleksunes, L.M. and C.D. Klaassen, Coordinated regulation of hepatic phase I and II drug-
metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARalpha-, and Nrf2-null 
mice. Drug Metab Dispos, 2012. 40(7): p. 1366-79. 
 
134. Chu, R., et al., Thyroid hormone (T3) inhibits ciprofibrate-induced transcription of genes 
encoding beta-oxidation enzymes: cross talk between peroxisome proliferator and T3 
signaling pathways. Proc Natl Acad Sci U S A, 1995. 92(25): p. 11593-7. 
 
135. Webb, S.J., et al., Regulation of CYP4A expression in rat by dehydroepiandrosterone and 
thyroid hormone. Mol Pharmacol, 1996. 49(2): p. 276-87. 
 
 115 
136. Joseph, S.B., et al., Direct and indirect mechanisms for regulation of fatty acid synthase 
gene expression by liver X receptors. J Biol Chem, 2002. 277(13): p. 11019-25. 
 
137. Mater, M.K., A.P. Thelen, and D.B. Jump, Arachidonic acid and PGE2 regulation of 
hepatic lipogenic gene expression. J Lipid Res, 1999. 40(6): p. 1045-52. 
 
138. Caton, P.W., et al., PPARalpha-LXR as a novel metabolostatic signalling axis in skeletal 
muscle that acts to optimize substrate selection in response to nutrient status. Biochem 
J, 2011. 437(3): p. 521-30. 
 
139. Mauvoisin, D. and C. Mounier, Hormonal and nutritional regulation of SCD1 gene 
expression. Biochimie, 2011. 93(1): p. 78-86. 
 
140. Nakamura, M.T., B.E. Yudell, and J.J. Loor, Regulation of energy metabolism by long-
chain fatty acids. Prog Lipid Res, 2014. 53: p. 124-44. 
 
141. Nakamura, K., et al., Nuclear pregnane X receptor cross-talk with FoxA2 to mediate drug-
induced regulation of lipid metabolism in fasting mouse liver. J Biol Chem, 2007. 282(13): 
p. 9768-76. 
 
142. David-Silva, A., et al., Hepatocyte nuclear factors 1alpha/4alpha and forkhead box A2 
regulate the solute carrier 2A2 (Slc2a2) gene expression in the liver and kidney of 
diabetic rats. Life Sci, 2013. 93(22): p. 805-13. 
 
143. Rysa, J., et al., Pregnane X receptor agonists impair postprandial glucose tolerance. Clin 
Pharmacol Ther, 2013. 93(6): p. 556-63. 
 
144. Liu, P.C., et al., Induction of endogenous genes by peroxisome proliferator activated 
receptor alpha ligands in a human kidney cell line and in vivo. J Steroid Biochem Mol 
Biol, 2003. 85(1): p. 71-9. 
 
145. Piao, L., et al., FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 
(PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary 
hypertension: therapeutic benefits of dichloroacetate. J Mol Med (Berl), 2013. 91(3): p. 
333-46. 
 
146. Jeong, J.Y., et al., Transcriptional regulation of pyruvate dehydrogenase kinase. Diabetes 
Metab J, 2012. 36(5): p. 328-35. 
 
 116 
147. Miquerol, L., et al., Expression of the L-type pyruvate kinase gene and the hepatocyte 
nuclear factor 4 transcription factor in exocrine and endocrine pancreas. J Biol Chem, 
1994. 269(12): p. 8944-51. 
 
148. Bhalla, S., et al., Ligand-activated pregnane X receptor interferes with HNF-4 signaling by 
targeting a common coactivator PGC-1alpha. Functional implications in hepatic 
cholesterol and glucose metabolism. J Biol Chem, 2004. 279(43): p. 45139-47. 
 
149. Galhardo, M., et al., Integrated analysis of transcript-level regulation of metabolism 
reveals disease-relevant nodes of the human metabolic network. Nucleic Acids Res, 
2014. 42(3): p. 1474-96. 
 
150. Moya, M., et al., Foxa1 reduces lipid accumulation in human hepatocytes and is down-
regulated in nonalcoholic fatty liver. PLoS One, 2012. 7(1): p. e30014. 
 
151. Mazzucotelli, A., et al., The transcriptional coactivator peroxisome proliferator activated 
receptor (PPAR)gamma coactivator-1 alpha and the nuclear receptor PPAR alpha control 
the expression of glycerol kinase and metabolism genes independently of PPAR gamma 
activation in human white adipocytes. Diabetes, 2007. 56(10): p. 2467-75. 
 
152. Nishiyori, A., et al., Determination of tissue specificity of the enhancer by combinatorial 
operation of tissue-enriched transcription factors. Both HNF-4 and C/EBP beta are 
required for liver-specific activity of the ornithine transcarbamylase enhancer. J Biol 
Chem, 1994. 269(2): p. 1323-31. 
 
153. Guei, T.R., et al., Identification of a liver-specific cAMP response element in the human 
argininosuccinate synthetase gene. Biochem Biophys Res Commun, 2008. 377(1): p. 257-
61. 
 
154. Walters, M.W. and K.B. Wallace, Urea cycle gene expression is suppressed by PFOA 
treatment in rats. Toxicol Lett, 2010. 197(1): p. 46-50. 
 
155. Kodama, S., et al., Human nuclear pregnane X receptor cross-talk with CREB to repress 
cAMP activation of the glucose-6-phosphatase gene. Biochem J, 2007. 407(3): p. 373-81. 
 
 117 
Appendix: Supplemental Data 
Supplemental Table 1. Clinical Chemistry Results at Termination for Male Rats fed Control Diet or 5X, 10X, or 15X Choline 
Supplemented Diets for Four Weeks 
Parameter Units 
Control (basal choline) 5X Choline 10X Choline 15X Choline 
Mean 
Standard 
Deviation 
N Mean 
Standard 
Deviation 
N Mean 
Standard 
Deviation 
N Mean 
Standard 
Deviation 
N 
Glucose mg/dL 160.4 37.1 5 147.5 33.1 6 159.8 27.8 6 182.2 78.9 6 
Aspartate 
aminotransferase  
U/L 107.8 21.7 5 97.8 11.1 6 97.0 10.1 6 98.5 22.7 6 
Alanine 
aminotransferase  
U/L 35.6 1.1 5 33.7 3.7 6 32.8 6.9 6 39.8 8.9 6 
Gamma glutamyl 
transferase1 
U/L <3 - 5 <3 - 6 <3 - 6 <3 - 6 
Alkaline  
Phosphatase 
U/L 137.8 18.4 5 124.5 12.6 6 146.3 26.0 6 148.7 24.7 6 
Total Bilirubin2 mg/dL <0.1 - 5 <0.1 - 6 <0.1 - 6 <0.1 - 6 
Direct Bilirubin2 mg/dL <0.1 - 5 <0.1 - 6 <0.1 - 6 <0.1 - 6 
Indirect Bilirubin2 mg/dL <0.1 - 5 <0.1 - 6 <0.1 - 6 <0.1 - 6 
Cholesterol mg/dL 80.8 5.9 5 92.3 10.3 6 87.5d 7.7 6 105.2a,c 11.3 6 
Triglycerides  mg/dL 54.6 15.1 5 48.3 4.2 6 50.3 13.0 6 42.5 3.4 6 
Total Protein g/dL 7.02 0.2 5 7.0 0.3 6 7.1 0.1 6 6.9 0.3 6 
Albumin g/dL 3.6 0.0 5 3.6 0.2 6 3.6 0.1 6 3.5 0.2 6 
Blood Urea 
Nitrogen 
mg/dL 16.4 1.5 5 16.3 2.1 6 16.3 1.5 6 16.8 2.1 6 
Creatinine mg/dL 0.3 0.1 5 0.3 0.0 6 0.3a 0.1 6 0.3a 0.1 6 
Phosphorus mg/dL 12.7 1.4 5 12.5 0.3 6 12.5 1.2 6 12.0 0.6 6 
Calcium mg/dL 12.12 0.6 5 12.3 0.3 6 12.4 0.5 6 12.5 0.4 6 
Sodium mmol/L 146.6 0.9 5 147.2 1.2 6 146.3 1.5 6 146.2 1.0 6 
Potassium mmol/L 8.54 1.1 5 8.4 0.7 6 8.7 1.4 6 7.9 1.0 6 
Chloride mmol/L 100.8 1.8 5 100.5 1.5 6 100.7 0.5 6 99.0 1.9 6 
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Supplemental Table 1. Clinical Chemistry Results at Termination for Male Rats fed Control Diet or 5X, 10X, or 15X Choline 
Supplemented Diets for Four Weeks 
Parameter Units 
Control (basal choline) 5X Choline 10X Choline 15X Choline 
Mean 
Standard 
Deviation 
N Mean 
Standard 
Deviation 
N Mean 
Standard 
Deviation 
N Mean 
Standard 
Deviation 
N 
Bicarbonate mmol/L 29.4 2.1 5 30.7 1.6 6 32.7 3.1 6 32.5 2.2 6 
Anion Gap mmol/L 25 3.1 5 24.3 1.0 6 22.0 3.8 6 22.5 2.2 6 
Creatine Kinase  U/L 463.6 624.3 5 186.7 94.4 6 166.2 33.0 6 389.2 592.7 6 
Lactate 
Dehydrogenase  
U/L 474.4 321.3 5 383.2 106.4 6 289.0 68.9 6 341.0 244.9 6 
Amylase U/L 693.2 163.9 5 661.7 97.3 6 814.0 145.3 6 717.2 84.9 6 
Lipase U/L 15.8 2.9 5 14.0 3.0 6 14.8 3.4 6 14.2 4.1 6 
Globulin g/dL 3.4 0.2 5 3.4 0.2 6 3.5 0.1 6 3.4 0.2 6 
A/G Ratio - 1.1 0.1 5 1.0 0.1 6 1.0 0.1 6 1.0 0.1 6 
Urea/Creatinine 
Ratio 
- 49.2 8.3 5 58.7 10.4 6 67.7 14.5 6 69.0a 10.2 6 
Na/K Ratio mmol/L 17.6 2.5 5 17.7 1.6 6 17.3 3.1 6 18.8 2.5 6 
High density 
lipoprotein  
mg/dL 27.6 1.5 5 27.0d 2.0 6 29.7 2.3 6 34.7a,b 5.1 6 
Low density 
lipoprotein  
mg/dL 8.2 1.6 5 9.5 1.6 6 9.0 2.4 6 10.7 1.9 6 
Letter code indicates significantly different parameter by group using one-way ANOVA with Tukey’s multiple comparisons test (p<0.05, GraphPad 
Prism®, v. 6.04). (a) vs. control, (b) vs. 5X, (c) vs. 10X, and (d) vs. 15X 
  
1.  All gamma glutamyl transferase values were below the limit of detection (3 U/L) 
2.  All total, direct, and indirect bilirubin values were below the limit of detection (0.1 mg/dL).  
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Supplemental Table 2. Clinical Chemistry Results at Termination for Female Rats fed Control Diet or 5X, 10X, or 15X 
Choline Supplemented Diets for Four Weeks 
  
Parameter Units 
Control (basal choline) 5X Choline 10X Choline 15X Choline 
Mean 
Standard 
Deviation 
N Mean 
Standard 
Deviation 
N Mean 
Standard 
Deviation 
N1 Mean 
Standard 
Deviation 
N 
Glucose mg/dL 83.2 9.3 5 79.7 8.0 6 95.0 10.6 4 92.3 13.0 6 
Aspartate 
aminotransferase  
U/L 103.2 13.0 5 109.5 7.7 6 100.8 9.5 4 98.8 6.9 6 
Alanine 
transaminase  
U/L 34.4 6.8 5 34.5 2.2 6 33.8 6.3 4 34.8 10.8 6 
Gamma glutamyl 
transferase1 
U/L <3 - 5 <3 - 6 <3 - 4 <3 - 6 
Alkaline  
Phosphatase 
U/L 102.6 25.0 5 105.8 13.9 6 95.8 12.0 4 90.7 11.0 6 
Total Bilirubin2 mg/dL ≤0.1 - 5 ≤0.1 - 6 ≤0.1 - 4 ≤0.1 - 6 
Direct Bilirubin2 mg/dL <0.1 - 5 <0.1 - 6 <0.1 - 4 <0.1 - 6 
Indirect Bilirubin2 mg/dL <0.1 - 5 <0.1 - 6 <0.1 - 4 <0.1 - 6 
Cholesterol mg/dL 86.4 9.4 5 94.5 9.9 6 100.0 24.7 4 89.2 14.9 6 
Triglycerides  mg/dL 40.4 6.6 5 48.2 10.8 6 41.3 12.4 4 36.3 3.7 6 
Total Protein g/dL 6.7 0.4 5 6.7 0.2 6 6.8 0.1 4 6.5 0.2 6 
Albumin g/dL 3.6 0.2 5 3.6d 0.1 6 3.5 0.1 4 3.3a,b 0.1 6 
Blood Urea 
Nitrogen 
mg/dL 19.2 1.8 5 17.3 2.4 6 18.0 1.6 4 17.2 2.7 6 
Creatinine mg/dL 0.4 0.1 5 0.3 0.1 6 0.3 0.1 4 0.3a 0.1 6 
Phosphorus mg/dL 12.4 0.7 5 11.2 0.5 6 12.6 0.6 4 12.7 1.5 6 
Calcium mg/dL 11.7 0.4 5 11.5 0.3 6 11.7 0.4 4 11.9 0.5 6 
Sodium mmol/L 145.0 1.0 5 143.8 1.5 6 143.3 1.9 4 142.7 1.2 6 
Potassium mmol/L 9.4 0.6 5 9.3 0.4 6 10.0 1.0 4 9.8 0.9 6 
Chloride mmol/L 101.2 1.1 5 101.7 1.2 6 102.0 0.8 4 101.3 1.2 6 
Bicarbonate mmol/L 31.8 1.8 5 30.3 2.5 6 29.0 0.8 4 29.7 2.2 6 
Anion Gap mmol/L 21.4 3.0 5 21.2 4.1 6 22.5 1.3 4 21.2 1.9 6 
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Supplemental Table 2. Clinical Chemistry Results at Termination for Female Rats fed Control Diet or 5X, 10X, or 15X 
Choline Supplemented Diets for Four Weeks 
  
Parameter Units 
Control (basal choline) 5X Choline 10X Choline 15X Choline 
Mean 
Standard 
Deviation 
N Mean 
Standard 
Deviation 
N Mean 
Standard 
Deviation 
N1 Mean 
Standard 
Deviation 
N 
Creatine Kinase  U/L 203.2 46.1 5 209.5 49.8 6 189.5 101.6 4 131.2 18.3 6 
Lactate 
Dehydrogenase  
U/L 436.4 78.7 5 453.3 154.7 6 324.8 99.9 4 272.0 137.1 6 
Amylase U/L 316.0 40.5 5 375.8 70.5 6 382.5 54.4 4 350.0 46.0 6 
Lipase U/L 12.0 1.7 5 13.2 2.9 6 13.0 0.8 4 15.8 7.2 6 
Globulin g/dL 3.2 0.2 5 3.2 0.2 6 3.3 0.1 4 3.2 0.1 6 
A/G Ratio - 1.1 0.0 5 1.1 0.1 6 1.1 0.0 4 1.1 0.1 6 
Urea/Creatinine 
Ratio 
- 54.0 6.5 5 53.5 12.9 6 56.3 9.4 4 66.7 19.3 6 
Na/K Ratio mmol/L 15.6 1.1 5 15.3 0.5 6 14.3 1.5 4 14.8 1.2 6 
High density 
lipoprotein  
mg/dL 27.8 2.7 5 32.7a 1.2 6 33.5a 3.7 4 32.3 3.2 6 
Low density 
lipoprotein  
mg/dL 6.4 0.9 5 6.3 0.8 6 6.8 1.0 4 7.3 1.0 6 
Letter code indicates significantly different parameter by group using one-way ANOVA with Tukey’s multiple comparisons test (p<0.05, GraphPad 
Prism®, v. 6.04). (a) vs. control, (b) vs. 5X, (c) vs. 10X, and (d) vs. 15X 
 
1.   Blood was not successfully collected from two females of the 10X choline group due to technician difficulties.  Sufficient animals remained for 
evaluation of this group.  
2.  All gamma glutamyl transferase values were below the limit of detection (3 U/L). 
3.  All total bilirubin values were at or below the limit of detection (0.1 mg/dL). 
4.  All direct and indirect bilirubin values were below the limit of detection (0.1 mg/dL). 
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Supplemental Table 3.  mRNA Targets and Primers used to Measure Liver mRNA in Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
Name Abbr. mRNA RefSeq Forward Primer (5’ → 3’) Reverse Primer (5’ → 3’) Product 
Length 
(base 
pairs) 
Rattus norvegicus 
enoyl-CoA hydratase 
and 3-hydroxyacyl 
CoA dehydrogenase  
Ehhadh NM_133606.1 
 
CTGGGGATTCTTCCTGGTGC TGTTGGGCAAGCTTGGAACT 247 
Rattus norvegicus 
stearoyl-CoA 
desaturase  
Scd1 NM_139192.2 CGAAACTTTCCTGCACAGCC AAGTTGATGTGCCAGCGGTA 240 
Rattus norvegicus 
CD36 molecule 
Cd36 NM_031561.2 AGAAACCAAGTGACCGGGAA CCACCGTTTCTTCAACTACAGA 250 
Rattus norvegicus cell 
death-inducing DFFA-
like effector c (fat-
specific protein) 
Fsp27 NM_001024333.2 GCTTGGGTCAGAGAAACAATGG CCATGATGCCTTTGCGAACC 226 
Rattus norvegicus 
glutathione S-
transferase theta 1, 
transcript variant X2 
Gsst1 XM_008772860.1 CTGCTGAGACCGAATAGCGA TTCCAACAGCCCAGGATGAG 230 
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Supplemental Table 4.  Dietary Choline and PFOS Concentrations in the Control, Choline Supplemented (CS), 
100 ppm PFOS, and 100 ppm PFOS + CS diets used in the Three Week Study (Chapter 3) 
Parameter 
Control (basal 
choline) 
Choline 
Supplemented 
(CS) 
100 ppm PFOS 
100 ppm PFOS + 
CS 
Target choline concentration 
(ppm) 
1700 5125 1700 5125 
Mean (±SD) choline 
concentration (ppm) 
1858 ± 153 4890 ± 395 1782 ± 128 4920 ± 313 
Coefficient of variation for 
choline concentrations 
8.2% 8.1% 7.2% 6.4% 
Target PFOS concentration 
(ppm) 
0 0 100 100 
Mean (±SD) PFOS 
concentration (ppm) 
<0.051 <0.051 92.0 ± 6.8* 94.3 ± 11.9 
Coefficient of variation for 
PFOS concentrations 
Not applicable Not applicable 7.4% 12.7% 
1. The limit of quantification for PFOS concentration in the diet was 0.05 ppm.  All values were below the limit of quantification 
except one sample from one choline supplemented box (0.07 ppm). 
* Significance difference between the mean PFOS concentration and the target concentration in the 100 ppm PFOS diet based on 
one-sample t-tests (p<0.05, GraphPad Prism®, v. 6.04).  There was no significant difference in PFOS concentration between the 
100 ppm PFOS and 100 ppm PFOS + CS groups based on a two-sample t-test (p>0.05, GraphPad Prism®, v. 6.04). 
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Supplemental Table 5. Day 2 Non-fasted Serum Clinical Chemistry Results in Male Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N Mean SD N Mean SD N1 Mean SD N 
Glucose mg/dL 126 11.6 12 128 13.1 12 126 8.0 12 124 15.1 12 
Aspartate 
aminotransferase  U/L 69 7.2 12 61 a 6.7 12 58 a 3.8 12 61 a 6.3 12 
Alanine 
aminotransferase  U/L 29 4.0 12 27 3.1 12 26 3.0 12 25 a 3.1 12 
Gamma glutamyl 
transferase  U/L 0.7 0.7 12 0.8 0.6 12 0.6 0.5 12 0.5 0.5 12 
Alkaline  
Phosphatase U/L 449 27.0 12 434 57.5 12 384 a 56.0 12 396 50.3 12 
Total Bilirubin mg/dL 0.02 0.0 12 0.03 0.0 12 0.01 0.03 12 0.01 0.03 12 
Direct Bilirubin mg/dL <0.1 - 12 <0.1 - 12 <0.1 - 12 <0.1 - 12 
Indirect Bilirubin mg/dL NC2 - 12 NC - 12 NC - 12 NC - 12 
Cholesterol mg/dL 104 9.6 12 103 12.0 12 97 9.4 12 101 5.5 12 
Triglycerides  mg/dL 117 40.6 12 159 57.6 12 119 39.1 12 115 51.2 12 
Total Protein g/dL 6.0 0.2 12 6.0 0.2 12 5.8 0.2 12 6.0  0.1 12 
Albumin g/dL 3.3 0.1 12 3.2 0.1 12 3.2 0.1 12 3.3 0.1 12 
Blood Urea 
Nitrogen mg/dL 15 1.8 12 16 c,d 2.7 12 13 b 2.5 12 13 b 2.1 12 
Creatinine mg/dL 0.1 0.1 12 0.1 0.05 12 0.1 0.04 11 0.1 0.1 12 
Phosphorus mg/dL 8.5 0.6 12 8.8 c,d 0.5 12 9.4 a,b 0.6 12 10 a,b 0.4 12 
Calcium mg/dL 10 0.2 12 10 0.4 12 10 0.3 12 11 a 0.2 12 
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Supplemental Table 5. Day 2 Non-fasted Serum Clinical Chemistry Results in Male Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N Mean SD N Mean SD N1 Mean SD N 
Sodium mmol/L 139 4.2 12 140 3.5 12 141 2.5 12 144 a 4.2 12 
Potassium mmol/L 5.9 0.4 12 5.7 d 0.5 12 5.9 0.2 12 6.2 b 0.3 12 
Chloride mmol/L 99 3.4 12 100 2.5 12 100 1.8 12 104 a 3.6 12 
Bicarbonate mmol/L 20 4.3 12 19 2.7 12 21 1.5 12 20 5.3 12 
Anion Gap mmol/L 26 4.8 12 26 3.7 12 25 2.0 12 26 6.3 12 
Creatine Kinase  U/L 142 41.8 12 115 43.8 12 107 23.2 12 127 31.2 12 
Lactate 
Dehydrogenase  U/L 298 186.0 12 171 142.6 12 119 a 65.2 12 161 a 57.8 12 
Amylase U/L 761 60.8 12 768 93.8 12 816 80.0 12 817 67.6 12 
Lipase U/L 6.4 1.0 12 7.3 c,d 1.3 12 4.1 a,b 0.8 12 3.9 a,b 1.4 12 
Globulin g/dL 2.7 0.1 12 2.7 0.2 12 2.6 0.1 12 2.8 0.1 12 
A/G Ratio - 1.2 0.1 12 1.2 0.1 12 1.2 0.1 12 1.2 0.1 12 
Urea/Creatinine 
Ratio - 121 47.0 12 142 45.1 12 123 40.8 11 104 36.6 12 
Na/K Ratio mmol/L 24 1.1 12 25 1.9 12 24 0.9 12 23 1.0 12 
High density 
lipoprotein  mg/dL 36 3.3 12 35 3.4 12 36 3.0 12 37 2.3 12 
Low density 
lipoprotein  mg/dL 22 2.7 12 21 c,d 3.3 12 17 a,b 2.3 12 17 a,b 1.6 12 
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Supplemental Table 5. Day 2 Non-fasted Serum Clinical Chemistry Results in Male Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N Mean SD N Mean SD N1 Mean SD N 
1. Insufficient serum was available due to technical difficulties which reduced the N for the indicated parameters.  These small 
differences in N are not expected to have affected the outcome of the study. 
2. NC indicates not calculated. 
 
Statistically significant differences are indicated for each group comparison vs. control (a), vs. CS (b), (c) vs. PFOS, and (d) vs. 
PFOS + CS. using one-way ANOVA with Tukey’s multiple comparisons test, p<0.05. 
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Supplemental Table 6. Day 9 Non-fasted Serum Clinical Chemistry Results in Male Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N Mean SD N Mean SD N Mean SD N 
Glucose mg/dL 108 15.6 12 101 10.5 12 110 b 9.4 12 123 16.6 12 
Aspartate 
aminotransferase  U/L 89 20.0 12 76 a 8.3 12 64 a 5.2 12 63 a 6.8 12 
Alanine 
aminotransferase  U/L 32 6.3 12 28 3.2 12 28 3.7 12 26 a 3.7 12 
Gamma glutamyl 
transferase  U/L 0.4 0.5 12 0.7 0.7 12 0.3 0.5 12 0.3 0.5 12 
Alkaline  
Phosphatase U/L 346 40.0 12 343 36.3 12 310 43.8 12 293 50.7 12 
Total Bilirubin mg/dL 0.1 0.1 12 0.0 a 0.1 12 0.02 a 0.04 12 0.01 a 0.03 12 
Direct Bilirubin mg/dL <0.1 - 12 <0.1 - 12 <0.1 - 12 <0.1 - 12 
Indirect Bilirubin mg/dL NC1 - 12 NC - 12 NC - 12 NC - 12 
Cholesterol mg/dL 96 9.4 12 106 a,c,d 7.7 12 74 a,b 8.1 12 81 a,b 7.9 12 
Triglycerides mg/dL 116 38.5 12 121 d 46.6 12 85 23.6 12 80 b 17.9 12 
Total Protein g/dL 6.4 0.3 12 6.4 0.2 12 6.5 0.2 12 6.3 0.2 12 
Albumin g/dL 3.6 0.1 12 3.5 c 0.1 12 3.7 a,b 0.1 12 3.6 c 0.1 12 
Blood Urea 
Nitrogen mg/dL 13 1.8 12 12 d 1.6 12 10 a 2.3 12 8.6 a,b 1.6 12 
Creatinine mg/dL 0.2 0.1 12 0.2 0.03 12 0.2 0.04 12 0.2 0.03 12 
Phosphorus mg/dL 8.8 0.5 12 8.5 0.5 12 8.0 0.5 12 8.4 0.5 12 
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Supplemental Table 6. Day 9 Non-fasted Serum Clinical Chemistry Results in Male Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N Mean SD N Mean SD N Mean SD N 
Calcium mg/dL 10 0.3 12 10 0.3 12 10 0.3 12 10 0.3 12 
Sodium mmol/L 143 3.7 12 141 4.4 12 142 2.6 12 142 3.7 12 
Potassium mmol/L 5.7 0.3 12 5.2 a 0.3 12 5.2 a 0.2 12 5.3 a 0.2 12 
Chloride mmol/L 100 2.7 12 97 3.2 12 100 1.5 12 101 2.0 12 
Bicarbonate mmol/L 19 2.5 12 20 1.7 12 22 a 0.7 12 20 1.9 12 
Anion Gap mmol/L 30 2.9 12 28 3.1 12 26 a 2.3 12 27 a 4.2 12 
Creatine Kinase  U/L 283 235.0 12 207 60.3 12 126 a 30.9 12 150 63.4 12 
Lactate 
Dehydrogenase  U/L 1008 584.2 12 789 c, d 326.3 12 381 a,b 142.8 12 337 a,b 156.2 12 
Amylase U/L 865 82.0 12 852 150.1 12 849 84.0 12 840 95.4 12 
Lipase U/L 5.8 1.3 12 7.9 a,c,d 0.9 12 4.3 b 1.1 12 4.8 b 2.8 12 
Globulin g/dL 2.8 0.2 12 2.9 0.1 12 2.8 0.1 12 2.8 0.1 12 
A/G Ratio - 1.3 0.1 12 1.2 c,d 0.05 12 1.4 a,b 0.1 12 1.3 b 0.1 12 
Urea/Creatinine 
Ratio - 56 12.4 12 59 9.8 12 54 22.1 12 47 15.9 12 
Na/K Ratio mmol/L 25 1.7 12 27 a 1.2 12 28 a 1.5 12 27 1.1 12 
High density 
lipoprotein  mg/dL 40 3.4 12 43 c,d 3.5 12 31 a,b 4.3 12 32 a,b 2.9 12 
Low density 
lipoprotein  mg/dL 17 2.2 12 16 c,d 1.9 12 13 a,b 2.3 12 13 a,b 2.2 12 
1. NC indicates not calculated. 
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Supplemental Table 6. Day 9 Non-fasted Serum Clinical Chemistry Results in Male Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N Mean SD N Mean SD N Mean SD N 
 
Statistically significant differences are indicated for each group comparison vs. control (a), vs. CS (b), (c) vs. PFOS, and (d) vs. 
PFOS + CS. using one-way ANOVA with Tukey’s multiple comparisons test, p<0.05. 
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Supplemental Table 7. Day 16 Non-fasted Serum Clinical Chemistry Results in Male Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N Mean SD N Mean SD N Mean SD N 
Glucose mg/dL 119 11.5 12 126 11.3 12 131 22.3 12 122 15.5 12 
Aspartate 
aminotransferase  U/L 63 8.3 12 58 4.6 12 62 7.2 12 57 5.5 12 
Alanine 
aminotransferase  U/L 28 7.2 12 26 3.7 12 30 7.0 12 25 7.2 12 
Gamma glutamyl 
transferase  U/L 0.2 0.4 12 0.3 0.5 12 0.0 0.0 12 0.1 0.3 12 
Alkaline  
Phosphatase U/L 281 36.0 12 293 24.1 12 303 36.2 12 273 43.0 12 
Total Bilirubin mg/dL 0.03 0.1 12 0.02 0.04 12 0.02 0.04 12 0.03 0.05 12 
Direct Bilirubin mg/dL <0.1 - 12 <0.1 - 12 <0.1 - 12 <0.1 - 12 
Indirect Bilirubin mg/dL NC1 - 12 NC - 12 NC - 12 NC - 12 
Cholesterol mg/dL 87 10.7 12 105 a,c,d 13.3 12 54 a,b 7.4 12 58 a,b 7.3 12 
Triglycerides  mg/dL 120 36.6 12 131 c,d 26.5 12 71 a,b 19.3 12 67 a,b 23.6 12 
Total Protein g/dL 6.3 0.2 12 6.3 0.3 12 6.5 0.3 12 6.2 c 0.2 12 
Albumin g/dL 3.5 0.1 12 3.5 c 0.2 12 3.8 a,b 0.2 12 3.6 c 0.1 12 
Blood Urea 
Nitrogen mg/dL 14 1.0 12 14 2.1 12 14 2.6 12 13 1.6 12 
Creatinine mg/dL 0.2 0.0 12 0.2 0.03 12 0.2 0.03 12 0.2 0.03 12 
Phosphorus mg/dL 7.5 0.4 12 7.6 0.6 12 7.8 0.6 12 7.6 0.6 12 
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Supplemental Table 7. Day 16 Non-fasted Serum Clinical Chemistry Results in Male Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N Mean SD N Mean SD N Mean SD N 
Calcium mg/dL 10 0.3 12 11 a 0.4 12 11 a 0.5 12 10 0.3 12 
Sodium mmol/L 140 3.7 12 142 3.2 12 144 a 3.3 12 140 c 2.1 12 
Potassium mmol/L 5.4 0.4 12 5.1 0.4 12 4.9 a 0.3 12 4.8 a 0.3 12 
Chloride mmol/L 100 2.3 12 101 2.3 12 103 a 2.6 12 102 1.6 12 
Bicarbonate mmol/L 20 1.9 12 21 c 1.5 12 19 b 2.1 12 18 1.7 12 
Anion Gap mmol/L 26 3.3 12 25 1.6 12 27 2.2 12 25 2.4 12 
Creatine Kinase  U/L 140 42.5 12 87 a 10.0 12 83 a 21.9 12 81 a 13.2 12 
Lactate 
Dehydrogenase  U/L 370 218 12 163 a 58.2 12 167 a 82.1 12 187 a 92.3 12 
Amylase U/L 846 76.7 12 860 135.5 12 837 78.9 12 804 69.2 12 
Lipase U/L 6.6 1.4 12 7.8 c,d 1.5 12 3.8 a,b 0.9 12 3.8 a,b 1.6 12 
Globulin g/dL 2.8 0.1 12 2.8 c,d 0.2 12 2.6 a,b 0.1 12 2.6 a,b 0.1 12 
A/G Ratio - 1.2 0.1 12 1.2 c,d 0.1 12 1.5 a,b 0.1 12 1.4 a,b 0.1 12 
Urea/Creatinine 
Ratio - 67 10.4 12 66 12.9 12 67 13.1 12 69 26.4 12 
Na/K Ratio mmol/L 26 1.8 12 28 1.9 12 30 a 1.8 12 29 a 2.0 12 
High density 
lipoprotein (HDL) mg/dL 38 3.9 12 41 c,d 3.9 12 26 a,b 2.6 12 25 a,b 3.3 12 
Low density 
lipoprotein (LDL) mg/dL 14 2.6 12 16 c,d 2.1 12 7.8 a,b 1.4 12 8.1 a,b 1.2 12 
1. NC indicates not calculated. 
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Supplemental Table 7. Day 16 Non-fasted Serum Clinical Chemistry Results in Male Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N Mean SD N Mean SD N Mean SD N 
 
Statistically significant differences are indicated for each group comparison vs. control (a), vs. CS (b), (c) vs. PFOS, and (d) vs. 
PFOS + CS. using one-way ANOVA with Tukey’s multiple comparisons test, p<0.05. 
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Supplemental Table 8. Day 23 Fasted Serum Clinical Chemistry Results in Male Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N1 Mean SD N Mean SD N Mean SD N1 
Glucose mg/dL 107 34.3 12 117 42.2 12 116 22.4 12 112 12.0 12 
Aspartate 
aminotransferase  U/L 80 8.9 12 80 7.5 12 95 15.2 12 96 31.2 12 
Alanine 
aminotransferase  U/L 25 4.7 12 25 c,d 4.7 12 54 a,b 16.2 12 49 a,b 22.8 12 
Gamma glutamyl 
transferase  U/L 0.1 0.3 12 0.0 0.0 12 0.0 0.0 12 0.0 0.0 12 
Alkaline  
Phosphatase U/L 136 104 12 114 7.2 12 146 20.6 12 143 16.5 12 
Total Bilirubin mg/dL 0.1 0.1 12 0.1 c,d 0.0 12 0.3 a,b,d 0.1 12 0.2 a,b,c 0.1 12 
Direct Bilirubin mg/dL <0.1 - 12 <0.1 - 12 <0.1 - 12 <0.1 - 12 
Indirect Bilirubin mg/dL NC2 - 12 NC - 12 NC - 12 NC - 12 
Cholesterol mg/dL 84 10.8 12 89 c,d 9.5 12 46 a,b 5.2 12 47 a,b 7.3 12 
Triglycerides  mg/dL 57 9.3 12 53 c,d 14.9 12 28 a,b 6.3 12 31 a,b 5.0 12 
Total Protein g/dL 6.5 0.4 12 6.4 c,d 0.3 12 6.9 a,b 0.3 12 6.9 a,b 0.2 11 
Albumin g/dL 3.6 0.2 12 3.6 c,d 0.2 12 3.9 a,b 0.1 12 3.9 a,b 0.1 12 
Blood Urea 
Nitrogen mg/dL 15 1.7 12 13 a,c,d 1.0 12 18 a,b 2.1 12 16 b 2.0 12 
Creatinine mg/dL 0.3 0.1 12 0.3 c,d 0.0 12 0.2 a,b 0.04 12 0.2 a,b 0.04 12 
Phosphorus mg/dL 12 1.3 12 12 1.2 12 12 0.8 12 11 1.0 12 
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Supplemental Table 8. Day 23 Fasted Serum Clinical Chemistry Results in Male Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N1 Mean SD N Mean SD N Mean SD N1 
Calcium mg/dL 12 0.7 12 12 c,d 0.4 12 13 a,b 0.3 12 12 a,b 0.3 12 
Sodium mmol/L 143 4.6 11 143 d 2.1 12 145 1.3 12 146 a,b 2.0 12 
Potassium mmol/L 9.0 1.2 11 8.8 1.0 12 8.4 0.5 12 8.6 1.4 12 
Chloride mmol/L 99 2.4 11 97 d 2.1 12 98 1.6 12 100 b 1.2 12 
Bicarbonate mmol/L 27 2.9 12 28 2.8 12 31 a 3.4 12 31 a 3.4 12 
Anion Gap mmol/L 26 2.3 11 26 3.4 12 25 4.1 12 24 3.5 12 
Creatine Kinase  U/L 119 39.5 12 117 75.7 12 118 28.6 12 98 48.3 12 
Lactate 
Dehydrogenase  U/L 358 148 12 270 c,d 83.3 12 678 b 134 12 627 b 594 12 
Amylase U/L 592 79.2 12 638 c,d 130.6 12 525 b 75.2 12 498 b 50.6 12 
Lipase U/L 8.3 2.2 12 9.4 c,d 2.5 12 5.5 a,b 2.1 12 5.1 a,b 2.3 11 
Globulin g/dL 2.9 0.2 12 2.8 0.2 12 3.0 0.2 12 3.0 0.2 11 
A/G Ratio - 1.3 0.1 12 1.3 0.1 12 1.3 0.1 12 1.3 0.1 11 
Urea/Creatinine 
Ratio - 52 37.4 12 43 c,d 9.3 12 84 a,b 14.7 12 94 a,b 25.7 12 
Na/K Ratio mmol/L 16 2.8 11 16 1.9 12 17 1.2 12 17 2.5 12 
High density 
lipoprotein  mg/dL 25 3.7 12 27 c 3.1 12 22 b 2.9 12 24 b 3.4 12 
Low density 
lipoprotein  mg/dL 14 3.8 12 11 a,c,d 1.6 12 3.6 a,b 0.7 12 4.1 a,b 1.3 12 
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Supplemental Table 8. Day 23 Fasted Serum Clinical Chemistry Results in Male Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N1 Mean SD N Mean SD N Mean SD N1 
1. Insufficient serum was available due to technical difficulties during blood collection which reduced the N for the indicated 
parameters.  These differences in the number of sera analyzed did not affect the interpretation of the study results. 
2. NC indicates not calculated. 
 
Statistically significant differences are indicated for each group comparison vs. control (a), vs. CS (b), (c) vs. PFOS, and (d) vs. 
PFOS + CS using one-way ANOVA with Tukey’s multiple comparisons test, p<0.05. 
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Supplemental Table 9. Day 2 Non-fasted Serum Clinical Chemistry Results in Female Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N1 Mean SD N1 Mean SD N Mean SD N1 
Glucose mg/dL 95.5 16.8 12 119 a 13.6 12 115 a 7.7 12 121 a 8.3 12 
Aspartate 
aminotransferase  U/L 65 7.0 11 60 c 8.1 12 70 b 9.9 12 60 c 5.0 12 
Alanine 
aminotransferase  U/L 19 3.6 12 20 1.9 12 21 3.2 12 21 2.3 12 
Gamma glutamyl 
transferase  U/L 0.6 0.5 7 0.8 0.4 12 0.8 0.6 12 0.3 0.5 12 
Alkaline  
Phosphatase U/L 295 56.4 12 311 46.8 12 268 49.4 12 268 53.5 12 
Total Bilirubin mg/dL 0.0 0.0 8 0.01 0.03 12 0.01 0.0 12 0.0 0.0 12 
Direct Bilirubin mg/dL <0.1 - 8 <0.1 - 12 <0.1 - 12 <0.1 - 12 
Indirect Bilirubin mg/dL NC2 - 12 NC - 12 NC - 12 NC - 12 
Cholesterol mg/dL 82 15.0 12 93 9.0 12 97a 12.9 12 98a 15.7 12 
Triglycerides mg/dL 50 13.6 12 52 20.2 12 70 38.3 12 54 18.6 12 
Total Protein g/dL 5.4 0.7 7 5.4 0.3 12 5.7 0.3 12 5.8a, b 0.2 11 
Albumin g/dL 3.1 0.5 8 3.2 0.2 12 3.3 0.2 12 3.3 0.1 11 
Blood Urea 
Nitrogen mg/dL 15.7 3.1 12 14.4 2.8 12 12.9 2.3 12 12.4a 2.6 12 
Creatinine mg/dL 0.1 0.0 6 0.1 0.03 12 0.2 0.1 12 0.1 0.0 12 
Phosphorus mg/dL 7.9 0.7 7 8.3 0.6 12 8.9 a 0.6 12 9.1 a 0.7 11 
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Supplemental Table 9. Day 2 Non-fasted Serum Clinical Chemistry Results in Female Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N1 Mean SD N1 Mean SD N Mean SD N1 
Calcium mg/dL 9.9 0.3 6 9.7 0.4 12 9.9 0.4 12 9.8 0.3 12 
Sodium mmol/L 143 3.8 6 137a 2.0 12 139a 1.5 12 139a 1.8 12 
Potassium mmol/L 5.7 0.5 6 5.8 0.3 12 5.6 0.3 12 5.9 0.2 12 
Chloride mmol/L 104 3.1 6 101 1.9 12 99.8a 2.6 12 102c 1.6 12 
Bicarbonate mmol/L 20.0 2.1 6 18.3 2.9 12 19.8 2.8 12 18.2 2.8 12 
Anion Gap mmol/L 24.8 3.2 6 23.6 3.0 12 25.3 3.1 12 24.8 3.5 12 
Creatine Kinase  U/L 145 30.3 8 124 37.1 12 191b 66.0 12 115c 36.9 12 
Lactate 
Dehydrogenase  U/L 457 97.9 8 291c 185 12 565b, d 320 12 210c 91.0 12 
Amylase U/L 445 53.7 8 499 120 12 549a 84 12 460 33.7 12 
Lipase U/L 1.9 0.9 7 2.2c 1.1 11 3.7 a, b 1.2 12 2.3c 1.0 12 
Globulin g/dL 2.2 0.4 7 2.3d 0.1 12 2.4a 0.1 12 2.5a, b 0.1 11 
A/G Ratio - 1.5 0.3 7 1.4 0.1 12 1.4 0.1 12 1.3 0.1 11 
Urea/Creatinine 
Ratio - 145.8 40.8 6 137 31.8 12 99.6 44.9 12 102 34.5 12 
Na/K Ratio mmol/L 25.0 1.3 6 23.8c 1.1 12 25.2b, d 1.6 12 23.7c 0.9 12 
High density 
lipoprotein  mg/dL 29.8 3.5 9 29.6 2.5 12 30.8 2.7 12 30.6 2.9 12 
Low density 
lipoprotein  mg/dL 12.9 1.8 10 14.2 2.2 12 14.8 2.4 12 13.6 2.5 12 
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Supplemental Table 9. Day 2 Non-fasted Serum Clinical Chemistry Results in Female Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N1 Mean SD N1 Mean SD N Mean SD N1 
1. Insufficient serum was available due to technical difficulties which reduced the N for the indicated parameters.  These small 
differences in N are not expected to have affected the outcome of the study. 
2. NC indicates not calculated. 
 
Statistically significant differences are indicated for each group comparison vs. control (a), vs. CS (b), (c) vs. PFOS, and (d) vs. 
PFOS + CS using one-way ANOVA with Tukey’s multiple comparisons test, p<0.05. 
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Supplemental Table 10. Day 9 Non-fasted Serum Clinical Chemistry Results in Female Rats fed Control, 
Choline Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N1 Mean SD N Mean SD N Mean SD N 
Glucose mg/dL 114 11.4 12 121 10.9 12 120 10.5 12 133 a,b,c 10.2 12 
Aspartate 
aminotransferase U/L 70 7.5 12 59a 5.1 12 59 a 5.3 12 58 a 3.9 12 
Alanine 
aminotransferase  U/L 26 5.1 12 22 4.3 12 26 5.9 12 24 3.8 12 
Gamma glutamyl 
transferase  U/L 1.0 0.0 12 0.8 0.4 12 0.6 0.5 12 0.8 0.5 12 
Alkaline  
Phosphatase U/L 360 47.6 12 325 94.1 12 272 a 46.8 12 285 a 28.9 12 
Total Bilirubin mg/dL 0.0 0.0 12 0.0 0.0 12 0.0 0.0 12 0.0 0.0 12 
Direct Bilirubin mg/dL <0.1 - 12 <0.1 - 12 <0.1 - 12 <0.1 - 12 
Indirect Bilirubin mg/dL NC1 - 12 NC - 12 NC - 12 NC - 12 
Cholesterol mg/dL 92 7.6 12 99 c,d 12.3 12 82 b 12.0 12 83b 11.4 12 
Triglycerides  mg/dL 46 6.8 12 54 23.8 12 50.6 9.3 12 57 13.1 12 
Total Protein g/dL 6.2 0.2 12 6.2 c 0.2 12 6.5 a,b 0.2 12 6.2 c 0.2 12 
Albumin g/dL 3.7 0.1 12 3.6 c,d 0.1 12 3.9 a, b, d 0.1 12 3.7 b, c 0.2 12 
Blood Urea 
Nitrogen mg/dL 14 2.1 12 15 c,d 2.8 12 11 a, b 3.0 12 11 a, b 2.1 12 
Creatinine mg/dL 0.2 0.04 12 0.2 0.05 12 0.2 0.1 12 0.2 0.0 12 
Phosphorus mg/dL 7.7 0.5 12 8.2 d 0.7 12 7.9 0.5 12 7.5 b 0.4 12 
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Supplemental Table 10. Day 9 Non-fasted Serum Clinical Chemistry Results in Female Rats fed Control, 
Choline Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N1 Mean SD N Mean SD N Mean SD N 
Calcium mg/dL 10 0.3 12 10 0.3 12 11 a 0.2 12 11 a 0.3 12 
Sodium mmol/L 137 6.1 12 137 c 4.8 12 142 a, b 2.0 12 140 1.5 12 
Potassium mmol/L 5.1 0.4 12 5.0 0.4 12 5.2 0.4 12 4.8 0.3 12 
Chloride mmol/L 98.8 5.7 12 99.6 c 3.8 12 104 a, b 1.9 12 103 a 1.8 12 
Bicarbonate mmol/L 21.3 1.2 12 18.9 2.0 12 19.2 5.0 12 19.8 2.1 12 
Anion Gap mmol/L 22.2 2.2 12 23.8 2.3 12 24.3 5.8 12 21.6  1.7 12 
Creatine Kinase U/L 167 47.6 12 135 44.0 12 120 a, b 29.4 12 82.8 a 17.0 12 
Lactate 
Dehydrogenase  U/L 507 196.4 12 282 a,d 159 12 209 a 66.3 12 124 a, b 72.9 12 
Amylase U/L 539 78.8 12 533 106 12 632 a, b 85.9 12 597 58.8 12 
Lipase U/L 4.4 0.7 12 6.0 a,c,d 1.3 12 4.3 b, d 0.9 12 2.9 a, b, c 0.7 12 
Globulin g/dL 2.5 0.1 12 2.6 0.1 12 2.6 0.1 12 2.5 b, c 0.1 12 
A/G Ratio - 1.4 0.1 12 1.4 c,d 0.0 12 1.5 b 0.1 12 1.5 b 0.1 12 
Urea/Creatinine 
Ratio - 74.0 12.7 12 66.0 15.4 12 53.5 23.5 12 59.6 27.2 12 
Na/K Ratio mmol/L 27.2 1.5 12 27.7 1.6 12 27.8 2.4 12 29.3 a 2.3 12 
High density 
lipoprotein mg/dL 33.4 2.5 12 34.7 c 2.3 12 32.4 b 3.4 12 30.8 2.1 12 
Low density 
lipoprotein mg/dL 13.0 2.2 12 13.1 2.5 12 10.9 2.4 12 11.0 2.7 12 
1. NC indicates not calculated. 
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Supplemental Table 10. Day 9 Non-fasted Serum Clinical Chemistry Results in Female Rats fed Control, 
Choline Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N1 Mean SD N Mean SD N Mean SD N 
 
Statistically significant differences are indicated for each group comparison vs. control (a), vs. CS (b), (c) vs. PFOS, and (d) vs. 
PFOS + CS using one-way ANOVA with Tukey’s multiple comparisons test, p<0.05. 
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Supplemental Table 11. Day 16 Non-fasted Serum Clinical Chemistry Results in Female Rats fed Control, 
Choline Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N Mean SD N Mean SD N Mean SD N1 
Glucose mg/dL 118 8.4 12 119 12.5 12 121 10.1 12 117 12.3 11 
Aspartate 
aminotransferase  U/L 65 6.2 12 58 a 5.4 12 60 4.5 12 60 5.4 11 
Alanine 
aminotransferase  U/L 28 4.5 12 27 2.8 12 27 3.9 12 30 6.4 11 
Gamma glutamyl 
transferase  U/L 0.8 0.6 12 0.4 0.5 12 0.2 0.4 12 0.5 0.5 11 
Alkaline  
Phosphatase U/L 353 47.5 12 345 c, d 69.1 12 246 a, b 55.5 12 254 a, b 42.9 11 
Total Bilirubin mg/dL 0.03 0.05 12 0.0 c 0.0 12 0.04 b, d 0.1 12 0.0 c 0.0 11 
Direct Bilirubin mg/dL <0.1 - 12 <0.1 - 12 <0.1 - 12 <0.1 - 11 
Indirect Bilirubin mg/dL NC2 - 12 NC - 12 NC - 12 NC - 11 
Cholesterol mg/dL 89 10.3 12 94 c, d 8.0 12 68 a, b 7.8 12 73 a, b 16.7 11 
Triglycerides mg/dL 53 15.6 12 54 15.3 12 58 17.3 12 41 10.0 11 
Total Protein g/dL 6.4 0.2 12 6.4 c 0.2 12 6.8 a, b 0.2 12 6.5 0.3 11 
Albumin g/dL 3.7 0.1 12 3.7 c, d 0.1 12 4.0 a, b 0.1 12 3.9 b, c 0.2 11 
Blood Urea 
Nitrogen mg/dL 16 1.9 12 16 c, d 1.7 12 12 a, b 2.4 12 13 a, b 3.3 11 
Creatinine mg/dL 0.2 0.0 12 0.2 0.0 12 0.3 0.1 12 0.2 0.0 11 
Phosphorus mg/dL 7.1 0.4 12 7.4 0.7 12 7.0 0.6 12 6.7 b 0.6 11 
 142 
Supplemental Table 11. Day 16 Non-fasted Serum Clinical Chemistry Results in Female Rats fed Control, 
Choline Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N Mean SD N Mean SD N Mean SD N1 
Calcium mg/dL 10 0.3 12 10 0.3 12 11 0.3 12 11 0.4 11 
Sodium mmol/L 140 2.5 12 140 c, d 0.9 12 144 a, b 3.0 12 144 a, b 3.0 11 
Potassium mmol/L 5.0 0.3 12 5.0 0.3 12 4.9 0.3 12 4.7 a 0.2 11 
Chloride mmol/L 102 2.7 12 103 1.1 12 105 a 2.7 12 105 a 2.7 11 
Bicarbonate mmol/L 21.3 3.4 12 20.3 c 1.8 12 16.8 a, b 2.8 12 18.1 a 3.1 11 
Anion Gap mmol/L 22.6 3.8 12 22.5 c 1.7 12 27.5 a, b 4.1 12 25.4 3.9 11 
Creatine Kinase U/L 142 39.9 12 110 a 31.4 12 105 a 22.4 12 83.1 a 13.9 11 
Lactate 
Dehydrogenase  U/L 419 145 12 230 a 117 12 277 a 96.0 12 203 a 80.3 11 
Amylase U/L 507 55.6 12 550 c, d 81.7 12 744 a, b 134 12 664 a, b 74.1 11 
Lipase U/L 6.4 0.9 12 6.1 c, d 1.1 12 4.6 a, b, d 0.7 12 3.3 a, b, c 0.6 11 
Globulin g/dL 2.7 0.1 12 2.7 0.2 12 2.8 0.2 12 2.7 0.2 11 
A/G Ratio - 1.4 0.0 12 1.4 0.1 12 1.5 0.1 12 1.5 0.1 11 
Urea/Creatinine 
Ratio - 73 19.4 12 71 c 12.4 12 49 a, b 16.2 12 63 16.6 11 
Na/K Ratio mmol/L 28 1.5 12 28 d 1.7 12 30 1.7 12 31 a, b 1.3 11 
High density 
lipoprotein  mg/dL 36 3.0 12 37 c, d 2.2 12 30 a, b 3.3 12 30 a, b 4.9 11 
Low density 
lipoprotein  mg/dL 10.3 1.5 12 9.4 1.2 12 9.3 1.8 12 9.5 3.0 11 
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Supplemental Table 11. Day 16 Non-fasted Serum Clinical Chemistry Results in Female Rats fed Control, 
Choline Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N Mean SD N Mean SD N Mean SD N1 
1. Insufficient serum was available due to technical difficulties which reduced the N for the indicated parameters.  These small 
differences in N are not expected to have affected the outcome of the study. 
2. NC indicates not calculated. 
 
Statistically significant differences are indicated for each group comparison vs. control (a), vs. CS (b), (c) vs. PFOS, and (d) vs. 
PFOS + CS using one-way ANOVA with Tukey’s multiple comparisons test, p<0.05. 
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Supplemental Table 12. Day 23 Fasted Serum Clinical Chemistry Results in Female Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N1 Mean SD N Mean SD N Mean SD N 
Glucose mg/dL 62.8 6.1 12 
83.5 a, c, 
d 10.0 12 152 a,b 38.9 12 177 a,b 53.7 12 
Aspartate 
aminotransferase  U/L 92 24.5 11 69.5 a 5.6 12 67 a 7.4 12 72 a 14.5 12 
Alanine 
aminotransferase  U/L 32 20.1 12 21 3.8 12 25 4.2 12 29 6.6 12 
Gamma glutamyl 
transferase  U/L 0.1 0.3 11 0.2 0.4 12 0.0 0.0 12 0.0 0.0 12 
Alkaline  
Phosphatase U/L 87 25.6 12 85 18.6 12 89 16.0 12 92 15.7 12 
Total Bilirubin mg/dL 0.1 0.1 12 0.0 0.0 12 0.1 0.1 12 0.1 0.0 12 
Direct Bilirubin mg/dL <0.1 - 12 <0.1 - 12 <0.1 - 12 <0.1 - 12 
Indirect Bilirubin mg/dL NC2 - 12 NC - 12 NC - 12 NC - 12 
Cholesterol mg/dL 93 10.5 12 94 13.1 12 79 14.3 12 78 18.5 12 
Triglycerides  mg/dL 48 8.7 12 37 3.7 12 36 4.6 12 44 21.6 12 
Total Protein g/dL 6.7 0.3 12 6.4 c, d 0.2 12 7.4 a, b 0.3 12 7.3 a, b 0.6 12 
Albumin g/dL 3.9 0.2 12 3.6 a, c, d 0.1 12 4.4 a, b 0.2 12 4.2 a, b 0.4 12 
Blood Urea 
Nitrogen mg/dL 15 1.2 12 14d 2.2 12 19 1.8 12 22 a, b 10.4 12 
Creatinine mg/dL 0.4 0.1 12 0.3 0.1 12 0.3 a 0.0 12 0.3 a 0.1 12 
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Supplemental Table 12. Day 23 Fasted Serum Clinical Chemistry Results in Female Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N1 Mean SD N Mean SD N Mean SD N 
Phosphorus mg/dL 14 2.2 11 12 0.8 12 11 a 1.0 12 12 4.0 12 
Calcium mg/dL 12 0.8 11 12 a, c, d 0.4 12 13 a, b 0.4 12 13 a, b 0.5 12 
Sodium mmol/L 142 1.9 11 145 a 2.5 12 145 a 1.3 12 146 a 2.8 12 
Potassium mmol/L 11 1.6 11 9.4 a 1.1 12 8.6 a 0.6 12 9.6 a 0.9 12 
Chloride mmol/L 101 1.3 11 101 2.0 12 102 1.8 12 102 1.8 12 
Bicarbonate mmol/L 28.3 4.6 11 29.4 4.1 12 29.2 2.7 12 27.0 6.0 12 
Anion Gap mmol/L 23.5 4.4 11 24.3 5.1 12 22.6 2.6 12 26.2 8.5 12 
Creatine Kinase  U/L 296 327 12 68.3 a 6.8 12 102 a 18.8 12 92.4 a 14.2 12 
Lactate 
Dehydrogenase  U/L 680 885 12 165 a 30.8 12 347 76.4 12 281 90.0 12 
Amylase U/L 297 29.2 12 354 69.6 12 401 82.2 12 599 723.4 12 
Lipase U/L 9.9 2.5 12 7.4 1.7 12 5.3 1.1 12 12 22.1 12 
Globulin g/dL 2.8 0.2 12 2.8 0.2 12 3.0 0.2 12 3.1 a 0.3 12 
A/G Ratio - 1.4 0.1 12 1.3 c, d 0.1 12 1.5 a, b, d 0.1 12 1.4 c 0.1 12 
Urea/Creatinine 
Ratio - 44.0 11.0 12 51.8 c, d 13.2 12 75 a ,b 20.4 12 86 a ,b 20.9 12 
Na/K Ratio mmol/L 13.5 2.1 11 15.4 a 1.7 12 17 a, d 1.2 12 15 c 1.6 12 
High density 
lipoprotein mg/dL 31.1 2.8 12 31.0 3.1 12 30.0 4.0 12 31 4.5 12 
Low density 
lipoprotein mg/dL 9.8 1.7 12 10.8c 2.0 12 8.1 b 2.0 12 8.5 3.3 12 
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Supplemental Table 12. Day 23 Fasted Serum Clinical Chemistry Results in Female Rats fed Control, Choline 
Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
 
Control (basal 
choline) 
Choline 
Supplemented (CS) 100 ppm PFOS 100 ppm PFOS + CS 
Parameter Units Mean SD N1 Mean SD N Mean SD N Mean SD N 
1. Insufficient serum was available due to technical difficulties which reduced the N for the indicated parameters.  These 
differences in the number of sera analyzed did not affect the interpretation of the study results. 
2. NC indicates not calculated. 
 
Statistically significant differences are indicated for each group comparison vs. control (a), vs. CS (b), (c) vs. PFOS, and (d) vs. 
PFOS + CS using one-way ANOVA with Tukey’s multiple comparisons test, p<0.05. 
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Supplemental Table 13.  Incidence and Severity of Liver Histopathology Results In Male and Female Sprague Dawley 
Rats fed Control, Choline Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
Sex Male Female 
Group 
Control 
(basal 
diet) 
Choline 
Supplemented 
(CS) 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS 
Control 
(basal 
diet) 
Choline 
Supplemented 
(CS) 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS 
Number of 
animals 12 12 12 12 12 12 12 12 
Parameter 
(severity)   
Anatomic 
deformity 1 [a] 0 0 0 0 0 0 0 
Fibrosis 1 [a] 0 0 0 0 0 0 0 
 - Minimal 1 - [b] - - - - - - 
Ground-glass 
cytoplasmic 
alteration 0 0 12 12 0 0 0 0 
 - Mild - - 4 11 - - - - 
 - Moderate - - 8 1 - - - - 
Vacuolation, 
microvesicular 1 0 1 0 0 0 1 0 
 - Minimal 1 0 1 0 - - 1 - 
Hypertrophy 0 0 9 1 0 0 7 2 
 - Minimal - - 7 1 - - 5 2 
 - Mild - - 2 - - - 2 - 
Necrosis 0 0 1 4 0 0 2 2 
 - Minimal - - - 1 - - - 1 
 - Mild - - - 3 - - 2 - 
 - Moderate - - 1 - - - - 1 
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Supplemental Table 13.  Incidence and Severity of Liver Histopathology Results In Male and Female Sprague Dawley 
Rats fed Control, Choline Supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS + CS Diets for Three Weeks 
Sex Male Female 
Group 
Control 
(basal 
diet) 
Choline 
Supplemented 
(CS) 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS 
Control 
(basal 
diet) 
Choline 
Supplemented 
(CS) 
100 ppm 
PFOS 
100 ppm 
PFOS + 
CS 
Lipid 
accumulation, 
microvesicular (Oil 
Red O Qualitative 
Evaluation) 11 12 12 12 12 12 11 12 
 - Minimal 11 12 - - 12 2 10 9 
 - Mild - - - 3 - 10 1 3 
 - Moderate - - 6 9 - - - - 
 - Severe - - 6 - - - - - 
[a] One control male rat had a cleft across the sampled lobe of the liver which was associated with fibrosis. 
[b] – indicates there were no observations for this group at this severity. 
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Supplemental Table 14.  Liver mRNA Fold Change of Rats that were fed 100 ppm PFOS Diet Relative to Rats that were 
fed the Control Diet for Three Weeks (n = 4/sex/group) 
mRNA 
100 ppm PFOS 
Male Female 
Ehhadh 3.74 ± 0.26* 4.14 ± 0.58* 
Scd1 2.07 ± 1.2 9.04 ± 1.8* 
Cd36 1.32 ± 0.2 1.58 ± 1.0 
Fsp27 1.77 ± 0.5 1.23 ± 0.2 
Gsst1 2.43 ± 1.1 1.93 ± 1.0 
* Significantly different from the control group within sex using one-way ANOVA with Tukey’s multiple comparisons test (p<0.05, GraphPad 
Prism®, v. 6.04). 
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Supplemental Table 15. In vitro fold activation of nuclear receptors in luciferase assays 
 
Agonist Assays 
Inverse Agonist 
Assay 
PFOS 
Concentration 
(µM) 
Rat Liver X 
Receptor Beta 
Human Liver X 
Receptor Alpha 
Mouse/Rat 
Peroxisome 
Proliferator Activated 
Receptor Gamma 
Rat Pregnane X 
Receptor 
Rat Constitutive 
Androstane 
Receptor 
0 (DMSO 
vehicle) 
1.0 
(100%)1 
1.0 
(100%) 
1.0 
(100%) 
1.0 
(100%) 
1.0 
(100%) 
0.4 0.98 
(99%) 
0.92 
(98%) 
0.98 
(98%) 
1.2 
(104%) 
-11 
(110%) 
1.2 1.1 
(99%) 
1.3 
(102%) 
1.1 
(100%) 
1.3 
(105%) 
-0.71 
(107%) 
3.7 1.1 
(100%) 
1.3 
(101%) 
1.0 
(101%) 
1.4 
(105%) 
1.7 
(108%) 
11.1 0.96 
(103%) 
1.3 
(104%) 
1.2 
(103%) 
1.3 
(100%) 
9.5 
(96%) 
33.3 1.1 
(99%) 
1.1 
(96%) 
1.6 
(98%) 
1.1 
(100%) 
7.6 
(100%) 
100.0 0.73 
(100%) 
1.1 
(101%) 
4.2 
(100%) 
1.5 
(104%) 
-11 
(105%) 
1. Values are presented as fold activation relative to the vehicle control.  Values in ( ) are % viable cells relative to the vehicle control. 
 
